S8299100B2	NNP	O
-	:	O
Potent	NN	O
and	CC	O
selective	JJ	O
neuronal	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	NN	O
inhibitors	NNS	O
with	IN	O
improved	JJ	O
membrane	NN	O
permeability	NN	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
This	DT	O
application	NN	O
claims	VBZ	O
priority	NN	O
benefit	NN	O
from	IN	O
application	NN	O
Ser.	.	O
No.	.	O
61/205,770	CD	O
filed	VBD	O
Jan.	NNP	O
23,	,	O
2009,	,	O
the	DT	O
entirety	NN	O
of	IN	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference.	.	O
This	DT	O
invention	NN	O
was	VBD	O
made	VBN	O
with	IN	O
government	NN	O
support	NN	O
under	IN	O
Grant	NNP	O
No.	.	O
R01	NNP	O
GM49725	NNP	O
awarded	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Institutes	NNPS	O
of	IN	O
Health	NNP	O
to	TO	O
Northwestern	NNP	O
University.	.	O
The	DT	O
government	NN	O
has	VBZ	O
certain	JJ	O
rights	NNS	O
in	IN	O
the	DT	O
invention.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Neuronal	NNP	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
(nNOS)	)	O
catalyzes	VBZ	O
the	DT	O
oxidation	NN	O
of	IN	O
L-arginine	NNP	O
to	TO	O
L-citrulline	NNP	O
in	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system,	,	O
generating	VBG	O
nitric	JJ	O
oxide	NN	O
(NO),	,	O
a	DT	O
critical	JJ	O
neurotransmitter.	.	O
Significant	NNP	O
research	NN	O
has	VBZ	O
implicated	VBN	O
the	DT	O
overexpression	NN	O
of	IN	O
nNOS—and	JJ	O
overproduction	NN	O
of	IN	O
NO—in	NNP	O
various	JJ	O
neurological	JJ	O
diseases,	,	O
including	VBG	O
Parkinson's,	,	O
Alzheimer's,	,	O
and	CC	O
Huntington's	POS	O
diseases,	,	O
as	RB	O
well	RB	O
as	IN	O
neuronal	JJ	O
damage	NN	O
due	JJ	O
to	TO	O
stroke	VB	O
Inhibiting	NNP	O
endothelial	JJ	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
(eNOS)	)	O
and	CC	O
inducible	JJ	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
(iNOS)	)	O
is,	,	O
however,	,	O
undesirable,	,	O
because	IN	O
these	DT	O
isozymes	NNS	O
are	VBP	O
responsible	JJ	O
for	IN	O
maintaining	VBG	O
crucial	JJ	O
body	NN	O
function.	.	O
Thus,	,	O
selective	JJ	O
inhibition	NN	O
of	IN	O
nNOS	NN	O
over	IN	O
its	PRP$	O
closely	RB	O
related	JJ	O
isoforms,	,	O
eNOS	NN	O
and	CC	O
iNOS,	,	O
can	MD	O
provide	VB	O
a	DT	O
promising	JJ	O
strategy	NN	O
in	IN	O
developing	VBG	O
therapeutics	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
neurodegenerative	JJ	O
diseases.	.	O
Through	IN	O
on-going	JJ	O
research	NN	O
of	IN	O
nNOS	JJ	O
selective	JJ	O
inhibitors,	,	O
a	DT	O
pyrrolidine-based	JJ	O
compound	NN	O
(1,	,	O
FIG.	.	O
1),	,	O
was	VBD	O
found	VBN	O
to	TO	O
provide	VB	O
great	JJ	O
potency	NN	O
(Ki=15	NNP	O
nM)	)	O
and	CC	O
very	RB	O
high	JJ	O
selectivity	NN	O
for	IN	O
nNOS	NN	O
over	IN	O
eNOS	NN	O
(2100	CD	O
fold)	)	O
and	CC	O
iNOS	NN	O
(630	CD	O
fold).	.	O
However,	,	O
despite	IN	O
the	DT	O
promising	JJ	O
inhibitory	JJ	O
activity	NN	O
of	IN	O
1,	,	O
further	JJ	O
application	NN	O
to	TO	O
neurodegenerative	JJ	O
therapeutics	NNS	O
has	VBZ	O
been	VBN	O
impeded	VBN	O
by	IN	O
several	JJ	O
structural	JJ	O
characteristics.	.	O
First,	,	O
the	DT	O
flexible	JJ	O
m-fluorophenyl	JJ	O
ethanamino	NN	O
tail	NN	O
brought	VBD	O
multiple	JJ	O
rotatable	JJ	O
bonds	NNS	O
to	TO	O
the	DT	O
inhibitor,	,	O
limits	VBZ	O
the	DT	O
potency	NN	O
and	CC	O
selectivity	NN	O
of	IN	O
1.	.	O
In	IN	O
addition,	,	O
the	DT	O
benzylic	JJ	O
position	NN	O
of	IN	O
the	DT	O
m-fluorophenyl	JJ	O
ring	NN	O
is	VBZ	O
highly	RB	O
susceptible	JJ	O
to	TO	O
metabolic	JJ	O
oxidation	NN	O
reactions.	.	O
More	RBR	O
importantly,	,	O
the	DT	O
two	CD	O
positive	JJ	O
charges	NNS	O
of	IN	O
1	CD	O
at	IN	O
physiological	JJ	O
pH,	,	O
derived	VBN	O
from	IN	O
the	DT	O
two	CD	O
amino	NN	O
groups,	,	O
decreases	VBZ	O
the	DT	O
chance	NN	O
of	IN	O
1	CD	O
to	TO	O
penetrate	VB	O
the	DT	O
blood	NN	O
brain	NN	O
barrier	NN	O
(BBB).	.	O
SUMMARY	NN	O
OF	IN	O
THE	DT	O
INVENTION	NNP	O
In	IN	O
light	NN	O
of	IN	O
the	DT	O
foregoing,	,	O
it	PRP	O
is	VBZ	O
an	DT	O
object	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
provide	VB	O
compounds,	,	O
compositions	NNS	O
and	CC	O
related	JJ	O
methods	NNS	O
of	IN	O
use	NN	O
for	IN	O
the	DT	O
selective	JJ	O
inhibition	NN	O
of	IN	O
neuronal	JJ	O
nitric	JJ	O
oxide	NN	O
synthase,	,	O
thereby	RB	O
overcoming	VBG	O
various	JJ	O
deficiencies	NNS	O
and	CC	O
shortcomings	NNS	O
of	IN	O
the	DT	O
prior	JJ	O
art	NN	O
including	VBG	O
those	DT	O
outlined	VBN	O
above.	.	O
It	PRP	O
would	MD	O
be	VB	O
understood	VBN	O
by	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
one	CD	O
or	CC	O
more	JJR	O
aspects	NNS	O
of	IN	O
this	DT	O
invention	NN	O
can	MD	O
meet	VB	O
certain	JJ	O
objectives,	,	O
while	IN	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
aspects	NNS	O
can	MD	O
meet	VB	O
certain	JJ	O
other	JJ	O
objectives.	.	O
Each	DT	O
objective	NN	O
may	MD	O
not	RB	O
apply	VB	O
equally,	,	O
in	IN	O
all	DT	O
its	PRP$	O
respects,	,	O
to	TO	O
every	DT	O
aspect	NN	O
of	IN	O
this	DT	O
invention.	.	O
As	IN	O
such,	,	O
the	DT	O
following	JJ	O
objects	NNS	O
can	MD	O
be	VB	O
viewed	VBN	O
in	IN	O
the	DT	O
alternative	NN	O
with	IN	O
respect	NN	O
to	TO	O
any	DT	O
one	CD	O
aspect	NN	O
of	IN	O
this	DT	O
invention.	.	O
It	PRP	O
is	VBZ	O
an	DT	O
object	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
provide	VB	O
one	CD	O
or	CC	O
more	JJR	O
small	JJ	O
molecule	NN	O
and/or	IN	O
non-peptide	JJ	O
compounds	NNS	O
exhibiting	VBG	O
selective	JJ	O
nNOS	JJ	O
inhibition	NN	O
over	IN	O
other	JJ	O
enzyme	JJ	O
isoforms	NNS	O
and	CC	O
providing	VBG	O
improved	VBN	O
membrane	JJ	O
permeability	NN	O
and	CC	O
bioavailability.	.	O
It	PRP	O
can	MD	O
be	VB	O
another	DT	O
object	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
provide	VB	O
an	DT	O
enantiomerically-pure	JJ	O
compound	NN	O
to	TO	O
affect	VB	O
binding	VBG	O
orientation	NN	O
and	CC	O
improved	JJ	O
potency	NN	O
and	CC	O
selectivity	NN	O
over	IN	O
the	DT	O
corresponding	JJ	O
racemic	JJ	O
mixtures.	.	O
It	PRP	O
can	MD	O
be	VB	O
another	DT	O
object	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention,	,	O
alone	RB	O
or	CC	O
in	IN	O
conjunction	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
preceding	VBG	O
objectives,	,	O
to	TO	O
reduce	VB	O
basicity	NN	O
of	IN	O
an	DT	O
ethanamino	NN	O
nitrogen	NN	O
center,	,	O
as	IN	O
can	MD	O
be	VB	O
accomplished	VBN	O
by	IN	O
incorporation	NN	O
of	IN	O
an	DT	O
electron-withdrawing	JJ	O
moiety	NN	O
adjacent	NN	O
or	CC	O
proximate	NN	O
thereto,	,	O
to	TO	O
reduce	VB	O
molecular	JJ	O
cationic	JJ	O
character	NN	O
at	IN	O
physiological	JJ	O
pH	NN	O
and	CC	O
to	TO	O
enhance	VB	O
bioavailability	NN	O
by	IN	O
improved	JJ	O
penetration	NN	O
of	IN	O
the	DT	O
BBB.	.	O
It	PRP	O
can	MD	O
be	VB	O
another	DT	O
object	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
provide	VB	O
one	CD	O
or	CC	O
more	JJR	O
such	JJ	O
non-peptide	JJ	O
compounds	NNS	O
for	IN	O
in	IN	O
vitro	NN	O
use	NN	O
and	CC	O
study	NN	O
under	IN	O
conditions	NNS	O
promoting	VBG	O
nitric	JJ	O
oxide	JJ	O
production,	,	O
indicative	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
mammalian	JJ	O
disease	NN	O
states.	.	O
Alternatively,	,	O
it	PRP	O
can	MD	O
also	RB	O
be	VB	O
an	DT	O
object	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
provide	VB	O
one	CD	O
or	CC	O
more	JJR	O
such	JJ	O
compounds	NNS	O
enabling	VBG	O
in	IN	O
vivo	JJ	O
treatment	NN	O
of	IN	O
such	JJ	O
disease	NN	O
states.	.	O
Other	JJ	O
objects,	,	O
features,	,	O
benefits	NNS	O
and	CC	O
advantages	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
be	VB	O
apparent	JJ	O
from	IN	O
this	DT	O
summary	JJ	O
and	CC	O
the	DT	O
following	JJ	O
descriptions	NNS	O
of	IN	O
certain	JJ	O
embodiments	NNS	O
of	IN	O
such	JJ	O
compounds,	,	O
compositions	NNS	O
and/or	VBP	O
methods	NNS	O
and	CC	O
will	MD	O
be	VB	O
readily	RB	O
apparent	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
having	VBG	O
knowledge	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
techniques	NNS	O
described	VBN	O
herein.	.	O
Such	JJ	O
objectives,	,	O
features,	,	O
benefits	NNS	O
and	CC	O
advantages	NNS	O
will	MD	O
be	VB	O
apparent	JJ	O
from	IN	O
the	DT	O
above	NN	O
as	IN	O
taken	VBN	O
into	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
accompanying	VBG	O
examples,	,	O
data,	,	O
figures	NNS	O
and	CC	O
references	NNS	O
incorporated	VBN	O
herein,	,	O
together	RB	O
with	IN	O
all	DT	O
reasonable	JJ	O
inferences	NNS	O
to	TO	O
be	VB	O
drawn	VBN	O
therefrom.	.	O
Accordingly,	,	O
in	IN	O
part,	,	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
relate	VB	O
to	TO	O
compounds	NNS	O
of	IN	O
a	DT	O
formula	NN	O
wherein	NN	O
X	NN	O
can	MD	O
be	VB	O
selected	VBN	O
from	IN	O
divalent	JJ	O
electron-withdrawing	JJ	O
moieties	NNS	O
or	CC	O
groups	NNS	O
and/or	JJ	O
substituents	NNS	O
thereof,	,	O
together	RB	O
with	IN	O
salts,	,	O
hydrates	NNS	O
and/or	VBP	O
solvates	NNS	O
of	IN	O
such	JJ	O
compounds;	:	O
and	CC	O
to	TO	O
pharmaceutical	JJ	O
compositions	NNS	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
such	JJ	O
compounds,	,	O
optionally	RB	O
together	RB	O
with	IN	O
an	DT	O
acceptable	JJ	O
carrier	NN	O
component.	.	O
In	IN	O
certain	JJ	O
embodiments,	,	O
without	IN	O
limitation,	,	O
such	JJ	O
moieties/groups	NNS	O
can	MD	O
be	VB	O
selected	VBN	O
from	IN	O
ether,	,	O
cyclopropyl,	,	O
monofluoroethylene	NN	O
and	CC	O
difluoroethylene,	,	O
such	JJ	O
groups/moieties	NNS	O
as	IN	O
are	VBP	O
illustrated	VBN	O
below	IN	O
and	CC	O
discussed	VBD	O
more	RBR	O
fully	RB	O
elsewhere	RB	O
herein.	.	O
More	RBR	O
generally,	,	O
such	JJ	O
groups/moieties	NNS	O
and	CC	O
substituents	NNS	O
thereof	NNS	O
are	VBP	O
limited	VBN	O
only	RB	O
by	IN	O
electron-withdrawing	JJ	O
function,	,	O
as	IN	O
can	MD	O
be	VB	O
considered	VBN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
mitigation	NN	O
or	CC	O
partial	JJ	O
removal	NN	O
of	IN	O
a	DT	O
degree	NN	O
of	IN	O
positive	JJ	O
charge	NN	O
from	IN	O
an	DT	O
amine	JJ	O
functionality,	,	O
such	JJ	O
as	IN	O
at	IN	O
physiological	JJ	O
pH.	.	O
Accordingly,	,	O
without	IN	O
limitation,	,	O
in	IN	O
certain	JJ	O
such	JJ	O
embodiments,	,	O
such	PDT	O
a	DT	O
compound	NN	O
can	MD	O
be	VB	O
present	JJ	O
as	IN	O
an	DT	O
acid	NN	O
salt,	,	O
either	CC	O
partially	RB	O
or	CC	O
fully	RB	O
protonated.	.	O
In	IN	O
certain	JJ	O
such	JJ	O
embodiments,	,	O
the	DT	O
counter	NN	O
ion(s)	)	O
can	MD	O
be	VB	O
a	DT	O
conjugate	JJ	O
base	NN	O
of	IN	O
a	DT	O
protic	JJ	O
acid.	.	O
Regardless,	,	O
Φ	NNS	O
can	MD	O
be	VB	O
selected	VBN	O
from	IN	O
moieties	NNS	O
capable	JJ	O
of	IN	O
contribution	NN	O
to	TO	O
or	CC	O
affect	VB	O
on	IN	O
enzyme	JJ	O
binding	NN	O
or	CC	O
interaction.	.	O
Without	IN	O
limitation,	,	O
Φ	WP	O
can	MD	O
be	VB	O
as	IN	O
discussed	JJ	O
below.	.	O
More	RBR	O
generally,	,	O
as	IN	O
demonstrated	VBN	O
below,	,	O
the	DT	O
structure	NN	O
of	IN	O
such	JJ	O
a	DT	O
compound	NN	O
is	VBZ	O
limited	VBN	O
only	RB	O
by	IN	O
choice	NN	O
of	IN	O
starting	VBG	O
material	NN	O
or	CC	O
reagent,	,	O
enroute	NN	O
to	TO	O
a	DT	O
pyridine	JJ	O
substructure	NN	O
(I),	,	O
pyrrolidine	JJ	O
substructure	NN	O
(II)	)	O
and/or	VBZ	O
lipophilic	JJ	O
tail	NN	O
substructure	NN	O
(III),	,	O
such	JJ	O
substructures	NNS	O
as	IN	O
are	VBP	O
discussed	VBN	O
more	RBR	O
fully	RB	O
below	IN	O
and/or	NNS	O
in	IN	O
co-pending	JJ	O
application	NN	O
Ser.	.	O
No.	.	O
11/906,283	CD	O
and	CC	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
7,470,790,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety.	.	O
Accordingly,	,	O
various	JJ	O
compounds	NNS	O
of	IN	O
this	DT	O
invention	NN	O
can,	,	O
optionally,	,	O
comprise	VBP	O
various	JJ	O
other	JJ	O
substructures	NNS	O
I,	,	O
II	NNP	O
and/or	VBZ	O
III	NNP	O
or	CC	O
other	JJ	O
moieties	NNS	O
and/or	VBP	O
substituents	NNS	O
thereof,	,	O
such	JJ	O
as	IN	O
the	DT	O
substructures,	,	O
moieties	NNS	O
and/or	VBP	O
groups	NNS	O
described	VBN	O
in	IN	O
the	DT	O
aforementioned	JJ	O
incorporated	JJ	O
references.	.	O
As	IN	O
such,	,	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
broader	JJR	O
aspects	NNS	O
of	IN	O
this	DT	O
invention,	,	O
the	DT	O
present	JJ	O
compounds	NNS	O
are	VBP	O
without	IN	O
stereochemical	JJ	O
limitation.	.	O
Where	WRB	O
such	JJ	O
compounds	NNS	O
and/or	VBP	O
their	PRP$	O
intermediates	NNS	O
are	VBP	O
available	JJ	O
as	IN	O
racemic	JJ	O
mixtures,	,	O
the	DT	O
respective	JJ	O
isomers	NNS	O
can	MD	O
be	VB	O
resolved.	.	O
Likewise,	,	O
as	IN	O
such	JJ	O
compounds	NNS	O
are	VBP	O
diastereomers,	,	O
the	DT	O
corresponding	JJ	O
enantiomers	NNS	O
can	MD	O
be	VB	O
separated.	.	O
Accordingly,	,	O
any	DT	O
such	JJ	O
stereocenter	NN	O
can	MD	O
be	VB	O
(S)	)	O
or	CC	O
(R)	)	O
with	IN	O
respect	NN	O
to	TO	O
any	DT	O
other	JJ	O
stereocenter(s),	,	O
whether	IN	O
such	PDT	O
a	DT	O
compound	NN	O
is	VBZ	O
present	JJ	O
as	IN	O
a	DT	O
salt,	,	O
hydrate	NN	O
and/or	NN	O
solvate	NN	O
thereof.	.	O
In	IN	O
part,	,	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
also	RB	O
provide	VB	O
a	DT	O
method	NN	O
of	IN	O
inhibiting	VBG	O
a	DT	O
nitric	JJ	O
oxide	NN	O
synthase,	,	O
such	PDT	O
a	DT	O
method	NN	O
comprising	VBG	O
contacting	VBG	O
a	DT	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
any	DT	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
present	JJ	O
compounds,	,	O
including,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
those	DT	O
illustrated	VBN	O
by	IN	O
the	DT	O
following	JJ	O
examples,	,	O
referenced	VBD	O
figures	NNS	O
and/or	RP	O
accompanying	VBG	O
synthetic	JJ	O
schemes.	.	O
More	RBR	O
specifically,	,	O
as	IN	O
also	RB	O
supported	VBN	O
herein,	,	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
provide	VB	O
a	DT	O
method	NN	O
of	IN	O
using	VBG	O
an	DT	O
electron	NN	O
withdrawing	VBG	O
moiety	NN	O
to	TO	O
inhibit	VB	O
such	JJ	O
a	DT	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
and/or	NN	O
for	IN	O
selective	JJ	O
inhibition	NN	O
of	IN	O
neuronal	JJ	O
nitric	JJ	O
oxide	NN	O
synthase.	.	O
Such	JJ	O
a	DT	O
method	NN	O
can	MD	O
comprise	VB	O
providing	VBG	O
a	DT	O
compound	NN	O
or	CC	O
a	DT	O
related	JJ	O
composition	NN	O
of	IN	O
this	DT	O
invention;	:	O
and	CC	O
contacting	VBG	O
a	DT	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
enzyme	NN	O
with	IN	O
such	PDT	O
a	DT	O
compound/composition,	,	O
such	JJ	O
contact	NN	O
as	IN	O
can	MD	O
selectively	RB	O
inhibit	VB	O
neuronal	JJ	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
over	IN	O
inducible	JJ	O
and/or	JJ	O
endothelial	JJ	O
isoforms.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIG.	.	O
1	CD	O
shows	NNS	O
development	NN	O
and	CC	O
design	NN	O
of	IN	O
several	JJ	O
non-limiting	JJ	O
compounds	NNS	O
of	IN	O
this	DT	O
invention	NN	O
from	IN	O
prior	JJ	O
art	NN	O
compound	NN	O
1.	.	O
FIGS.	.	O
2	CD	O
A-B.	.	O
The	DT	O
nNOS	JJ	O
active	JJ	O
site	NN	O
with	IN	O
inhibitor	NN	O
2da	CD	O
(A)	)	O
or	CC	O
2db	CD	O
(B)	)	O
bound.	.	O
The	DT	O
sigmaA	NN	O
weighted	VBD	O
2Fo−Fc	CD	O
density	NN	O
for	IN	O
inhibitor	NN	O
is	VBZ	O
also	RB	O
shown	VBN	O
at	IN	O
contour	JJ	O
level	NN	O
of	IN	O
1	CD	O
σ.	JJ	O
Hydrogen	NNP	O
bonds	NNS	O
are	VBP	O
depicted	VBN	O
with	IN	O
dashed	JJ	O
lines.	.	O
Alternate	NNP	O
conformations	NNS	O
for	IN	O
2db	CD	O
and	CC	O
E592	NNP	O
were	VBD	O
observed.	.	O
FIGS.	.	O
2,	,	O
3,	,	O
and	CC	O
4	CD	O
were	VBD	O
prepared	VBN	O
with	IN	O
PyMol,	,	O
an	DT	O
open-source,	,	O
user-sponsored	JJ	O
molecular	JJ	O
visualization	NN	O
system	NN	O
well-known	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art.	.	O
FIGS.	.	O
3A-D	CD	O
The	DT	O
nNOS	NN	O
active	JJ	O
site	NN	O
with	IN	O
2dc	CD	O
(A),	,	O
2dd	CD	O
(B),	,	O
2e	CD	O
(C),	,	O
or	CC	O
2f	CD	O
(D)	)	O
bound.	.	O
Around	IN	O
each	DT	O
inhibitor	NN	O
is	VBZ	O
the	DT	O
sigmaA	NN	O
weighted	VBD	O
2Fo−Fc	CD	O
density	NN	O
contoured	VBN	O
at	IN	O
1	CD	O
σ.	.	O
Major	JJ	O
hydrogen	NN	O
bonds	NNS	O
are	VBP	O
depicted	VBN	O
with	IN	O
dashed	JJ	O
lines.	.	O
Note	VB	O
the	DT	O
alternate	NN	O
conformations	NNS	O
for	IN	O
E592	NNP	O
occur	NN	O
when	WRB	O
the	DT	O
inhibitor	NN	O
shows	VBZ	O
multiple	JJ	O
conformations	NNS	O
in	IN	O
the	DT	O
nNOS-2dd	JJ	O
or	CC	O
nNOS-2e	JJ	O
structure.	.	O
FIGS.	.	O
4A-B.	.	O
The	DT	O
eNOS	NN	O
active	JJ	O
site	NN	O
with	IN	O
2db	CD	O
(A)	)	O
and	CC	O
2f	CD	O
(B)	)	O
bound.	.	O
Around	IN	O
each	DT	O
inhibitor	NN	O
is	VBZ	O
the	DT	O
sigmaA	NN	O
weighted	VBD	O
2Fo−Fc	CD	O
density	NN	O
contoured	VBN	O
at	IN	O
1	CD	O
σ.	.	O
Major	JJ	O
hydrogen	NN	O
bonds	NNS	O
are	VBP	O
depicted	VBN	O
with	IN	O
dashed	JJ	O
lines.	.	O
As	IN	O
observed	VBN	O
with	IN	O
nNOS,	,	O
alternate	JJ	O
conformations	NNS	O
for	IN	O
Glu363	NNP	O
occur	NN	O
in	IN	O
the	DT	O
eNOS-2db	JJ	O
structure.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	NNP	O
CERTAIN	NNP	O
EMBODIMENTS	NNP	O
To	TO	O
address	VB	O
permeability	NN	O
problems	NNS	O
of	IN	O
the	DT	O
sort	NN	O
discussed	VBD	O
above,	,	O
different	JJ	O
strategies	NNS	O
have	VBP	O
been	VBN	O
applied	VBN	O
to	TO	O
improve	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
the	DT	O
prior	JJ	O
art	NN	O
compounds—including,	,	O
without	IN	O
limitation,	,	O
the	DT	O
design,	,	O
synthesis,	,	O
and	CC	O
biological	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
new	JJ	O
series	NN	O
of	IN	O
low	JJ	O
pKa	NN	O
inhibitors	NNS	O
(e.g.,	,	O
compounds	VBZ	O
2a-d	CD	O
of	IN	O
FIG.	.	O
1).	.	O
In	IN	O
representative	JJ	O
such	JJ	O
embodiments,	,	O
different	JJ	O
electron	NN	O
withdrawing	VBG	O
groups,	,	O
including	VBG	O
ether	NN	O
(2a),	,	O
cyclopropyl	NN	O
(2b),	,	O
monofluoromethylene	NN	O
(2c),	,	O
and	CC	O
difluoromethylene	NN	O
(2d),	,	O
were	VBD	O
introduced	VBN	O
at	IN	O
the	DT	O
position	NN	O
adjacent	NN	O
or	CC	O
proximate	NN	O
to	TO	O
the	DT	O
pendent	JJ	O
amine	NN	O
group	NN	O
in	IN	O
the	DT	O
lipophilic	JJ	O
tail	NN	O
of	IN	O
1	CD	O
(FIG.	.	O
1).	.	O
While	IN	O
the	DT	O
chemical	JJ	O
structures	NNS	O
of	IN	O
these	DT	O
inhibitors	NNS	O
are	VBP	O
related	VBN	O
to	TO	O
that	DT	O
of	IN	O
1,	,	O
the	DT	O
predicted	JJ	O
pKa	NN	O
values	NNS	O
of	IN	O
these	DT	O
compounds	NNS	O
are	VBP	O
significantly	RB	O
and	CC	O
unexpectedly	RB	O
lower	JJR	O
than	IN	O
1	CD	O
(Table	JJ	O
1):	:	O
supporting	VBG	O
the	DT	O
hypothesis	NN	O
was	VBD	O
that	IN	O
an	DT	O
additional	JJ	O
electron	NN	O
withdrawing	VBG	O
group,	,	O
which	WDT	O
can	MD	O
be	VB	O
considered	VBN	O
to	TO	O
mitigate	VB	O
or	CC	O
partially	RB	O
remove	VB	O
the	DT	O
positive	JJ	O
charge	NN	O
from	IN	O
the	DT	O
amine	NN	O
functionality	NN	O
through	IN	O
electronegative	JJ	O
induction,	,	O
would	MD	O
decrease	VB	O
cationic	JJ	O
character	NN	O
of	IN	O
inhibitors	NNS	O
2a-d	JJ	O
compared	VBN	O
to	TO	O
1,	,	O
and	CC	O
therefore,	,	O
improve	VB	O
membrane	NN	O
permeability	NN	O
of	IN	O
the	DT	O
inhibitors.	.	O
Illustrating	VBG	O
various	JJ	O
such	JJ	O
embodiments	NNS	O
of	IN	O
this	DT	O
invention,	,	O
a	DT	O
series	NN	O
of	IN	O
nNOS	JJ	O
inhibitors	NNS	O
(2)	)	O
provides	VBZ	O
a	DT	O
structurally	RB	O
constrained	VBN	O
cyclopropyl	NN	O
ring	VBG	O
inserted	VBN	O
in	IN	O
the	DT	O
position	NN	O
adjacent	NN	O
to	TO	O
the	DT	O
amine	JJ	O
group	NN	O
of	IN	O
the	DT	O
ethanamino	NN	O
tail.	.	O
The	DT	O
introduction	NN	O
of	IN	O
the	DT	O
cyclopropyl	NN	O
group	NN	O
of	IN	O
the	DT	O
new	JJ	O
inhibitors	NNS	O
(2)	)	O
can	MD	O
potentially	RB	O
enhance	VB	O
the	DT	O
inhibitory	NN	O
activity	NN	O
by	IN	O
stabilizing	VBG	O
a	DT	O
biologically	RB	O
active	JJ	O
conformer	NN	O
(therefore	IN	O
reducing	VBG	O
the	DT	O
energetic	JJ	O
penalty	NN	O
on	IN	O
binding	VBG	O
to	TO	O
the	DT	O
enzyme),	,	O
and	CC	O
improve	VB	O
selectivity	NN	O
by	IN	O
eliminating	VBG	O
bioactive	JJ	O
conformers	NNS	O
that	WDT	O
give	VBP	O
undesired	JJ	O
biological	JJ	O
responses.	.	O
In	IN	O
addition,	,	O
the	DT	O
insertion	NN	O
of	IN	O
a	DT	O
cyclopropyl	JJ	O
fragment	NN	O
can	MD	O
block	VB	O
the	DT	O
potential	JJ	O
metabolic	JJ	O
oxidation	NN	O
at	IN	O
the	DT	O
benzylic	JJ	O
position	NN	O
of	IN	O
the	DT	O
m-fluorophenyl	JJ	O
ring.	.	O
Furthermore,	,	O
the	DT	O
electro-withdrawing	JJ	O
character	NN	O
of	IN	O
the	DT	O
cyclopropyl	NN	O
ring	NN	O
decreases	VBZ	O
the	DT	O
basicity	NN	O
of	IN	O
the	DT	O
adjacent	JJ	O
amino	NN	O
group.	.	O
The	DT	O
calculated	JJ	O
pKa	NN	O
value	NN	O
of	IN	O
the	DT	O
amino	NN	O
group	NN	O
in	IN	O
the	DT	O
lipophilic	JJ	O
tail	NN	O
of	IN	O
such	JJ	O
embodiments	NNS	O
of	IN	O
inhibitor	NN	O
2	CD	O
was	VBD	O
˜7.4,	,	O
which	WDT	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
of	IN	O
1.	.	O
As	IN	O
a	DT	O
result,	,	O
pseudo-monocationic	JJ	O
cyclopropyl	NN	O
variations	NNS	O
of	IN	O
inhibitor	NN	O
2	CD	O
should	MD	O
have	VB	O
improved	VBN	O
BBB	NNP	O
permeability.	.	O
Generally,	,	O
a	DT	O
representative	JJ	O
synthesis	NN	O
of	IN	O
4b	CD	O
is	VBZ	O
detailed	VBN	O
in	IN	O
Scheme	NNP	O
1a,	,	O
below.	.	O
Acid-catalyzed	JJ	O
esterification	NN	O
of	IN	O
carboxylic	JJ	O
acid	NN	O
5	CD	O
provided	VBD	O
methyl	NN	O
ester	NN	O
6,	,	O
which	WDT	O
was	VBD	O
treated	VBN	O
with	IN	O
diazomethane	NN	O
(CH2N2)	)	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
catalytic	JJ	O
amount	NN	O
of	IN	O
Pd(OAc)2	CD	O
to	TO	O
generate	VB	O
cyclopropyl	NN	O
methyl	NN	O
ester	NN	O
7	CD	O
in	IN	O
excellent	JJ	O
yields.	.	O
Saponification	NN	O
of	IN	O
7	CD	O
in	IN	O
aqueous	JJ	O
NaOH	NNP	O
(2N)	)	O
gave	VBD	O
carboxylic	JJ	O
acid	NN	O
8,	,	O
which	WDT	O
was	VBD	O
converted	VBN	O
to	TO	O
a	DT	O
Boc-protected	JJ	O
amine	NN	O
9	CD	O
through	IN	O
a	DT	O
Curtius	NNP	O
rearrangement.	.	O
Tchilibon,	,	B
S.;	:	I
Kim,	,	I
S.-K.;	:	I
Gao,	,	I
Z.-G.;	:	I
Harris,	,	I
B.	.	I
A.;	:	I
Blaustein,	,	I
J.	.	I
B.;	:	I
Gross,	,	I
A.	NNP	I
S.;	:	I
Duong,	,	I
H.	NNP	I
T.;	:	I
Melman,	,	I
N.;	:	I
Jacobson,	,	I
K.	NNP	I
A.	.	I
Exploring	VBG	I
distal	JJ	I
regions	NNS	I
of	IN	I
the	DT	I
A3	NNP	I
adenosine	NN	I
receptor	NN	I
binding	VBG	I
site:	:	I
sterically	RB	I
constrained	VBN	I
N6-(2-phenylethyl)adenosine	NN	I
derivatives	NNS	I
as	IN	I
potent	JJ	I
ligands.	.	I
Bioorg.	.	I
Med.	.	I
Chem.	.	I
2004,	,	I
12,	,	I
2021-2034.)(	)	O
Finally,	,	O
the	DT	O
Boc-protecting	NNP	O
group	NN	O
of	IN	O
9	CD	O
was	VBD	O
removed	VBN	O
with	IN	O
TFA	NNP	O
to	TO	O
provide	VB	O
4b	CD	O
as	IN	O
a	DT	O
TFA	NNP	O
salt	NN	O
in	IN	O
high	JJ	O
yields.	.	O
Alternatively,	,	O
illustrating	VBG	O
another	DT	O
synthetic	JJ	O
route,	,	O
consider	VB	O
the	DT	O
preparation	NN	O
of	IN	O
3a-c	JJ	O
shown	VBN	O
in	IN	O
Scheme	NNP	O
1b.	.	O
(As	IN	O
a	DT	O
departure	NN	O
from	IN	O
the	DT	O
aforementioned	JJ	O
general	JJ	O
numbering	NN	O
format,	,	O
the	DT	O
following	JJ	O
compounds	NNS	O
4-9	JJ	O
are	VBP	O
illustrated	VBN	O
in	IN	O
Schemes	NNP	O
1b-e	JJ	O
(and	CC	O
described	VBN	O
in	IN	O
examples	NNS	O
5-29)	)	O
en	FW	O
route	NN	O
to	TO	O
several	JJ	O
non-limiting	JJ	O
representative	JJ	O
variations	NNS	O
of	IN	O
inhibitor	NN	O
compound	NN	O
2b:	:	O
for	IN	O
instance,	,	O
cyclopropyl	JJ	O
inhibitors	NNS	O
2ba-2bd,	,	O
in	IN	O
Scheme	NNP	O
1d,	,	O
below).	.	O
Rhodium	NNP	O
(II)-catalyzed	VBD	O
cyclopropanation	NN	O
of	IN	O
1-substituted-3-vinylbenzene	JJ	O
(4a-c)	)	O
provided	VBD	O
5a-c	JJ	O
as	IN	O
a	DT	O
cis/trans	JJ	O
mixture	NN	O
in	IN	O
good	JJ	O
yields.	.	O
Next,	,	O
ethyl	JJ	O
ester	NN	O
5a-c	JJ	O
were	VBD	O
treated	VBN	O
with	IN	O
NaOMe	NNP	O
in	IN	O
refluxing	VBG	O
EtOH	NNP	O
to	TO	O
induce	VB	O
the	DT	O
epimerization	NN	O
reaction,	,	O
generating	VBG	O
the	DT	O
thermodynamically	RB	O
more	RBR	O
stable	JJ	O
trans	NNS	O
isomers,	,	O
which	WDT	O
were	VBD	O
hydrolyzed	VBN	O
in	IN	O
aqueous	JJ	O
LiOH	NNP	O
to	TO	O
provide	VB	O
6a-c	JJ	O
in	IN	O
good	JJ	O
yields.	.	O
(See,	,	O
Pryde,	,	B
D.	NNP	I
C.;	:	I
Cook,	,	I
A.	NNP	I
S.;	:	I
Burring,	,	I
D.	NNP	I
J.;	:	I
Jones,	,	I
L.	NNP	I
H.;	:	I
Foll,	,	I
S.;	:	I
Platts,	,	I
M.	NNP	I
Y.;	:	I
Sanderson,	,	I
V.;	:	I
Corless,	,	I
M.;	:	I
Stobie,	,	I
A.;	:	I
Middleton,	,	I
D.	NNP	I
S.;	:	I
Foster,	,	I
L.;	:	I
Barker,	,	I
L.;	:	I
Graaf,	,	I
P.	NNP	I
V.	NNP	I
D.;	:	I
Stacey,	,	I
P.;	:	I
Kohl,	,	I
C.;	:	I
Coggon,	,	I
S.;	:	I
Beaumont,	,	I
K.	NNP	I
“Novel	NNP	I
Selective	NNP	I
Inhibitors	NNP	I
of	IN	I
Neutral	NNP	I
Endopeptidase	NNP	I
for	IN	I
the	DT	I
Treatment	NNP	I
of	IN	I
Female	NNP	I
Sexual	NNP	I
Arousal	NNP	I
Disorder.”	NNP	I
Bioor.	.	I
Med.	.	I
Chem.	.	I
2007,	,	I
15,	,	I
142.)Carboxylic	)	O
acids	JJ	O
6a-c	NNS	O
were	CD	O
converted	VBD	O
to	VBN	O
Boc-protected	TO	O
amines	JJ	O
(7a-c)	NNS	O
through	)	O
Curtius	IN	O
rearrangement	NNP	O
reactions	JJ	O
in	NNS	O
reasonable	IN	O
yields.	JJ	O
(See,	.	O
Tchilibon,	,	O
S.,	,	O
et	,	O
al.,	FW	O
supra.)	,	O
Finally,	)	O
the	,	O
Boc-protecting	DT	O
groups	NNP	O
of	NNS	O
7a-c	IN	O
were	JJ	O
removed	VBD	O
in	VBN	O
trifluoroacetic	IN	O
acid	JJ	O
(TFA)	NN	O
to	)	O
provide	TO	O
3a-c	VB	O
as	JJ	O
TFA	IN	O
salts	NNP	O
in	NNS	O
high	IN	O
yields.	JJ	O
The	.	O
two	DT	O
enantiomers	CD	O
of	NNS	O
3c	IN	O
were	CD	O
resolved	VBD	O
through	VBN	O
their	IN	O
camphanic	PRP$	O
amides	JJ	O
(Scheme	NNS	O
1c).	NNP	O
First	.	O
the	RB	O
racemic	DT	O
mixture	JJ	O
of	NN	O
3c	IN	O
was	CD	O
treated	VBD	O
with	VBN	O
(S)-(−)	IN	O
camphanic	)	O
chloride	NN	O
in	NN	O
the	IN	O
presence	DT	O
of	NN	O
triethylamine	IN	O
(TEA)	NN	O
to	)	O
generate	TO	O
two	VB	O
separable	CD	O
diastereomers	JJ	O
8a	NNS	O
and	CD	O
8b	CC	O
in	CD	O
high	IN	O
yields.	JJ	O
Next,	.	O
the	,	O
amide	DT	O
bonds	JJ	O
of	NNS	O
8a	IN	O
and	CD	O
8b	CC	O
were	CD	O
hydrolyzed	VBD	O
in	VBN	O
concentrated	IN	O
HCl	JJ	O
to	NNP	O
provide	TO	O
single	VB	O
enantiomers	JJ	O
3d	NNS	O
and	CD	O
3e	CC	O
in	CD	O
good	IN	O
yields.	JJ	O
As	.	O
illustrated	IN	O
in	VBN	O
Scheme	IN	O
1d,	NNP	O
reductive	,	O
amination	JJ	O
of	NN	O
aldehyde	IN	O
8	JJ	O
with	CD	O
amines	IN	O
3a-d	NNS	O
using	CD	O
NaHB(OAc)3	VBG	O
as	CD	O
a	IN	O
reducing	DT	O
reagent	VBG	O
gave	NN	O
9a-d	VBD	O
in	CD	O
high	IN	O
yields.	JJ	O
Next,	.	O
the	,	O
three	DT	O
Boc-protecting	CD	O
groups	JJ	O
of	NNS	O
9a-d	IN	O
were	CD	O
removed	VBD	O
in	VBN	O
HCl	IN	O
to	NNP	O
yield	TO	O
the	VB	O
final	DT	O
inhibitors	JJ	O
(2ba-bd)	NNS	O
in	)	O
excellent	IN	O
yields.	JJ	O
For	.	O
purpose	IN	O
of	NN	O
comparison	IN	O
and	NN	O
to	CC	O
demonstrate	TO	O
the	VB	O
relative	DT	O
effectiveness	JJ	O
of	NN	O
inhibitors	IN	O
2a-d,	NNS	O
compound	,	O
10	VBD	O
was	CD	O
synthesized	VBD	O
as	VBN	O
shown	IN	O
in	VBN	O
Scheme	IN	O
1e.	NNP	O
Reductive	.	O
amination	JJ	O
of	NN	O
aldehyde	IN	O
11	JJ	O
with	CD	O
amine	IN	O
3e	JJ	O
provided	CD	O
the	VBD	O
corresponding	DT	O
secondary	JJ	O
amine,	JJ	O
which	,	O
was	WDT	O
then	VBD	O
protected	RB	O
by	VBN	O
a	IN	O
Boc-protecting	DT	O
group	NNP	O
to	NN	O
give	TO	O
12	VB	O
in	CD	O
reasonable	IN	O
yields.	JJ	O
Catalytic	.	O
hydrogenation	JJ	O
of	NN	O
12	IN	O
using	CD	O
Pd(OH)2/C	VBG	O
as	CD	O
a	IN	O
catalyst	DT	O
at	NN	O
60°	IN	O
C.	CD	O
removed	NNP	O
the	VBD	O
Bn-protecting	DT	O
group.	NNP	O
At	.	O
the	IN	O
same	DT	O
time,	JJ	O
the	,	O
cyclopropyl	DT	O
group	NN	O
was	NN	O
reduced	VBD	O
to	VBN	O
generate	TO	O
compound	VB	O
13	NN	O
as	CD	O
a	IN	O
single	DT	O
enantiomer.	JJ	O
Finally,	.	O
the	,	O
three	DT	O
Boc-protecting	CD	O
groups	JJ	O
were	NNS	O
removed	VBD	O
in	VBN	O
HCl	IN	O
to	NNP	O
provide	TO	O
inhibitor	VB	O
10	NN	O
as	CD	O
an	IN	O
HCl	DT	O
salt	NNP	O
in	NN	O
good	IN	O
yields.	JJ	O
As	.	O
shown	IN	O
in	VBN	O
Scheme	IN	O
2,	NNP	O
the	,	O
synthesis	DT	O
of	NN	O
4c	IN	O
began	CD	O
with	VBD	O
3-fluorostyrene	IN	O
10.	JJ	O
Bromofluorination	.	O
of	NN	O
10	IN	O
using	CD	O
NBS	VBG	O
and	NNP	O
Et3N.3HF	CC	O
generated	NNP	O
1-(2-bromo-1-fluoroethyl)-3-fluorobenzene	VBD	O
11	VBZ	O
in	CD	O
a	IN	O
high	DT	O
yield.	JJ	O
(See,	.	O
Rosen,	,	O
T.	,	O
C.;	NNP	O
Yoshida,	:	O
S.;	,	O
Fröhlich,	:	O
R.;	,	O
Kirk,	:	O
K.	,	O
L.;	NNP	O
Haufe,	:	O
G.	,	O
Fluorinated	NNP	O
phenylcyclopropylamines.	NNP	O
2.	.	O
Effects	.	O
of	NNS	O
aromatic	IN	O
ring	JJ	O
substitution	NN	O
and	NN	O
of	CC	O
absolute	IN	O
configuration	JJ	O
on	NN	O
inhibition	IN	O
of	NN	O
microbial	IN	O
tyramine	JJ	O
oxidase.	NN	O
J.	.	O
Med.	NNP	O
Chem.	.	O
2004,	.	O
47,	,	O
5860-5871.)	,	O
Next,	)	O
11	,	O
was	CD	O
converted	VBD	O
to	VBN	O
azide	TO	O
(12)	VB	O
using	)	O
NaN3	VBG	O
in	NNP	O
DMSO	IN	O
at	NNP	O
65°	IN	O
C.	CD	O
in	NNP	O
a	IN	O
good	DT	O
yield.	JJ	O
(Other	.	O
solvents	JJ	O
such	NNS	O
as	JJ	O
THF	IN	O
and	NNP	O
DMF	CC	O
did	NNP	O
not	VBD	O
give	RB	O
satisfactory	VB	O
yields.)	JJ	O
Finally,	)	O
catalytic	,	O
hydrogenation	JJ	O
of	NN	O
12	IN	O
in	CD	O
a	IN	O
mixture	DT	O
of	NN	O
EtOH	IN	O
and	NNP	O
1	CC	O
N	CD	O
HCl	NNP	O
(2:1)	NNP	O
provided	)	O
4c	VBD	O
as	CD	O
a	IN	O
HCl	DT	O
salt	NNP	O
in	NN	O
an	IN	O
excellent	DT	O
yield.	JJ	O
Generally,	.	O
a	,	O
representative	DT	O
synthesis	JJ	O
of	NN	O
a	IN	O
difluoroethanamine	DT	O
is	NN	O
as	VBZ	O
shown	IN	O
in	VBN	O
Scheme	IN	O
3.	NNP	O
2-Bromo-3′-fluoroacetophenone	.	O
13	CD	O
was	CD	O
treated	VBD	O
with	VBN	O
diethylaminosulfur	IN	O
trifluoride	JJ	O
(DAST)	NN	O
to	)	O
give	TO	O
1-(2-bromo-1,1-difluoroethyl)-3-fluorobenzene	VB	O
14	VBZ	O
in	CD	O
good	IN	O
yield.	JJ	O
(See,	.	O
Lakshmipathi,	,	O
P.;	,	O
Crévisy,	:	O
C.;	,	O
Grée,	:	O
R.	,	O
Reaction	NNP	O
monitoring	NNP	O
in	NN	O
LPOS	IN	O
by	NNP	O
19F	IN	O
NMR.	CD	O
Study	.	O
of	NNP	O
soluble	IN	O
polymer	JJ	O
supports	NN	O
with	NNS	O
fluorine	IN	O
in	NN	O
spacer	IN	O
or	NN	O
linker	CC	O
components	NN	O
of	NNS	O
supports.	IN	O
J.	.	O
Comb.	NNP	O
Chem.	.	O
2002,	.	O
4,	,	O
612-621.)	,	O
Next,	)	O
14	,	O
was	CD	O
allowed	VBD	O
to	VBN	O
react	TO	O
with	VB	O
NaN3	IN	O
in	NNP	O
DMSO	IN	O
at	NNP	O
110°	IN	O
C.	CD	O
to	NNP	O
give	TO	O
azide	VB	O
(15)	NN	O
in	)	O
a	IN	O
good	DT	O
yield.	JJ	O
Finally,	.	O
15	,	O
was	CD	O
subjected	VBD	O
to	VBN	O
catalytic	TO	O
hydrogenation	JJ	O
under	NN	O
acidic	IN	O
conditions	JJ	O
to	NNS	O
give	TO	O
4d	VB	O
as	CD	O
an	IN	O
HCl	DT	O
salt	NNP	O
in	NN	O
a	IN	O
good	DT	O
yield.	JJ	O
With	.	O
4a-d	IN	O
in	JJ	O
hand,	IN	O
the	,	O
syntheses	DT	O
of	NNS	O
inhibitors	IN	O
2a-d	NNS	O
were	JJ	O
completed	VBD	O
using	VBN	O
a	VBG	O
three-step	DT	O
procedure	JJ	O
(Scheme	NN	O
4).	NNP	O
First,	.	O
reductive	,	O
amination	JJ	O
between	NN	O
3	IN	O
and	CD	O
4a-d	CC	O
using	JJ	O
NaHB(OAc)3	VBG	O
gave	CD	O
16a-d	VBD	O
in	CD	O
modest	IN	O
yields.	JJ	O
To	.	O
simplify	TO	O
the	VB	O
purification	DT	O
process,	NN	O
the	,	O
resulting	DT	O
secondary	VBG	O
amines	JJ	O
(16a-d)	NNS	O
were	)	O
protected	VBD	O
with	VBN	O
(Boc)2O	IN	O
to	CD	O
give	TO	O
17a-d.	VB	O
Finally,	.	O
the	,	O
Bn-protecting	DT	O
group	NNP	O
and	NN	O
the	CC	O
three	DT	O
Boc-protecting	CD	O
groups	JJ	O
were	NNS	O
removed	VBD	O
at	VBN	O
the	IN	O
same	DT	O
time	JJ	O
in	NN	O
a	IN	O
mixture	DT	O
of	NN	O
EtOH	IN	O
and	NNP	O
12	CC	O
N	CD	O
HCl	NNP	O
(2:1)	NNP	O
under	)	O
high	IN	O
pressure	JJ	O
catalytic	NN	O
hydrogenation	JJ	O
conditions	NN	O
to	NNS	O
provide	TO	O
2a-d	VB	O
as	JJ	O
HCl	IN	O
salts	NNP	O
in	NNS	O
good	IN	O
yields.	JJ	O
Alternatively,	.	O
as	,	O
a	IN	O
variation	DT	O
on	NN	O
the	IN	O
aforementioned	DT	O
embodiments,	JJ	O
enantiomerically-pure	,	O
inhibitors	JJ	O
can	NNS	O
be	MD	O
prepared,	VB	O
examples	,	O
of	NNS	O
which	IN	O
are	WDT	O
shown	VBP	O
below.	VBN	O
(As	.	O
a	IN	O
departure	DT	O
from	NN	O
the	IN	O
aforementioned	DT	O
general	JJ	O
numbering	JJ	O
format,	NN	O
the	,	O
following	DT	O
compounds	JJ	O
4-10	NNS	O
are	JJ	O
illustrated	VBP	O
in	VBN	O
Schemes	IN	O
5-8	NNP	O
(and	JJ	O
described	CC	O
in	VBN	O
examples	IN	O
43-57)	NNS	O
en	)	O
route	FW	O
to	NN	O
several	TO	O
non-limiting	JJ	O
representative	JJ	O
variations	JJ	O
of	NNS	O
inhibitor	IN	O
compound	NN	O
2d;	NN	O
for	:	O
instance,	IN	O
enantiomerically	,	O
difluoromethylene	RB	O
inhibitors	JJ	O
2da-2dd	NNS	O
in	JJ	O
Scheme	IN	O
6,	NNP	O
below.	,	O
Synthesis	.	O
of	NN	O
enantiomerically	IN	O
pure	RB	O
pyrrolidine	JJ	O
core	NN	O
(4a-b)	NN	O
is	)	O
shown	VBZ	O
in	VBN	O
Scheme	IN	O
5.	NNP	O
First,	.	O
the	,	O
racemic	DT	O
trans-alcohol	JJ	O
5	NN	O
underwent	CD	O
a	NN	O
Mitsunobu	DT	O
reaction	NNP	O
using	NN	O
(S)-(−)	VBG	O
camphanic	)	O
acid	NN	O
as	NN	O
a	IN	O
nucleophile	DT	O
to	NN	O
produce	TO	O
two	VB	O
separable	CD	O
diastereomers	JJ	O
(6a	NNS	O
and	CD	O
6b)	CC	O
in	)	O
excellent	IN	O
yields.	JJ	O
Next,	.	O
the	,	O
ester	DT	O
linkage	NN	O
in	NN	O
6a	IN	O
and	CD	O
6b	CC	O
was	CD	O
hydrolyzed	VBD	O
in	VBN	O
aqueous	IN	O
Na2CO3	JJ	O
to	NNP	O
generate	TO	O
4a	VB	O
and	CD	O
4b	CC	O
in	CD	O
high	IN	O
yields.	JJ	O
As	.	O
shown	IN	O
in	VBN	O
Scheme	IN	O
6,	NNP	O
single	,	O
enantiomer	JJ	O
4a	NN	O
or	CD	O
4b	CC	O
was	CD	O
treated	VBD	O
with	VBN	O
NaH,	IN	O
and	,	O
the	CC	O
resulting	DT	O
anion	VBG	O
was	NN	O
allowed	VBD	O
to	VBN	O
react	TO	O
with	VB	O
allyl	IN	O
bromide	JJ	O
to	NN	O
generate	TO	O
7a	VB	O
and	CD	O
7b	CC	O
in	CD	O
excellent	IN	O
yields.	JJ	O
Ozonolysis	.	O
of	NN	O
7a	IN	O
and	CD	O
7b	CC	O
using	CD	O
Zn	VBG	O
dust	NNP	O
as	NN	O
reducing	IN	O
reagent	VBG	O
yielded	NN	O
8a	VBD	O
and	CD	O
8b	CC	O
in	CD	O
good	IN	O
yields.	JJ	O
Aldehydes	.	O
8a	NNS	O
or	CD	O
8b	CC	O
were	CD	O
subjected	VBD	O
to	VBN	O
reductive	TO	O
amination	VB	O
reactions	NN	O
with	NNS	O
different	IN	O
ethanamines	JJ	O
in	NNS	O
the	IN	O
presence	DT	O
of	NN	O
NaHB(OAc)3	IN	O
to	CD	O
generate	TO	O
secondary	VB	O
amines,	JJ	O
which	,	O
were	WDT	O
further	VBD	O
protected	RBR	O
by	VBN	O
another	IN	O
Boc-protecting	DT	O
group	NNP	O
to	NN	O
produce	TO	O
the	VB	O
fully	DT	O
protected	RB	O
inhibitors	JJ	O
9a-d	NNS	O
in	CD	O
good	IN	O
yields.	JJ	O
Next,	.	O
the	,	O
benzyl-protecting	DT	O
group	JJ	O
was	NN	O
removed	VBD	O
by	VBN	O
a	IN	O
catalytic	DT	O
hydrogenation	JJ	O
reaction	NN	O
using	NN	O
Pd(OH)2	VBG	O
at	CD	O
60°	IN	O
C.	CD	O
to	NNP	O
provide	TO	O
10a-d	VB	O
in	JJ	O
modest	IN	O
yields.	JJ	O
Finally,	.	O
the	,	O
three	DT	O
Boc-protecting	CD	O
groups	JJ	O
were	NNS	O
removed	VBD	O
at	VBN	O
the	IN	O
same	DT	O
time	JJ	O
in	NN	O
HCl	IN	O
to	NNP	O
generate	TO	O
inhibitors	VB	O
2da-2dd	NNS	O
in	JJ	O
high	IN	O
yields.	JJ	O
As	.	O
relates	IN	O
to	NNS	O
the	TO	O
binding	DT	O
studies	NN	O
discussed	NNS	O
below,	VBN	O
inhibitor	,	O
compounds	NN	O
2e-f	NNS	O
were	JJ	O
also	VBD	O
prepared.	RB	O
The	.	O
synthesis	DT	O
of	NN	O
inhibitor	IN	O
2e	NN	O
began	CD	O
with	VBD	O
9a	IN	O
(Scheme	CD	O
7).	NNP	O
Catalytic	.	O
hydrogenation	JJ	O
of	NN	O
9a	IN	O
using	CD	O
Pd(OH)2	VBG	O
at	CD	O
accelerated	IN	O
temperature	JJ	O
removed	NN	O
the	VBD	O
benzyl-protecting	DT	O
group,	JJ	O
and	,	O
at	CC	O
the	IN	O
same	DT	O
time,	JJ	O
the	,	O
pyridinyl	DT	O
ring	NN	O
was	NN	O
reduced	VBD	O
to	VBN	O
generate	TO	O
10e	VB	O
in	CD	O
modest	IN	O
yields.	JJ	O
Then,	.	O
three	,	O
Boc-protecting	CD	O
groups	JJ	O
were	NNS	O
removed	VBD	O
in	VBN	O
HCl	IN	O
to	NNP	O
generate	TO	O
inhibitor	VB	O
2e	NN	O
in	CD	O
high	IN	O
yields.	JJ	O
The	.	O
synthesis	DT	O
of	NN	O
inhibitor	IN	O
2f	NN	O
is	CD	O
shown	VBZ	O
in	VBN	O
Scheme	IN	O
8.	NNP	O
Reductive	.	O
amination	JJ	O
of	NN	O
aldehyde	IN	O
8b	JJ	O
with	CD	O
2,2-difluoro-2-(pyridin-2-yl)ethanamine	IN	O
(e.g.,	NN	O
as	,	O
prepared	RB	O
as	JJ	O
described	IN	O
above)	VBN	O
generated	)	O
a	VBD	O
secondary	DT	O
amine,	JJ	O
which	,	O
was	WDT	O
further	VBD	O
protected	RBR	O
by	VBN	O
another	IN	O
Boc-protecting	DT	O
group	NNP	O
to	NN	O
provide	TO	O
9f	VB	O
in	CD	O
good	IN	O
yields.	JJ	O
Next,	.	O
catalytic	,	O
hydrogenation	JJ	O
of	NN	O
9f	IN	O
removed	CD	O
the	VBD	O
benzyl	DT	O
protecting	NN	O
group,	VBG	O
and	,	O
also	CC	O
reduced	RB	O
the	VBD	O
pyridinyl	DT	O
group	NN	O
adjacent	NN	O
to	VBD	O
the	TO	O
CF2	DT	O
group	NNP	O
to	NN	O
generate	TO	O
10f	VB	O
in	CD	O
modest	IN	O
yields.	JJ	O
Finally,	.	O
the	,	O
three	DT	O
Boc-protecting	CD	O
groups	JJ	O
were	NNS	O
removed	VBD	O
at	VBN	O
the	IN	O
same	DT	O
time	JJ	O
in	NN	O
HCl	IN	O
to	NNP	O
generate	TO	O
the	VB	O
final	DT	O
inhibitor	JJ	O
2f	NN	O
in	CD	O
high	IN	O
yields.	JJ	O
Crystal	.	O
Structures	JJ	O
of	NNS	O
nNOS	IN	O
Bound	JJ	O
with	NNP	O
Inhibitor	IN	O
Compounds	NNP	O
2da-2dd	NNP	O
and	JJ	O
2e-f	CC	O
Consistent	JJ	O
with	NNP	O
the	IN	O
binding	DT	O
preference	VBG	O
of	NN	O
the	IN	O
enantiomerically	DT	O
pure	JJ	O
parental	JJ	O
compound	JJ	O
1,	NN	O
the	,	O
binding	DT	O
mode	VBG	O
of	NN	O
these	IN	O
difluorine	DT	O
derivatives	JJ	O
was	NNS	O
found	VBD	O
also	VBN	O
to	RB	O
be	TO	O
dependent	VB	O
on	JJ	O
the	IN	O
configuration	DT	O
around	NN	O
the	IN	O
two	DT	O
chiral	CD	O
centers:	JJ	O
the	:	O
3′	DT	O
and	CD	O
4′	CC	O
positions	CD	O
of	NNS	O
the	IN	O
pyrrolidine	DT	O
ring.	NN	O
While	.	O
the	IN	O
(S,S)	DT	O
inhibitor	)	O
2da	NN	O
was	CD	O
found	VBD	O
to	VBN	O
bind	TO	O
with	VB	O
its	IN	O
aminopyridine	PRP$	O
moiety	NN	O
hydrogen	NN	O
bonded	NN	O
to	VBD	O
the	TO	O
side	DT	O
chain	NN	O
of	NN	O
Glu592	IN	O
in	NNP	O
nNOS	IN	O
(FIG.	NN	O
2A),	.	O
the	,	O
(R,R)	DT	O
inhibitor	)	O
2db	NN	O
adopted	CD	O
a	VBD	O
‘flipped’	DT	O
binding	JJ	O
mode	NN	O
with	NN	O
its	IN	O
aminopyridine	PRP$	O
making	NN	O
bifurcated	NN	O
hydrogen	VBD	O
bonds	JJ	O
with	NNS	O
the	IN	O
heme	DT	O
propionate	NN	O
off	VB	O
pyrrole	RP	O
ring	JJ	O
D	NN	O
(FIG.	NNP	O
2B).	.	O
To	.	O
leave	TO	O
room	VB	O
for	NN	O
these	IN	O
new	DT	O
hydrogen	JJ	O
bonds,	NN	O
the	,	O
Tyr706	DT	O
side	NNP	O
chain	NN	O
rotates	NN	O
away	VBZ	O
and	RB	O
stacks	CC	O
against	NNS	O
the	IN	O
aminopyridine	DT	O
ring	JJ	O
of	NN	O
inhibitor.	IN	O
The	.	O
pyrrolidine	DT	O
nitrogen	NN	O
in	NN	O
2db	IN	O
also	CD	O
makes	RB	O
favorable	VBZ	O
hydrogen	JJ	O
bonds	JJ	O
with	NNS	O
propionate	IN	O
A	NN	O
as	NN	O
well	RB	O
as	RB	O
the	IN	O
O4	DT	O
atom	NNP	O
of	NN	O
H4B.	IN	O
In	.	O
comparison,	IN	O
the	,	O
pyrrolidine	DT	O
nitrogen	NN	O
in	NN	O
2da	IN	O
was	CD	O
only	VBD	O
loosely	RB	O
hydrogen	RB	O
bonded	NN	O
to	VBD	O
Glu592.	TO	O
The	.	O
long,	DT	O
flexible	,	O
linker	JJ	O
extending	NN	O
from	VBG	O
the	IN	O
pyrrolidine	DT	O
allowed	NN	O
the	VBD	O
tail	DT	O
fluorophenyl	NN	O
group	NN	O
in	NN	O
2db	IN	O
to	CD	O
reach	TO	O
the	VB	O
vicinity	DT	O
of	NN	O
Glu592	IN	O
and	NNP	O
to	CC	O
stack	TO	O
against	VB	O
the	IN	O
heme	DT	O
plane.	NN	O
The	.	O
amino	DT	O
group	NN	O
adjacent	NN	O
to	VBD	O
the	TO	O
CF2	DT	O
moiety	NNP	O
points	NN	O
toward	NNS	O
the	IN	O
Glu592	DT	O
side	NNP	O
chain,	NN	O
causing	,	O
the	VBG	O
formation	DT	O
of	NN	O
an	IN	O
alternate	DT	O
conformation	JJ	O
of	NN	O
the	IN	O
carboxylate	DT	O
to	NN	O
make	TO	O
a	VB	O
hydrogen	DT	O
bond	NN	O
between	NN	O
the	IN	O
amino	DT	O
nitrogen	NN	O
and	NN	O
the	CC	O
carboxylate	DT	O
oxygen	NN	O
(FIG.	NN	O
2B).	.	O
This	.	O
alternate	DT	O
conformation	JJ	O
of	NN	O
Glu592	IN	O
was	NNP	O
not	VBD	O
observed	RB	O
in	VBN	O
structure	IN	O
of	NN	O
nNOS	IN	O
bound	JJ	O
with	NN	O
2da	IN	O
because	CD	O
the	IN	O
tight	DT	O
bifurcated	JJ	O
hydrogen	JJ	O
bonds	NN	O
from	NNS	O
the	IN	O
inhibitor	DT	O
aminopyridine	NN	O
to	NN	O
the	TO	O
carboxylate	DT	O
of	NN	O
Glu592	IN	O
made	NNP	O
a	VBD	O
perfect	DT	O
match	JJ	O
to	NN	O
the	TO	O
original	DT	O
conformation	JJ	O
of	NN	O
the	IN	O
Glu	DT	O
side	NNP	O
chain.	NN	O
The	.	O
fit	DT	O
of	NN	O
the	IN	O
fluorophenyl	DT	O
group	NN	O
in	NN	O
2db	IN	O
to	CD	O
the	TO	O
site	DT	O
of	NN	O
Glu592	IN	O
is	NNP	O
not	VBZ	O
that	RB	O
ideal	IN	O
and	NN	O
in	CC	O
order	IN	O
to	NN	O
avoid	TO	O
close	VB	O
van	JJ	O
der	JJ	O
Waals	NN	O
contacts	NNS	O
with	NNS	O
the	IN	O
inhibitor,	DT	O
Glu592	,	O
adopts	NNP	O
an	VBZ	O
alternate	DT	O
conformation.	JJ	O
In	.	O
addition,	IN	O
the	,	O
fluorophenyl	DT	O
tail	NN	O
part	JJ	O
of	NN	O
2db	IN	O
is	CD	O
disordered	VBZ	O
as	VBN	O
indicated	IN	O
by	VBN	O
the	IN	O
weak	DT	O
electron	JJ	O
density	NN	O
for	NN	O
this	IN	O
group.	DT	O
When	.	O
only	WRB	O
one	RB	O
conformation	CD	O
of	NN	O
the	IN	O
tail	DT	O
was	NN	O
modeled	VBD	O
with	VBN	O
the	IN	O
two	DT	O
fluorine	CD	O
atoms	NN	O
pointing	NNS	O
away	VBG	O
from	RB	O
the	IN	O
heme	DT	O
plane,	NN	O
strong	,	O
negative	JJ	O
difference	JJ	O
density	NN	O
was	NN	O
clustered	VBD	O
around	VBN	O
fluorine	IN	O
atoms.	NN	O
Also,	.	O
the	,	O
electron	DT	O
density	NN	O
of	NN	O
the	IN	O
fluorophenyl	DT	O
ring	NN	O
could	NN	O
not	MD	O
be	RB	O
accounted	VB	O
for	VBN	O
with	IN	O
only	IN	O
one	JJ	O
ring	CD	O
orientation.	NN	O
The	.	O
tail	DT	O
portion	JJ	O
of	NN	O
2db	IN	O
was,	CD	O
therefore,	,	O
modeled	,	O
with	VBN	O
two	IN	O
different	CD	O
conformations	JJ	O
(0.6	NNS	O
and	CD	O
0.4	CC	O
occupancy)	CD	O
as	)	O
shown	IN	O
in	VBN	O
FIG.	IN	O
2B.	.	O
There	.	O
is	EX	O
a	VBZ	O
partially	DT	O
occupied	RB	O
water	JJ	O
molecule	NN	O
bridging	NN	O
between	VBG	O
the	IN	O
heme	DT	O
propionate	NN	O
and	NN	O
the	CC	O
amino	DT	O
group	NN	O
in	NN	O
the	IN	O
tail	DT	O
portion	JJ	O
of	NN	O
2db	IN	O
in	CD	O
its	IN	O
minor	PRP$	O
conformation.	JJ	O
In	.	O
contrast,	IN	O
the	,	O
fluorophenyl	DT	O
ring	NN	O
in	NN	O
2da	IN	O
fit	CD	O
in	NN	O
a	IN	O
pocket	DT	O
surrounded	NN	O
by	VBN	O
Met336,	IN	O
Leu337,	,	O
and	,	O
Tyr706	CC	O
(FIG.	NNP	O
2A),	.	O
but	,	O
the	CC	O
density	DT	O
for	NN	O
2da	IN	O
was	CD	O
clear	VBD	O
only	JJ	O
up	RB	O
to	RB	O
the	TO	O
position	DT	O
of	NN	O
the	IN	O
two	DT	O
fluorine	CD	O
atoms	NN	O
but	NNS	O
too	CC	O
poor	RB	O
toward	JJ	O
the	IN	O
end	DT	O
to	NN	O
give	TO	O
a	VB	O
definite	DT	O
fluorophenyl	JJ	O
ring	NN	O
orientation.	VBG	O
Inhibitor	.	O
2dc	NN	O
has	CD	O
its	VBZ	O
fluorine	PRP$	O
position	JJ	O
in	NN	O
the	IN	O
phenyl	DT	O
ring	NN	O
changed	VBG	O
from	VBN	O
the	IN	O
meta-	DT	O
in	NN	O
2db	IN	O
to	CD	O
the	TO	O
para-position.	DT	O
This	.	O
new	DT	O
position	JJ	O
of	NN	O
fluorine	IN	O
makes	NN	O
the	VBZ	O
tail	DT	O
portion	JJ	O
a	NN	O
bit	DT	O
longer	NN	O
in	RBR	O
2dc	IN	O
than	CD	O
in	IN	O
2db,	IN	O
which	,	O
resulted	WDT	O
in	VBD	O
a	IN	O
conformation	DT	O
with	NN	O
the	IN	O
two	DT	O
fluorine	CD	O
atoms	NN	O
pointing	NNS	O
downward	VBG	O
to	RB	O
the	TO	O
heme	DT	O
plane	NN	O
(FIG.	NN	O
3A).	.	O
This	.	O
conformation	DT	O
disrupts	NN	O
the	VBZ	O
hydrogen	DT	O
bond	NN	O
between	NN	O
the	IN	O
inhibitor	DT	O
amino	NN	O
group	NN	O
and	NN	O
Glu	CC	O
side	NNP	O
chain	NN	O
seen	NN	O
in	VBN	O
the	IN	O
major	DT	O
conformation	JJ	O
in	NN	O
2db,	IN	O
but	,	O
similar	CC	O
to	JJ	O
its	TO	O
minor	PRP$	O
conformation.	JJ	O
Inhibitor	.	O
2dd	NN	O
is	CD	O
a	VBZ	O
derivative	DT	O
of	JJ	O
2db	IN	O
and	CD	O
differs	CC	O
only	NNS	O
by	RB	O
the	IN	O
absence	DT	O
of	NN	O
the	IN	O
fluorine	DT	O
on	NN	O
the	IN	O
phenyl	DT	O
ring.	NN	O
Its	.	O
binding	PRP$	O
mode	NN	O
to	NN	O
nNOS	TO	O
is,	NN	O
therefore,	,	O
almost	,	O
identical	RB	O
to	JJ	O
that	TO	O
of	DT	O
2db	IN	O
(FIG.	CD	O
3B).	.	O
Without	.	O
the	IN	O
fluoro	DT	O
group	NN	O
the	NN	O
phenyl	DT	O
ring	NN	O
makes	NN	O
a	VBZ	O
looser	DT	O
contact	JJR	O
with	NN	O
the	IN	O
hydrophobic	DT	O
pocket	NN	O
defined	NN	O
by	VBN	O
Pro565,	IN	O
Va1567,	,	O
and	,	O
Phe584.	CC	O
The	.	O
phenyl	DT	O
tail	NN	O
portion	NN	O
in	NN	O
2db	IN	O
exhibits	CD	O
two	NNS	O
alternate	CD	O
conformations	VBP	O
similar	NNS	O
to	JJ	O
what	TO	O
is	WP	O
observed	VBZ	O
for	VBN	O
2db.	IN	O
Inhibitor	.	O
2e	NN	O
has	CD	O
its	VBZ	O
aminopyridine	PRP$	O
ring	JJ	O
partially	NN	O
reduced	RB	O
from	VBN	O
that	IN	O
in	DT	O
2dd,	IN	O
which	,	O
has	WDT	O
a	VBZ	O
negligible	DT	O
impact	JJ	O
on	NN	O
the	IN	O
binding	DT	O
mode	NN	O
of	NN	O
the	IN	O
inhibitor	DT	O
compared	NN	O
to	VBN	O
2dd	TO	O
(FIG.	CD	O
3C).	.	O
The	.	O
amino	DT	O
and	NN	O
the	CC	O
ring	DT	O
nitrogens	NN	O
remain	NNS	O
planar	VBP	O
and	JJ	O
are	CC	O
still	VBP	O
tightly	RB	O
hydrogen	RB	O
bonded	NN	O
to	VBD	O
the	TO	O
heme	DT	O
propionate	NN	O
off	VB	O
pyrrole	RP	O
D	JJ	O
and	NNP	O
the	CC	O
pyrrolidine	DT	O
nitrogen	NN	O
hydrogen	NN	O
bonded	NN	O
to	VBD	O
propionate	TO	O
A	VB	O
and	NNP	O
H4B.	CC	O
As	.	O
in	IN	O
2db	IN	O
and	CD	O
2dd,	CC	O
the	,	O
phenyl	DT	O
tail	NN	O
in	NN	O
2e	IN	O
shows	CD	O
two	NNS	O
conformations	CD	O
above	NNS	O
the	IN	O
heme	DT	O
plane	NN	O
while	NN	O
the	IN	O
Glu592	DT	O
side	NNP	O
chain	NN	O
has	NN	O
two	VBZ	O
conformations,	CD	O
correspondingly.	,	O
Another	.	O
(S,S)	DT	O
inhibitor,	)	O
2f,	,	O
is	,	O
similar	VBZ	O
to	JJ	O
2da	TO	O
except	CD	O
the	IN	O
fluorophenyl	DT	O
tail	NN	O
has	NN	O
been	VBZ	O
replaced	VBN	O
by	VBN	O
a	IN	O
piperidine	DT	O
ring.	NN	O
The	.	O
binding	DT	O
of	NN	O
2f	IN	O
is	CD	O
similar	VBZ	O
to	JJ	O
2da	TO	O
with	CD	O
its	IN	O
aminopyridine	PRP$	O
hydrogen	NN	O
bonded	NN	O
to	VBD	O
the	TO	O
Glu592	DT	O
side	NNP	O
chain	NN	O
while	NN	O
the	IN	O
piperidine	DT	O
ring	NN	O
fits	VBG	O
to	NNS	O
the	TO	O
pocket	DT	O
of	NN	O
Met336,	IN	O
Leu337,	,	O
and	,	O
Tyr706	CC	O
(FIG.	NNP	O
3D).	.	O
The	.	O
density	DT	O
for	NN	O
the	IN	O
tail	DT	O
portion	NN	O
is	NN	O
good	VBZ	O
only	JJ	O
up	RB	O
to	RB	O
the	TO	O
CF2	DT	O
moiety	NNP	O
with	NN	O
the	IN	O
piperidine	DT	O
partially	NN	O
disordered.	RB	O
Therefore,	.	O
the	,	O
orientation	DT	O
of	NN	O
the	IN	O
ring	DT	O
(position	NN	O
of	NN	O
nitrogen)	IN	O
is	)	O
not	VBZ	O
well	RB	O
defined.	RB	O
Crystal	.	O
Structures	JJ	O
of	NNS	O
eNOS	IN	O
Bound	NN	O
with	NNP	O
Inhibitor	IN	O
Compounds	NNP	O
2db	NNP	O
and	CD	O
2f	CC	O
The	CD	O
eNOS	DT	O
structure	NN	O
bound	NN	O
with	NN	O
the	IN	O
(R,R)	DT	O
inhibitor	)	O
2db	NN	O
(FIG.	CD	O
4A)	.	O
adopted	)	O
a	VBD	O
‘flipped’	DT	O
binding	JJ	O
mode,	NN	O
the	,	O
same	DT	O
orientation	JJ	O
as	NN	O
in	IN	O
nNOS.	IN	O
The	.	O
Tyr477	DT	O
side	NNP	O
chain	NN	O
rotates	NN	O
out,	VBZ	O
but	,	O
is	CC	O
farther	VBZ	O
away	RB	O
in	RB	O
eNOS	IN	O
and	NN	O
therefore	CC	O
does	RB	O
not	VBZ	O
experience	RB	O
optimized	VB	O
n-stacking	JJ	O
interactions	JJ	O
with	NNS	O
the	IN	O
aminopyridine	DT	O
of	NN	O
inhibitor	IN	O
observed	NN	O
in	VBN	O
nNOS.	IN	O
Similar	.	O
to	JJ	O
what	TO	O
was	WP	O
seen	VBD	O
in	VBN	O
nNOS,	IN	O
the	,	O
aminopyridine	DT	O
in	NN	O
2db	IN	O
makes	CD	O
bifurcated	VBZ	O
hydrogen	VBN	O
bonds	JJ	O
with	NNS	O
the	IN	O
heme	DT	O
propionate	NN	O
off	VB	O
pyrrole	RP	O
ring	JJ	O
D,	NN	O
while	,	O
the	IN	O
pyrrolidine	DT	O
nitrogen	JJ	O
makes	NN	O
favorable	VBZ	O
hydrogen	JJ	O
bonds	JJ	O
with	NNS	O
propionate	IN	O
A	NN	O
as	NN	O
well	RB	O
as	RB	O
the	IN	O
O4	DT	O
atom	NNP	O
of	NN	O
H4B	IN	O
(FIG.	NNP	O
4A).	.	O
A	.	O
hydrogen	DT	O
bond	NN	O
between	NN	O
the	IN	O
inhibitor	DT	O
amino	NN	O
group	NN	O
with	NN	O
alternate	IN	O
conformations	JJ	O
for	NNS	O
Glu363	IN	O
also	NNP	O
is	RB	O
observed.	VBZ	O
With	.	O
the	IN	O
available	DT	O
density	JJ	O
at	NN	O
the	IN	O
limited	DT	O
resolution	JJ	O
only	NN	O
one	RB	O
conformation	CD	O
of	NN	O
the	IN	O
fluorophenyl	DT	O
tail	JJ	O
portion	NN	O
can	NN	O
be	MD	O
modeled.	VB	O
The	.	O
binding	DT	O
of	NN	O
the	IN	O
(S,S)	DT	O
inhibitor	)	O
2f	NN	O
in	CD	O
eNOS	IN	O
is	NN	O
similar	VBZ	O
to	JJ	O
nNOS,	TO	O
with	,	O
its	IN	O
aminopyridine	PRP$	O
hydrogen	NN	O
bonded	NN	O
to	VBD	O
the	TO	O
Glu363	DT	O
side	NNP	O
chain	NN	O
(FIG.	NN	O
4B)	.	O
in	)	O
the	IN	O
standard	DT	O
binding	JJ	O
mode.	NN	O
The	.	O
pyrrolidine	DT	O
nitrogen	NN	O
also	NN	O
hydrogen	RB	O
bonds	JJ	O
with	NNS	O
the	IN	O
conserved	DT	O
glutamate	JJ	O
residue,	NN	O
but	,	O
the	CC	O
density	DT	O
for	NN	O
the	IN	O
tail	DT	O
portion	NN	O
is	NN	O
good	VBZ	O
only	JJ	O
up	RB	O
to	RB	O
the	TO	O
CF2	DT	O
moiety	NNP	O
with	NN	O
the	IN	O
piperidine	DT	O
partially	NN	O
disordered.	RB	O
Therefore,	.	O
the	,	O
orientation	DT	O
of	NN	O
the	IN	O
ring	DT	O
(position	NN	O
of	NN	O
nitrogen)	IN	O
and	)	O
the	CC	O
exact	DT	O
configuration	JJ	O
of	NN	O
the	IN	O
puckered	DT	O
ring	JJ	O
are	NN	O
not	VBP	O
clear.	RB	O
Inhibitors	.	O
2a-d	NNS	O
were	CD	O
evaluated	VBD	O
for	VBN	O
in	IN	O
vitro	IN	O
inhibition	JJ	O
against	NN	O
three	IN	O
isozymes	CD	O
of	NNS	O
NOS:	IN	O
rat	:	O
nNOS,	NN	O
bovine	,	O
eNOS	JJ	O
and	NN	O
murine	CC	O
iNOS	NN	O
using	NN	O
known	VBG	O
methods.	VBN	O
Hevel,	.	B
J.	,	I
M.;	NNP	I
Marletta,	:	I
M.	,	I
A.	NNP	I
Nitric-oxide	NNP	I
synthase	NNP	I
assays.	NN	I
Method	.	I
Enzymol.	NNP	I
1994,	.	I
233,	,	I
250-258)	,	I
(Inhibitor	)	O
2a,	NNP	O
with	,	O
an	IN	O
electronegative	DT	O
oxygen	JJ	O
atom	NN	O
inserted	NN	O
into	VBN	O
the	IN	O
lipophilic	DT	O
tail	JJ	O
of	NN	O
1,	IN	O
has	,	O
K,	VBZ	O
values	,	O
of	NNS	O
86	IN	O
nM,	CD	O
21	,	O
μM,	CD	O
and	,	O
18	CC	O
μM	CD	O
for	NN	O
nNOS,	IN	O
eNOS,	,	O
and	,	O
iNOS,	CC	O
respectively	,	O
(Table	RB	O
2).	JJ	O
Compared	.	O
to	VBN	O
the	TO	O
lead	DT	O
compound	NN	O
(I),	NN	O
inhibitor	,	O
2a	JJ	O
is	CD	O
almost	VBZ	O
six-fold	RB	O
less	JJ	O
potent,	RBR	O
while	,	O
the	IN	O
selectivity	DT	O
of	NN	O
this	IN	O
inhibitor	DT	O
for	NN	O
nNOS	IN	O
over	NN	O
eNOS	IN	O
and	NN	O
iNOS	CC	O
decreases	NN	O
by	NNS	O
ten	IN	O
fold	JJ	O
and	NN	O
three	CC	O
fold,	CD	O
respectively.	,	O
There	.	O
may	EX	O
be	MD	O
two	VB	O
considerations	CD	O
with	NNS	O
respect	IN	O
to	NN	O
these	TO	O
results.	DT	O
First,	.	O
compound	,	O
2a	NN	O
is	CD	O
one	VBZ	O
atom	CD	O
longer	NN	O
than	JJR	O
1,	IN	O
which	,	O
probably	WDT	O
makes	RB	O
it	VBZ	O
too	PRP	O
long	RB	O
to	RB	O
fit	TO	O
snugly	VB	O
into	RB	O
the	IN	O
active	DT	O
site	JJ	O
of	NN	O
nNOS.	IN	O
Moreover,	.	O
it	,	O
has	PRP	O
been	VBZ	O
shown	VBN	O
previously	VBN	O
that	RB	O
the	IN	O
positively	DT	O
charged	RB	O
amine	VBN	O
functionality	JJ	O
in	NN	O
the	IN	O
lipophilic	DT	O
tail	JJ	O
plays	NN	O
an	VBZ	O
important	DT	O
role	JJ	O
for	NN	O
tight	IN	O
binding	JJ	O
of	NN	O
1	IN	O
to	CD	O
nNOS,	TO	O
therefore,	,	O
partial	,	O
removal	JJ	O
of	NN	O
the	IN	O
positive	DT	O
charge	JJ	O
from	NN	O
this	IN	O
group	DT	O
may	NN	O
impair	MD	O
the	VB	O
activity	DT	O
of	NN	O
inhibitors	IN	O
Inhibitor	NNS	O
2b,	NNP	O
with	,	O
a	IN	O
cyclopropyl	DT	O
functionality	NN	O
in	NN	O
the	IN	O
lipophilic	DT	O
tail	JJ	O
is	NN	O
more	VBZ	O
potent	RBR	O
and	JJ	O
selective	CC	O
than	JJ	O
2a,	IN	O
retaining	,	O
the	VBG	O
high	DT	O
potency	JJ	O
and	NN	O
selectivity	CC	O
of	NN	O
1.	IN	O
Inhibitor	.	O
2c,	NN	O
with	,	O
monofluoromethylene	IN	O
adjacent	JJ	O
to	NN	O
the	TO	O
basic	DT	O
amino	JJ	O
group,	NN	O
shows	,	O
even	VBZ	O
better	RB	O
potency	RBR	O
for	NN	O
nNOS	IN	O
and	NN	O
excellent	CC	O
selectivity	JJ	O
for	NN	O
nNOS	IN	O
over	NN	O
eNOS	IN	O
and	NN	O
iNOS.	CC	O
Finally,	.	O
inhibitor	,	O
2d,	NN	O
with	,	O
a	IN	O
difluoromethylene	DT	O
in	NN	O
the	IN	O
lipophilic	DT	O
tail	JJ	O
of	NN	O
1,	IN	O
exhibited	,	O
a	VBD	O
2.2-fold	DT	O
drop	JJ	O
in	NN	O
potency	IN	O
relative	NN	O
to	NN	O
2c.	TO	O
The	.	O
introduction	DT	O
of	NN	O
the	IN	O
strongly	DT	O
electron-withdrawing	RB	O
difluoromethylene	JJ	O
group	NN	O
can	NN	O
significantly	MD	O
remove	RB	O
the	VB	O
positive	DT	O
charge	JJ	O
on	NN	O
the	IN	O
amino	DT	O
group	NN	O
in	NN	O
the	IN	O
lipophilic	DT	O
tail,	JJ	O
which	,	O
decreases	WDT	O
its	VBZ	O
ability	PRP$	O
for	NN	O
electrostatic	IN	O
interaction	JJ	O
with	NN	O
the	IN	O
heme	DT	O
carboxylate.	NN	O
However,	.	O
inhibitor	,	O
2d	NN	O
still	CD	O
showed	RB	O
very	VBD	O
good	RB	O
selectivity	JJ	O
for	NN	O
nNOS	IN	O
over	NN	O
eNOS	IN	O
and	NN	O
iNOS.	CC	O
From	.	O
the	IN	O
foregoing,	DT	O
the	,	O
three	DT	O
best	CD	O
inhibitors	JJS	O
(2b,	NNS	O
2c,	,	O
and	,	O
2d)	CC	O
from	)	O
this	IN	O
group	DT	O
of	NN	O
embodiments	IN	O
were	NNS	O
chosen,	VBD	O
together	,	O
with	RB	O
compound	IN	O
(I),	NN	O
to	,	O
test	TO	O
their	VB	O
potency	PRP$	O
in	NN	O
a	IN	O
cell-based	DT	O
assay.	JJ	O
This	.	O
assay	DT	O
can	NN	O
provide	MD	O
valuable	VB	O
data	JJ	O
about	NNS	O
membrane	IN	O
permeability.	NN	O
The	.	O
results	DT	O
are	NNS	O
summarized	VBP	O
in	VBN	O
Table	IN	O
3.	JJ	O
The	.	O
IC50	DT	O
values	NNP	O
of	NNS	O
inhibitors	IN	O
2b,	NNS	O
2c,	,	O
and	,	O
2d	CC	O
are	CD	O
comparable	VBP	O
to	JJ	O
that	TO	O
of	DT	O
compound	IN	O
1.	NN	O
The	.	O
ratios	DT	O
of	NNS	O
inhibition	IN	O
of	NN	O
purified	IN	O
nNOS	JJ	O
versus	JJ	O
the	IN	O
cell-based	DT	O
assay	JJ	O
(IC50/IC50(cell))	NN	O
were	)	O
calculated,	VBD	O
which	,	O
indicate	WDT	O
the	VBP	O
relative	DT	O
membrane	JJ	O
permeability	NN	O
of	NN	O
different	IN	O
inhibitors	JJ	O
(Table	NNS	O
3).	JJ	O
The	.	O
IC50/IC50(cell)	DT	O
values	)	O
of	NNS	O
all	IN	O
three	DT	O
low	CD	O
pKa	JJ	O
inhibitors	NN	O
are	NNS	O
higher	VBP	O
than	JJR	O
compound	IN	O
1,	NN	O
which	,	O
indicates	WDT	O
that	VBZ	O
by	IN	O
partially	IN	O
removing	RB	O
the	VBG	O
positive	DT	O
charge	JJ	O
on	NN	O
the	IN	O
amino	DT	O
group	NN	O
in	NN	O
1,	IN	O
inhibitors	,	O
with	NNS	O
improved	IN	O
cell	JJ	O
permeability	NN	O
can	NN	O
be	MD	O
achieved.	VB	O
Specifically,	.	O
inhibitor	,	O
2b	NN	O
shows	CD	O
a	VBZ	O
2.4-fold	DT	O
increase	JJ	O
through	NN	O
cells	IN	O
membrane	NNS	O
permeation	JJ	O
relative	NN	O
to	NN	O
1,	TO	O
while	,	O
inhibitors	IN	O
2c	NNS	O
and	CD	O
2d	CC	O
exhibited	CD	O
1.7-fold	VBN	O
and	JJ	O
2.0-fold	CC	O
increased	JJ	O
penetration,	JJ	O
respectively.	,	O
A	.	O
comparison	DT	O
of	NN	O
the	IN	O
IC50/IC50(cell)	DT	O
values	)	O
between	VBZ	O
2c	IN	O
and	CD	O
2d	CC	O
demonstrates	CD	O
that	NNS	O
the	IN	O
stronger	DT	O
difluoromethylene	JJR	O
electron-withdrawing	JJ	O
group,	JJ	O
which	,	O
significantly	WDT	O
decreased	RB	O
the	VBD	O
pKa	DT	O
compared	NN	O
to	VBN	O
the	TO	O
monofluoromethylene	DT	O
group,	NN	O
greatly	,	O
improved	RB	O
cell	VBN	O
permeability.	NN	O
Inhibitory	.	O
Assays	NNP	O
and	NNP	O
Structure-Based	CC	O
Evaluation	JJ	O
To	NN	O
continue	TO	O
the	VB	O
study,	DT	O
inhibitors	,	O
2da-2dd	NNS	O
and	CD	O
2e-2f	CC	O
were	CD	O
evaluated	VBD	O
for	VBN	O
in	IN	O
vitro	IN	O
inhibition	JJ	O
activities	NN	O
against	NNS	O
three	IN	O
isozymes	CD	O
of	NNS	O
NOSs	IN	O
including	NNP	O
rat	VBG	O
nNOS,	NN	O
bovine	,	O
eNOS	JJ	O
and	NN	O
murine	CC	O
iNOS	NN	O
(see,	NN	O
Havel,	,	O
supra)	,	O
as	)	O
summarized	IN	O
in	VBN	O
Table	IN	O
4.	JJ	O
Compared	.	O
to	VBN	O
the	TO	O
racemic	DT	O
compound	JJ	O
2d,	NN	O
the	,	O
(S,S)	DT	O
enantiomer	)	O
2da	VBP	O
is	CD	O
a	VBZ	O
weak	DT	O
inhibitor	JJ	O
for	NN	O
nNOS	IN	O
with	NN	O
the	IN	O
Ki	DT	O
values	NNP	O
of	NNS	O
390	IN	O
nM,	CD	O
which	,	O
is	WDT	O
five-fold	VBZ	O
less	JJ	O
potent	RBR	O
than	JJ	O
2d.	IN	O
In	.	O
addition,	IN	O
the	,	O
selectivity	DT	O
of	NN	O
this	IN	O
inhibitor	DT	O
for	NN	O
nNOS	IN	O
over	NN	O
eNOS	IN	O
and	NN	O
iNOS	CC	O
also	NN	O
decreases	RB	O
by	VBZ	O
3-fold	IN	O
and	JJ	O
2-fold,	CC	O
respectively.	,	O
The	.	O
(R,R)	DT	O
enantiomer	)	O
2db,	VBD	O
however,	,	O
shows	,	O
excellent	VBZ	O
potency	JJ	O
for	NN	O
nNOS	IN	O
(Ki=36	NN	O
nM)	NNP	O
and	)	O
remarkable	CC	O
selectivity	JJ	O
over	NN	O
eNOS	IN	O
(3800-fold)	NN	O
and	)	O
iNOS	CC	O
(1400-fold).	JJ	O
These	.	O
results	DT	O
indicate	NNS	O
that	VBP	O
the	IN	O
chirality	DT	O
around	NN	O
the	IN	O
cis-chiral	DT	O
pyrrolidine	JJ	O
core	NN	O
plays	NN	O
a	VBZ	O
key	DT	O
role	JJ	O
in	NN	O
determining	IN	O
the	VBG	O
potency	DT	O
and	NN	O
selectivity	CC	O
of	NN	O
inhibitors,	IN	O
as	,	O
we	IN	O
have	PRP	O
observed	VBP	O
for	VBN	O
another	IN	O
series	DT	O
of	NN	O
trans-	IN	O
or	JJ	O
cis-chiral	CC	O
pyrrolidine	JJ	O
inhibitors	NN	O
(1).	NNS	O
The	.	O
potency	DT	O
and	NN	O
selectivity	CC	O
shown	NN	O
with	VBN	O
the	IN	O
racemic	DT	O
compound	JJ	O
2d	NN	O
can	CD	O
be	MD	O
attributed	VB	O
mainly	VBN	O
to	RB	O
the	TO	O
(R,R)	DT	O
component	)	O
2db.	NN	O
We	.	O
now	PRP	O
know	RB	O
that	VBP	O
a	IN	O
large	DT	O
difference	JJ	O
in	NN	O
binding	IN	O
affinity	VBG	O
between	NN	O
2da	IN	O
and	CD	O
2db	CC	O
originates	CD	O
from	NNS	O
two	IN	O
different	CD	O
binding	JJ	O
modes.	VBG	O
(1)	.	O
The	)	O
flipped	DT	O
binding	JJ	O
mode	NN	O
of	NN	O
2db	IN	O
relative	CD	O
to	JJ	O
2da	TO	O
allows	CD	O
both	NNS	O
aminopyridine	DT	O
and	NN	O
pyrrolidine	CC	O
nitrogen	NN	O
atoms	NN	O
to	NNS	O
make	TO	O
extensive	VB	O
hydrogen	JJ	O
bonds	NN	O
with	NNS	O
the	IN	O
heme	DT	O
and	NN	O
H4B	CC	O
(FIG.	NNP	O
2B).	.	O
In	.	O
addition,	IN	O
as	,	O
we	IN	O
have	PRP	O
argued	VBP	O
elsewhere,	VBN	O
(1)	,	O
the	)	O
conformation	DT	O
of	NN	O
2da	IN	O
when	CD	O
bound	WRB	O
to	NN	O
NOS	TO	O
places	NNP	O
the	VBZ	O
pyrrolidine	DT	O
N	NN	O
atom	NNP	O
very	VBZ	O
close	RB	O
to	RB	O
the	TO	O
aminopyridine	DT	O
and	NN	O
owing	CC	O
to	VBG	O
electrostatic	TO	O
repulsion,	JJ	O
this	,	O
aminopyridine	DT	O
is	NN	O
only	VBZ	O
partially	RB	O
protonated.	RB	O
However,	.	O
in	,	O
the	IN	O
2db	DT	O
flipped	CD	O
orientation	VBD	O
the	NN	O
aminopyridine	DT	O
is	NN	O
farther	VBZ	O
from	RB	O
the	IN	O
pyrrolidine	DT	O
N	NN	O
atom	NNP	O
and	NN	O
remains	CC	O
fully	VBZ	O
protonated.	RB	O
Thus,	.	O
the	,	O
2db	DT	O
conformation	CD	O
provides	NN	O
greater	VBZ	O
electrostatic	JJR	O
stabilization	JJ	O
than	NN	O
the	IN	O
2da	DT	O
conformation	CD	O
which	NN	O
accounts	WDT	O
for	VBZ	O
the	IN	O
10-fold	DT	O
lower	JJ	O
K,	JJR	O
of	,	O
2db	IN	O
than	CD	O
2da.	IN	O
As	.	O
a	IN	O
p-fluorophenyl	DT	O
derivative	JJ	O
of	NN	O
2db,	IN	O
inhibitor	,	O
2dc	NN	O
shows	CD	O
a	VBZ	O
significant	DT	O
drop	JJ	O
in	NN	O
potency	IN	O
for	NN	O
nNOS	IN	O
(Ki=160	NN	O
nM),	NNP	O
which	,	O
is	WDT	O
4.5-fold	VBZ	O
less	JJ	O
potent	RBR	O
than	JJ	O
2db.	IN	O
More	.	O
interestingly,	RBR	O
2dc	,	O
also	CD	O
loses	RB	O
most	VBZ	O
of	JJS	O
the	IN	O
selectivity	DT	O
over	NN	O
eNOS	IN	O
and	NN	O
iNOS	CC	O
of	NN	O
2db	IN	O
by	CD	O
moving	IN	O
one	VBG	O
single	CD	O
F	JJ	O
atom	NNP	O
from	NN	O
the	IN	O
m-position	DT	O
to	NN	O
the	TO	O
p-position	DT	O
of	NN	O
the	IN	O
phenyl	DT	O
tail.	NN	O
The	.	O
new	DT	O
fluorine	JJ	O
position	JJ	O
leads	NN	O
to	VBZ	O
a	TO	O
‘difluorine-down’	DT	O
binding	JJ	O
mode	NN	O
of	NN	O
the	IN	O
inhibitor's	DT	O
phenyl	POS	O
tail.	JJ	O
As	.	O
a	IN	O
result,	DT	O
the	,	O
hydrogen	DT	O
bond	NN	O
between	NN	O
the	IN	O
Glu592	DT	O
side	NNP	O
chain	NN	O
and	NN	O
the	CC	O
amino	DT	O
nitrogen	NN	O
in	NN	O
the	IN	O
tail	DT	O
seen	NN	O
in	VBN	O
2db	IN	O
has	CD	O
been	VBZ	O
eliminated,	VBN	O
which	,	O
may	WDT	O
explain	MD	O
the	VB	O
weaker	DT	O
potency	JJR	O
of	NN	O
2dc.	IN	O
Inhibitor	.	O
2dd,	NN	O
with	,	O
the	IN	O
substituent	DT	O
F	NN	O
atom	NNP	O
removed	NN	O
from	VBD	O
the	IN	O
phenyl	DT	O
tail,	NN	O
has	,	O
restored	VBZ	O
good	VBN	O
potency	JJ	O
for	NN	O
nNOS	IN	O
(Ki=85	NN	O
nM)	NNP	O
and	)	O
high	CC	O
isozyme-selectivity	JJ	O
(1500-fold	NN	O
over	JJ	O
eNOS	IN	O
and	JJ	O
1000-fold	CC	O
over	JJ	O
iNOS).	IN	O
This	.	O
is	DT	O
because	VBZ	O
2dd	RB	O
has	CD	O
retained	VBZ	O
the	VBN	O
binding	DT	O
mode	VBG	O
of	NN	O
2db.	IN	O
The	.	O
only	DT	O
difference	JJ	O
is	NN	O
that	VBZ	O
without	IN	O
a	IN	O
fluorine	DT	O
on	NN	O
the	IN	O
phenyl	DT	O
ring	NN	O
the	VBG	O
van	DT	O
der	NN	O
Waals	NN	O
contacts	NNP	O
to	VBZ	O
the	TO	O
protein	DT	O
(Pro565,	NN	O
Va1567,	,	O
and	,	O
Phe584)	CC	O
are	)	O
less	VBP	O
optimal	RBR	O
compared	JJ	O
to	VBN	O
that	TO	O
for	DT	O
2db.	IN	O
This	.	O
results	DT	O
in	NNS	O
a	IN	O
bit	DT	O
less	NN	O
potency	JJR	O
and	NN	O
selectivity	CC	O
for	NN	O
2dd	IN	O
than	CD	O
2db.	IN	O
The	.	O
amidino	DT	O
inhibitor	NN	O
2e,	NN	O
with	,	O
the	IN	O
aromatic	DT	O
system	JJ	O
of	NN	O
the	IN	O
aminopyridine	DT	O
fragment	JJ	O
partially	NN	O
reduced,	RB	O
exhibits	,	O
a	VBZ	O
2-fold	DT	O
drop	JJ	O
in	NN	O
potency	IN	O
against	NN	O
nNOS	IN	O
compared	RB	O
to	VBN	O
2dd.	TO	O
This	.	O
result	DT	O
demonstrates	NN	O
that	VBZ	O
π-π	IN	O
stacking	JJ	O
in	NN	O
2dd	IN	O
between	CD	O
the	IN	O
aromatic	DT	O
aminopyridine	JJ	O
ring	NN	O
and	NN	O
the	CC	O
Tyr706	DT	O
side	NNP	O
chain	NN	O
contributes	NN	O
to	VBZ	O
its	TO	O
tighter	PRP$	O
binding.	NN	O
Moreover,	.	O
the	,	O
removal	DT	O
of	NN	O
the	IN	O
aromatic	DT	O
system	JJ	O
of	NN	O
the	IN	O
aminopyridine	DT	O
ring	JJ	O
from	NN	O
inhibitor	IN	O
2dd	NN	O
makes	CD	O
2e	VBZ	O
binds	CD	O
more	NNS	O
than	RBR	O
3-fold	IN	O
better	JJ	O
to	NN	O
iNOS	TO	O
thus	VB	O
exhibiting	RB	O
a	VBG	O
much	DT	O
less	RB	O
selectivity.	JJR	O
Finally,	.	O
inhibitor	,	O
2f,	NN	O
with	,	O
a	IN	O
(S,S)	DT	O
configuration	)	O
of	NN	O
the	IN	O
pyrrolidine	DT	O
core	NN	O
and	NN	O
a	CC	O
piperidinyl	DT	O
tail,	NN	O
showed	,	O
poor	VBD	O
inhibition	JJ	O
activity	NN	O
and	NN	O
isozyme-selectivity.	CC	O
Both	.	O
2da	DT	O
and	CD	O
2f	CC	O
have	CD	O
a	VBP	O
similar	DT	O
binding	JJ	O
orientation	NN	O
and	NN	O
rather	CC	O
poor	RB	O
potency	JJ	O
among	NN	O
the	IN	O
inhibitors	DT	O
reported	NNS	O
in	VBD	O
this	IN	O
work.	DT	O
This	.	O
result	DT	O
emphasizes	NN	O
again	VBZ	O
that	RB	O
the	IN	O
chirality	DT	O
of	NN	O
the	IN	O
pyrrolidine	DT	O
core	NN	O
is	NN	O
the	VBZ	O
key	DT	O
to	NN	O
higher	TO	O
inhibitory	JJR	O
activity	JJ	O
with	NN	O
(R,R)	IN	O
inhibitors.	)	O
In	.	O
addition,	IN	O
a	,	O
less	DT	O
polar	JJR	O
aromatic	JJ	O
ring	JJ	O
such	NN	O
as	JJ	O
the	IN	O
fluoro-phenyl	DT	O
group	JJ	O
in	NN	O
2da	IN	O
seems	CD	O
to	VBZ	O
fit	TO	O
better	VB	O
in	RBR	O
to	IN	O
the	TO	O
pocket	DT	O
surrounded	NN	O
by	VBN	O
Met336,	IN	O
Leu337,	,	O
and	,	O
Tyr706	CC	O
in	NNP	O
nNOS	IN	O
than	NN	O
does	IN	O
the	VBZ	O
polar	DT	O
piperidinyl	JJ	O
ring	NN	O
in	NN	O
2f.	IN	O
However,	.	O
both	,	O
2da	DT	O
and	CD	O
2f	CC	O
bind	CD	O
to	NN	O
eNOS	TO	O
with	VB	O
similar	IN	O
potency	JJ	O
possibly	NN	O
because	RB	O
of	IN	O
the	IN	O
smaller	DT	O
Va1106	JJR	O
side	NNP	O
chain	NN	O
in	NN	O
the	IN	O
pocket	DT	O
in	NN	O
eNOS	IN	O
compared	NN	O
to	VBN	O
Met336	TO	O
in	NNP	O
nNOS.	IN	O
Isoform	.	O
selection	NNP	O
from	NN	O
the	IN	O
inhibitors	DT	O
in	NNS	O
Table	IN	O
4	JJ	O
is	CD	O
not	VBZ	O
a	RB	O
straightforward	DT	O
structure-based	JJ	O
determination.	JJ	O
For	.	O
instance,	IN	O
for	,	O
any	IN	O
particular	DT	O
inhibitor	JJ	O
among	NN	O
those	IN	O
reported	DT	O
in	VBN	O
Table	IN	O
4	JJ	O
the	CD	O
binding	DT	O
mode	NN	O
in	NN	O
eNOS	IN	O
is	NN	O
no	VBZ	O
different	DT	O
from	JJ	O
that	IN	O
seen	DT	O
in	VBN	O
nNOS.	IN	O
As	.	O
discussed	IN	O
for	VBN	O
another	IN	O
series	DT	O
of	NN	O
chiral	IN	O
pyrrolidine	JJ	O
containing	NN	O
inhibitors,	VBG	O
one	,	O
of	CD	O
the	IN	O
potential	DT	O
reasons	JJ	O
for	NNS	O
the	IN	O
isoform	DT	O
selectivity	NN	O
shown	NN	O
by	VBN	O
2db	IN	O
is	CD	O
the	VBZ	O
difference	DT	O
in	NN	O
stacking	IN	O
interaction	VBG	O
between	NN	O
the	IN	O
aminopyridine	DT	O
and	NN	O
Tyr706	CC	O
in	NNP	O
nNOS	IN	O
(or	NN	O
Tyr	CC	O
477	NNP	O
in	CD	O
eNOS).	IN	O
It	.	O
has	PRP	O
been	VBZ	O
consistently	VBN	O
observed	RB	O
that	VBN	O
tighter	IN	O
interactions	JJR	O
between	NNS	O
this	IN	O
Tyr	DT	O
and	NNP	O
the	CC	O
aminopyridine	DT	O
with	NN	O
nNOS	IN	O
complexed	JJ	O
with	NN	O
inhibitors	IN	O
that	NNS	O
adopt	WDT	O
the	VBP	O
2db	DT	O
flipped	CD	O
orientation.	VBD	O
(Data	.	O
not	NNP	O
presented	RB	O
herein.)	VBD	O
In	)	O
part,	IN	O
as	,	O
demonstrated	IN	O
above,	VBN	O
the	,	O
present	DT	O
invention	JJ	O
provides	NN	O
a	VBZ	O
new	DT	O
series	JJ	O
of	NN	O
selective	IN	O
nNOS	JJ	O
inhibitors	NN	O
(e.g.,	NNS	O
2da-2dd	,	O
and	JJ	O
2e-2f)	CC	O
with	)	O
monocationic	IN	O
character	JJ	O
and,	NN	O
therefore,	,	O
better	,	O
bioavailability.	JJR	O
Biological	.	O
evaluation	JJ	O
of	NN	O
these	IN	O
new	DT	O
inhibitors	JJ	O
based	NNS	O
on	VBN	O
crystal	IN	O
structures	JJ	O
suggests,	NNS	O
for	,	O
instance,	IN	O
use	,	O
of	NN	O
inhibitor	IN	O
2db,	NN	O
which	,	O
not	WDT	O
only	RB	O
retains	RB	O
most	VBZ	O
of	JJS	O
the	IN	O
inhibitory	DT	O
activity	JJ	O
of	NN	O
the	IN	O
compound	DT	O
2d,	NN	O
but	,	O
also	CC	O
shows	RB	O
remarkable	VBZ	O
selectivity	JJ	O
for	NN	O
nNOS	IN	O
over	NN	O
both	IN	O
eNOS	DT	O
and	NNS	O
iNOS.	CC	O
Accordingly,	.	O
this	,	O
invention	DT	O
represents	NN	O
an	VBZ	O
advancement	DT	O
toward	NN	O
the	IN	O
goal	DT	O
of	NN	O
developing	IN	O
drugs	VBG	O
with	NNS	O
therapeutic	IN	O
potential	JJ	O
in	NN	O
treatment	IN	O
of	NN	O
diseases	IN	O
caused	NNS	O
by	VBN	O
unregulated	IN	O
NO	JJ	O
generation	NNP	O
from	NN	O
nNOS.	IN	O
EXAMPLES	.	O
OF	NNS	O
THE	IN	O
INVENTION	DT	O
The	NNP	O
following	DT	O
non-limiting	JJ	O
examples	JJ	O
and	NNS	O
data	CC	O
illustrate	NNS	O
various	VBP	O
aspects	JJ	O
and	NNS	O
features	CC	O
relating	NNS	O
to	VBG	O
the	TO	O
compounds,	DT	O
compositions	,	O
and/or	NNS	O
methods	VBP	O
of	NNS	O
the	IN	O
present	DT	O
invention,	JJ	O
including	,	O
the	VBG	O
preparation	DT	O
and	NN	O
use	CC	O
of	NN	O
various	IN	O
selective	JJ	O
neuronal	JJ	O
nitric	JJ	O
oxide	JJ	O
synthase	IN	O
inhibitors,	NN	O
as	,	O
are	IN	O
available	VBP	O
through	JJ	O
the	IN	O
synthetic	DT	O
methodologies	JJ	O
described	NNS	O
herein.	VBD	O
In	.	O
comparison	IN	O
with	NN	O
the	IN	O
prior	DT	O
art,	JJ	O
the	,	O
present	DT	O
compounds,	JJ	O
compositions	,	O
and/or	NNS	O
methods	VBP	O
provide	NNS	O
results	VBP	O
and	NNS	O
data	CC	O
which	NNS	O
are	WDT	O
surprising,	VBP	O
unexpected	,	O
and	JJ	O
contrary	CC	O
thereto.	JJ	O
While	.	O
the	IN	O
utility	DT	O
of	NN	O
this	IN	O
invention	DT	O
is	NN	O
illustrated	VBZ	O
through	VBN	O
use	IN	O
of	NN	O
several	IN	O
compounds	JJ	O
and	NNS	O
moieties,	CC	O
groups	,	O
or	NNS	O
substituents	CC	O
(e.g.,	NNS	O
halide,	,	O
alkyl,	,	O
etc.)	,	O
thereof,	)	O
it	,	O
will	PRP	O
be	MD	O
understood	VB	O
by	VBN	O
those	IN	O
skilled	DT	O
in	VBN	O
the	IN	O
art	DT	O
that	NN	O
comparable	WDT	O
results	JJ	O
are	NNS	O
obtainable	VBP	O
with	JJ	O
various	IN	O
other	JJ	O
compounds	JJ	O
and	NNS	O
moieties/groups/substituents	CC	O
(e.g.,	NNS	O
substituted	,	O
alkyl,	VBD	O
etc.),	,	O
as	,	O
are	IN	O
commensurate	VBP	O
with	JJ	O
the	IN	O
scope	DT	O
of	NN	O
this	IN	O
invention	DT	O
and	NN	O
would	CC	O
be	MD	O
understood	VB	O
by	VBN	O
those	IN	O
skilled	DT	O
in	VBN	O
the	IN	O
art	DT	O
and	NN	O
made	CC	O
aware	VBD	O
of	NN	O
this	IN	O
invention—using	DT	O
synthetic	JJ	O
techniques	JJ	O
of	NNS	O
the	IN	O
sort	DT	O
described	NN	O
herein	VBD	O
or	NN	O
in	CC	O
the	IN	O
incorporated	DT	O
references	JJ	O
or	NNS	O
straight-forward	CC	O
modifications	JJ	O
thereof,	NNS	O
such	,	O
techniques	JJ	O
limited	NNS	O
only	VBN	O
by	RB	O
available	IN	O
reagents	JJ	O
and	NNS	O
starting	CC	O
materials.	VBG	O
All	.	O
syntheses	DT	O
were	NNS	O
conducted	VBD	O
under	VBN	O
anhydrous	IN	O
conditions	JJ	O
in	NNS	O
an	IN	O
atmosphere	DT	O
of	NN	O
argon,	IN	O
using	,	O
flame-dried	VBG	O
apparatus	JJ	O
and	NN	O
employing	CC	O
standard	VBG	O
techniques	JJ	O
in	NNS	O
handling	IN	O
air	VBG	O
sensitive	NN	O
materials.	JJ	O
All	.	O
solvents	DT	O
were	NNS	O
distilled	VBD	O
and	VBN	O
stored	CC	O
under	VBN	O
an	IN	O
argon	DT	O
or	NN	O
nitrogen	CC	O
atmosphere	NN	O
before	RB	O
using.	IN	O
All	.	O
reagents	DT	O
were	NNS	O
used	VBD	O
as	VBN	O
received.	IN	O
Aqueous	.	O
solutions	JJ	O
of	NNS	O
sodium	IN	O
bicarbonate,	NN	O
sodium	,	O
chloride	NN	O
(brine),	NN	O
and	,	O
ammonium	CC	O
chloride	NN	O
were	NN	O
saturated.	VBD	O
Analytical	.	O
thin	NNP	O
layer	JJ	O
chromatography	NN	O
was	NN	O
visualized	VBD	O
by	VBN	O
ultraviolet,	IN	O
ninhydrin,	,	O
or	,	O
phosphomolybdic	CC	O
acid	JJ	O
(PMA).	NN	O
Flash	.	O
column	NNP	O
chromatography	NN	O
was	NN	O
carried	VBD	O
out	VBN	O
under	RP	O
a	IN	O
positive	DT	O
pressure	JJ	O
of	NN	O
nitrogen.	IN	O
1H	.	O
NMR	CD	O
spectra	NNP	O
were	NN	O
recorded	VBD	O
on	VBN	O
500	IN	O
MHz	CD	O
spectrometers.	NNP	O
Data	.	O
are	NNS	O
presented	VBP	O
as	VBN	O
follows:	IN	O
chemical	:	O
shift	NN	O
(in	NN	O
ppm	IN	O
on	NN	O
the	IN	O
δ	DT	O
scale	NNP	O
relative	NN	O
to	NN	O
δ=0.00	TO	O
ppm	VB	O
for	NN	O
the	IN	O
protons	DT	O
in	NNS	O
TMS),	IN	O
integration,	,	O
multiplicity	,	O
(s=singlet,	NN	O
d=doublet,	,	O
t=triplet,	,	O
q=quartet,	,	O
m=multiplet,	,	O
br=broad),	,	O
coupling	,	O
constant	VBG	O
(J/Hz).	JJ	O
Coupling	.	O
constants	VBG	O
were	NNS	O
taken	VBD	O
directly	VBN	O
from	RB	O
the	IN	O
spectra	DT	O
and	NN	O
are	CC	O
uncorrected.	VBP	O
13C	.	O
NMR	CD	O
spectra	NNP	O
were	NN	O
recorded	VBD	O
at	VBN	O
125	IN	O
MHz,	CD	O
and	,	O
all	CC	O
chemical	DT	O
shift	NN	O
values	NN	O
are	NNS	O
reported	VBP	O
in	VBN	O
ppm	IN	O
on	NN	O
the	IN	O
δ	DT	O
scale,	NNP	O
with	,	O
an	IN	O
internal	DT	O
reference	JJ	O
of	NN	O
δ	IN	O
77.0	$	O
or	CD	O
49.0	CC	O
for	CD	O
CDCl3	IN	O
or	NNP	O
MeOD,	CC	O
respectively.	,	O
High-resolution	.	O
mass	NNP	O
spectra	NN	O
were	NN	O
measured	VBD	O
on	VBN	O
liquid	IN	O
chromatography/time	NN	O
of	NN	O
flight	IN	O
mass	NN	O
spectrometry	NN	O
(LC-TOF).	NN	O
Characterization	.	O
of	NN	O
New	IN	O
Compounds	NNP	O
Example	NNP	O
1	NNP	O
(E)-Methyl	CD	O
3-(3-fluorophenyl)acrylate	VBZ	O
(6).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
(E)-3-(3-fluorophenyl)acrylic	IN	O
acid	JJ	O
(5,	NN	O
6.0	,	O
g,	CD	O
32.7	,	O
mmol)	CD	O
in	)	O
MeOH	IN	O
(150	NNP	O
mL)	CD	O
at	)	O
0°	IN	O
C.	CD	O
was	NNP	O
added	VBD	O
concentrated	VBN	O
H2SO4	JJ	O
(3.0	NNP	O
mL)	CD	O
slowly.	)	O
The	.	O
reaction	DT	O
was	NN	O
heated	VBD	O
under	VBN	O
reflux	IN	O
for	NN	O
24	IN	O
h	CD	O
then	NN	O
cooled	RB	O
to	VBD	O
room	TO	O
temperature	NN	O
and	NN	O
neutralized	CC	O
with	VBN	O
Na2CO3	IN	O
(1.0	NNP	O
g).	CD	O
The	.	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation	JJ	O
and	NN	O
the	CC	O
resulting	DT	O
yellow	VBG	O
oil	JJ	O
partitioned	NN	O
between	VBN	O
EtOAc	IN	O
(300	NNP	O
mL)	CD	O
and	)	O
saturated	CC	O
NaHCO3	VBN	O
(300	NNP	O
mL).	CD	O
The	.	O
aqueous	DT	O
layer	JJ	O
was	NN	O
extracted	VBD	O
with	VBN	O
EtOAc	IN	O
(2×100	NNP	O
mL).	CD	O
The	.	O
combined	DT	O
organic	JJ	O
layers	JJ	O
were	NNS	O
washed	VBD	O
with	VBN	O
brine	IN	O
(200	NN	O
mL)	CD	O
and	)	O
dried	CC	O
over	VBN	O
Na2SO4.	IN	O
The	.	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation	JJ	O
to	NN	O
yield	TO	O
6	VB	O
as	CD	O
a	IN	O
low	DT	O
melting	JJ	O
(<25°	NN	O
C.)	CD	O
white	)	O
solid	JJ	O
(32.0	JJ	O
mmol,	CD	O
99%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
3.79	VBZ	O
(s,	CD	O
3H),	,	O
6.39-6.43	,	O
(d,	JJ	O
J=16.0	,	O
Hz,	NNP	O
1H),	,	O
7.04-7.07	,	O
(dt,	JJ	O
J=2.0,	,	O
8.0	,	O
Hz,	CD	O
1H),	,	O
7.18-7.20	,	O
(d,	JJ	O
J=9.0	,	O
Hz,	NNP	O
1H),	,	O
7.25-7.26	,	O
(d,	JJ	O
J=8.0	,	O
Hz,	NNP	O
1H),	,	O
7.30-7.35	,	O
(m,	JJ	O
1H),	,	O
7.60-7.64	,	O
(d,	JJ	O
J=16.0	,	O
Hz,	NNP	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
52.0,	VBD	O
114.4,	,	O
114.6,	,	O
117.3,	,	O
117.4,	,	O
119.4,	,	O
124.29,	,	O
124.32,	,	O
130.6,	,	O
130.7,	,	O
136.8,	,	O
136.9,	,	O
143.6,	,	O
143.7,	,	O
162.2,	,	O
164.2,	,	O
167.2;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C10H10FO2	IN	O
181.	NNP	O
found	CD	O
181.	VBD	O
Example	.	O
2	RB	O
Methyl	CD	O
2-(3-fluorophenyl)cyclopropanecarboxylate	NNP	O
(7).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
KOH	IN	O
(2.5	NNP	O
g,	CD	O
45	,	O
mmol)	CD	O
in	)	O
H2O	IN	O
(4	NNP	O
mL)	CD	O
in	)	O
a	IN	O
Mini	DT	O
Diazald	NNP	O
apparatus	NNP	O
(Aldrich	NN	O
Z108898)	NNP	O
was	)	O
added	VBD	O
dropwise	VBN	O
2-(2-ethoxyethoxy)ethanol	NN	O
(14.0	NN	O
mL)	CD	O
and	)	O
ether	CC	O
(8.0	$	O
mL).	CD	O
To	.	O
the	TO	O
condenser	DT	O
of	NN	O
the	IN	O
apparatus	DT	O
was	NN	O
attached	VBD	O
a	VBN	O
round-bottom	DT	O
receiving	JJ	O
flask	NN	O
(Caution:	NN	O
this	:	O
flask	DT	O
must	NN	O
have	MD	O
a	VB	O
clear-seal	DT	O
joint).	JJ	O
The	.	O
receiving	DT	O
flask	NN	O
was	NN	O
put	VBD	O
in	VBN	O
a	IN	O
Dry	DT	O
Ice-acetone	NNP	O
bath.	NNP	O
A	.	O
glass	DT	O
tube	NN	O
(Caution:	NN	O
this	:	O
tube	DT	O
must	NN	O
have	MD	O
fire-polished	VB	O
ends)	JJ	O
was	)	O
attached	VBD	O
to	VBN	O
the	TO	O
side	DT	O
arm	NN	O
of	NN	O
the	IN	O
apparatus,	DT	O
which	,	O
ended	WDT	O
in	VBD	O
an	IN	O
ether	DT	O
(˜5	NN	O
mL)	NNP	O
trap	)	O
in	NN	O
a	IN	O
Dry	DT	O
Ice-acetone	NNP	O
bath.	NNP	O
A	.	O
separate	DT	O
clear-seal-joint	JJ	O
funnel	NN	O
was	NN	O
placed	VBD	O
over	VBN	O
the	IN	O
reaction	DT	O
vessel.	NN	O
This	.	O
funnel	DT	O
was	NN	O
charged	VBD	O
with	VBN	O
a	IN	O
solution	DT	O
of	NN	O
Diazald	IN	O
(5.0	NNP	O
g,	CD	O
23	,	O
mmol)	CD	O
in	)	O
ether	IN	O
(30	NN	O
mL).	CD	O
The	.	O
reaction	DT	O
vessel	NN	O
was	NN	O
warmed	VBD	O
slowly	VBN	O
to	RB	O
65°	TO	O
C.	CD	O
The	NNP	O
Diazald	DT	O
solution	NNP	O
was	NN	O
added	VBD	O
slowly	VBN	O
to	RB	O
the	TO	O
reaction	DT	O
vessel	NN	O
over	NN	O
a	IN	O
period	DT	O
of	NN	O
20	IN	O
min.	CD	O
Afterward,	.	O
additional	,	O
ether	JJ	O
(10	NN	O
mL)	CD	O
was	)	O
added	VBD	O
to	VBN	O
the	TO	O
reaction	DT	O
vessel	NN	O
through	NN	O
the	IN	O
top	DT	O
funnel	JJ	O
at	NN	O
the	IN	O
same	DT	O
temperature.	JJ	O
The	.	O
distillation	DT	O
was	NN	O
continued	VBD	O
until	VBN	O
the	IN	O
yellow	DT	O
distillate	JJ	O
became	NN	O
colorless.	VBD	O
To	.	O
a	TO	O
flame-dried	DT	O
round-bottom	JJ	O
flask	JJ	O
containing	NN	O
ether	VBG	O
(50	NN	O
mL)	CD	O
and	)	O
CH2Cl2	CC	O
(150	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
6	VBN	O
(900	CD	O
mg,	CD	O
5.0	,	O
mmol)	CD	O
and	)	O
Pd(OAc)2	CC	O
(5.80	CD	O
mg)	CD	O
at	)	O
0°	IN	O
C.	CD	O
To	NNP	O
this	TO	O
flask	DT	O
was	NN	O
added	VBD	O
the	VBN	O
freshly	DT	O
prepared	RB	O
diazomethane	JJ	O
solution	NN	O
through	NN	O
a	IN	O
cannula,	DT	O
and	,	O
then	CC	O
the	RB	O
reaction	DT	O
solution	NN	O
was	NN	O
slowly	VBD	O
warmed	RB	O
to	VBN	O
room	TO	O
temperature	NN	O
over	NN	O
a	IN	O
period	DT	O
of	NN	O
30	IN	O
min	CD	O
and	NN	O
allowed	CC	O
to	VBN	O
stir	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
an	IN	O
additional	DT	O
2	JJ	O
h.	CD	O
The	PDT	O
reaction	DT	O
mixture	NN	O
was	NN	O
washed	VBD	O
with	VBN	O
H2O	IN	O
(150	NNP	O
mL)	CD	O
and	)	O
brine	CC	O
(150	NN	O
mL)	CD	O
and	)	O
dried	CC	O
over	VBN	O
NaSO4.	IN	O
The	.	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation	JJ	O
to	NN	O
yield	TO	O
7	VB	O
as	CD	O
a	IN	O
colorless	DT	O
oil	NN	O
(965	NN	O
mg,	CD	O
5.0	,	O
mmol,	CD	O
100%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.30-1.35	VBZ	O
(ddd,	JJ	O
J=5.0,	,	O
7.0,	,	O
8.5	,	O
Hz,	CD	O
1H),	,	O
1.60-1.66	,	O
(dt,	JJ	O
J=5.0,	,	O
10.0	,	O
Hz,	CD	O
1H),	,	O
1.90-1.94	,	O
(ddd,	JJ	O
J=4.0,	,	O
5.0,	,	O
8.5	,	O
Hz,	CD	O
1H),	,	O
2.51-2.54	,	O
(dt,	JJ	O
J=2.5,	,	O
5.5	,	O
Hz,	CD	O
1H),	,	O
3.74	,	O
(s,	CD	O
3H),	,	O
6.70-6.80	,	O
(td,	JJ	O
J=2.0,	,	O
10.0	,	O
Hz,	CD	O
1H),	,	O
6.90-6.95	,	O
(m,	JJ	O
2H),	,	O
7.23-7.28	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
17.4,	VBD	O
24.4,	,	O
26.1,	,	O
52.3,	,	O
113.2,	,	O
113.4,	,	O
113.6,	,	O
113.8,	,	O
122.2,	,	O
130.1,	,	O
130.2,	,	O
142.9,	,	O
143.0,	,	O
164.2,	,	O
173.8;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C11H12FO2	IN	O
195.	NNP	O
found	CD	O
195.	VBD	O
Example	.	O
3	JJ	O
2-(3-Fluorophenyl)cyclopropanecarboxylic	CD	O
acid	JJ	O
(8).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
7	IN	O
(390	CD	O
mg,	CD	O
2.0	,	O
mmol)	CD	O
in	)	O
MeOH	IN	O
(5	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
2N	VBN	O
NaOH	CD	O
(5	NNP	O
mL)	CD	O
slowly.	)	O
The	.	O
reaction	DT	O
solution	NN	O
was	NN	O
stirred	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
for	NN	O
2	IN	O
h	CD	O
then	NN	O
diluted	RB	O
with	VBD	O
H2O	IN	O
(25	NNP	O
mL).	CD	O
After	.	O
extraction	IN	O
with	NN	O
ether	IN	O
(20	NN	O
mL),	CD	O
the	,	O
aqueous	DT	O
layer	JJ	O
was	NN	O
acidified	VBD	O
with	VBN	O
2N	IN	O
HCl	CD	O
(2.1	NNP	O
mL).	CD	O
The	.	O
resulting	DT	O
solution	VBG	O
was	NN	O
extracted	VBD	O
with	VBN	O
ether	IN	O
(3×40	NN	O
mL).	CD	O
The	.	O
combined	DT	O
organic	JJ	O
layers	JJ	O
were	NNS	O
dried	VBD	O
over	VBN	O
MgSO4	IN	O
and	NNP	O
concentrated	CC	O
to	VBD	O
give	TO	O
8	VB	O
(325	CD	O
mg,	CD	O
1.8	,	O
mmol,	CD	O
99%)	,	O
as	)	O
a	IN	O
light	DT	O
yellow	JJ	O
oil:	JJ	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
0.87-0.91	VBZ	O
(dd,	JJ	O
J=6.0,	,	O
13.5	,	O
Hz,	CD	O
1H),	,	O
1.21-1.29	,	O
(m,	JJ	O
1H),	,	O
1.39-1.43	,	O
(ddd,	JJ	O
J=5.0,	,	O
6.5,	,	O
8.0	,	O
Hz,	CD	O
1H),	,	O
1.67-1.72	,	O
(m,	JJ	O
1H),	,	O
1.90-1.94	,	O
(m,	JJ	O
1H),	,	O
2.58-2.63	,	O
(m,	JJ	O
1H),	,	O
6.79-6.82	,	O
(dd,	JJ	O
J=2.0,	,	O
5.5	,	O
Hz,	CD	O
1H),	,	O
6.90-6.95	,	O
(m,	JJ	O
2H),	,	O
7.24-7.28	,	O
(m,	JJ	O
1H),	,	O
8.90-11.00	,	O
(br	JJ	O
s,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
17.8,	VBD	O
24.4,	,	O
26.9,	,	O
31.8,	,	O
113.3,	,	O
113.5,	,	O
113.8,	,	O
114.0,	,	O
122.30,	,	O
122.32,	,	O
130.2,	,	O
130.3,	,	O
142.4,	,	O
142.5,	,	O
162.2,	,	O
164.2,	,	O
179.8;	,	O
LCQ-MS	:	O
(M−H+)	NNP	O
calcd	)	O
for	NN	O
C10H8FO2	IN	O
179.	NNP	O
found	CD	O
179.	VBD	O
Example	.	O
4	JJ	O
tent-Butyl	CD	O
2-(3-fluorophenyl)cyclopropylcarbamate	JJ	O
(9).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
8	IN	O
(300	CD	O
mg,	CD	O
1.67	,	O
mmol)	CD	O
in	)	O
dry	IN	O
t-BuOH	JJ	O
(5.0	NN	O
mL)	CD	O
was	)	O
added	VBD	O
diphenyl	VBN	O
phosphorazidate	NN	O
(DPPA,	NN	O
400	,	O
μL,	CD	O
1.83	,	O
mmol)	CD	O
and	)	O
triethylamine	CC	O
(Et3N,	NN	O
350	,	O
μL,	CD	O
2.51	,	O
mmol).	CD	O
The	.	O
reaction	DT	O
solution	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
at	VB	O
85°	IN	O
C.	CD	O
for	NNP	O
two	IN	O
days,	CD	O
then	,	O
cooled	RB	O
to	VBD	O
room	TO	O
temperature	NN	O
and	NN	O
concentrated.	CC	O
The	.	O
resulting	DT	O
solution	VBG	O
was	NN	O
partitioned	VBD	O
between	VBN	O
ether	IN	O
(30	NN	O
mL)	CD	O
and	)	O
saturated	CC	O
NaHCO3	VBN	O
(30	NNP	O
mL).	CD	O
The	.	O
aqueous	DT	O
layer	JJ	O
was	NN	O
extracted	VBD	O
with	VBN	O
ether	IN	O
(2×30	NN	O
mL).	CD	O
The	.	O
combined	DT	O
organic	JJ	O
layers	JJ	O
were	NNS	O
dried	VBD	O
over	VBN	O
Na2SO4	IN	O
and	NNP	O
concentrated.	CC	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
chromatography	NN	O
to	NN	O
yield	TO	O
9	VB	O
(325	CD	O
mg,	CD	O
1.30	,	O
mmol,	CD	O
82%)	,	O
as	)	O
a	IN	O
white	DT	O
solid:	JJ	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.10-1.25	VBZ	O
(m,	JJ	O
2H),	,	O
1.40-1.55	,	O
(m,	JJ	O
10H),	,	O
2.00-2.10	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.73	,	O
(br	CD	O
s,	NN	O
1H),	,	O
5.04	,	O
(br	CD	O
s,	NN	O
1H),	,	O
6.82-6.88	,	O
(m,	JJ	O
2H),	,	O
6.92-6.94	,	O
(d,	JJ	O
J=7.5	,	O
Hz,	NNP	O
1H),	,	O
7.20-7.25	,	O
(dd,	JJ	O
J=7.5,	,	O
14.0	,	O
Hz,	CD	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
16.6,	VBD	O
25.1,	,	O
28.6,	,	O
32.9,	,	O
113.0,	,	O
113.2,	,	O
113.4,	,	O
113.6,	,	O
122.4,	,	O
129.9,	,	O
130.0,	,	O
130.1,	,	O
143.77,	,	O
143.83,	,	O
162.2,	,	O
164.1;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C14H19FNO2	IN	O
252.	NNP	O
found	CD	O
252.	VBD	O
2-(3-Fluorophenyl)cyclopropanamine	.	O
trifluoroacetic	NN	O
acid	JJ	O
salt	NN	O
(4b).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
9	IN	O
(560	CD	O
mg,	CD	O
2.2	,	O
mmol)	CD	O
in	)	O
CH2Cl2	IN	O
(15	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
trifluoroacetic	VBN	O
acid	JJ	O
(15	NN	O
mL).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
stirred	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
for	NN	O
30	IN	O
min.	CD	O
The	.	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
yellow	DT	O
oil	JJ	O
was	NN	O
put	VBD	O
under	VBN	O
vacuum	IN	O
for	NN	O
24	IN	O
h	CD	O
to	NN	O
give	TO	O
crude	VB	O
amine	NN	O
4b	NN	O
(579	CD	O
mg,	CD	O
2.2	,	O
mmol,	CD	O
100%)	,	O
as	)	O
a	IN	O
yellow	DT	O
oil,	JJ	O
which	,	O
was	WDT	O
used	VBD	O
in	VBN	O
the	IN	O
next	DT	O
step	JJ	O
without	NN	O
further	IN	O
purification:	JJ	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.10-1.30	VBZ	O
(br	JJ	O
s,	JJ	O
1H),	,	O
1.40-1.60	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.30-2.50	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.70-2.90	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
6.70-6.72	,	O
(m,	JJ	O
1H),	,	O
6.72-6.77	,	O
(m,	JJ	O
1H),	,	O
6.89-7.00	,	O
(m,	JJ	O
1H),	,	O
7.10-7.30	,	O
(m,	JJ	O
1H),	,	O
7.80-8.20	,	O
(br	JJ	O
s,	JJ	O
2H),	,	O
10.8-11.8	,	O
(br	JJ	O
s,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
13.2,	VBD	O
21.5,	,	O
31.6,	,	O
113.5,	,	O
113.7,	,	O
114.2,	,	O
114.4,	,	O
122.29,	,	O
122.31,	,	O
130.4,	,	O
130.5,	,	O
140.1,	,	O
140.2,	,	O
162.2,	,	O
164.1;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C9H11FN	IN	O
152.	NNP	O
found	CD	O
152;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C9H11FN	IN	O
152.08755.	NNP	O
found	CD	O
152.08703.	VBD	O
Examples	.	O
5-29	NNS	O
can	NNS	O
be	MD	O
considered	VB	O
in	VBN	O
the	IN	O
context	DT	O
of	NN	O
Schemes	IN	O
1b-1e,	NNP	O
above.	,	O
Example	.	O
5	RB	O
General	CD	O
Method	NNP	O
(A)	NNP	O
for	)	O
Rhodium	IN	O
(II)-catalyzed	NNP	O
cyclopropanation.	VBD	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
styrene	IN	O
derivative	JJ	O
4a-c	JJ	O
(20	JJ	O
mmol)	CD	O
in	)	O
dry	IN	O
toluene	JJ	O
(40	NN	O
mL)	CD	O
was	)	O
added	VBD	O
catalyst	VBN	O
Rh2(OAc)4	NN	O
(0.4	CD	O
mmol).	CD	O
The	.	O
resulting	DT	O
mixture	JJ	O
was	NN	O
heated	VBD	O
at	VBN	O
80°	IN	O
C.	CD	O
for	NNP	O
30	IN	O
min,	CD	O
then	,	O
EtO2CCHN2	RB	O
(10	NNP	O
mmol)	CD	O
was	)	O
added	VBD	O
dropwise	VBN	O
at	NN	O
the	IN	O
same	DT	O
temperature	JJ	O
over	NN	O
a	IN	O
period	DT	O
of	NN	O
1	IN	O
h.	CD	O
The	NN	O
reaction	DT	O
mixture	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
at	VB	O
85°	IN	O
C.	CD	O
for	NNP	O
an	IN	O
additional	DT	O
2	JJ	O
h,	CD	O
and	,	O
then	CC	O
cooled	RB	O
to	VBD	O
room	TO	O
temperature.	NN	O
The	.	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation	JJ	O
and	NN	O
the	CC	O
resulting	DT	O
oil	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
chromatography	NN	O
(1-10%	NN	O
EtOAc	NN	O
in	NNP	O
hexanes)	IN	O
to	)	O
generate	TO	O
5a-c	VB	O
as	JJ	O
mixtures	IN	O
of	NNS	O
cis/trans	IN	O
isomers.	NNS	O
Example	.	O
6	RB	O
General	CD	O
Method	NNP	O
(B)	NNP	O
for	)	O
Epimerization	IN	O
and	NN	O
hydrolysis.	CC	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
5a-c	IN	O
(10	NNP	O
mmol)	CD	O
in	)	O
EtOH	IN	O
(10	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
NaOMe	VBN	O
(40	NNP	O
mL)	CD	O
in	)	O
portion.	IN	O
The	.	O
reaction	DT	O
solution	NN	O
was	NN	O
heated	VBD	O
under	VBN	O
reflux	IN	O
for	NN	O
40	IN	O
h,	CD	O
and	,	O
then	CC	O
concentrated	RB	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
resulting	DT	O
residue	VBG	O
was	NN	O
partitioned	VBD	O
between	VBN	O
DCM	IN	O
(200	NNP	O
mL)	CD	O
and	)	O
H2O	CC	O
(100	NNP	O
mL).	CD	O
The	.	O
aqueous	DT	O
layer	JJ	O
was	NN	O
extracted	VBD	O
with	VBN	O
DCM	IN	O
(2×100	NNP	O
mL).	CD	O
The	.	O
combined	DT	O
organic	JJ	O
layers	JJ	O
were	NNS	O
dried	VBD	O
over	VBN	O
Na2SO4	IN	O
and	NNP	O
concentrated.	CC	O
The	.	O
crude	DT	O
ethyl	NN	O
ester	NN	O
was	NN	O
taken	VBD	O
up	VBN	O
in	RP	O
MeOH	IN	O
(70	NNP	O
mL),	CD	O
to	,	O
which	TO	O
was	WDT	O
added	VBD	O
LiOH	VBN	O
(345	NNP	O
mg,	CD	O
15	,	O
mmol)	CD	O
and	)	O
H2O	CC	O
(70	NNP	O
mL).	CD	O
The	.	O
reaction	DT	O
was	NN	O
heated	VBD	O
at	VBN	O
70°	IN	O
C.	CD	O
for	NNP	O
16	IN	O
h.	CD	O
After	NN	O
cooling	IN	O
to	VBG	O
room	TO	O
temperature,	NN	O
MeOH	,	O
was	NNP	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
resulting	DT	O
aqueous	VBG	O
solution	JJ	O
was	NN	O
acidified	VBD	O
by	VBN	O
concentrated	IN	O
HCl	JJ	O
to	NNP	O
pH	TO	O
1,	VB	O
which	,	O
was	WDT	O
extracted	VBD	O
with	VBN	O
EtOAc	IN	O
(3×150	NNP	O
mL).	CD	O
The	.	O
combined	DT	O
organic	JJ	O
layers	JJ	O
were	NNS	O
dried	VBD	O
over	VBN	O
Na2SO4,	IN	O
and	,	O
concentrated.	CC	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
chromatography	NN	O
to	NN	O
yield	TO	O
6a-c	VB	O
(75-80%)	JJ	O
as	)	O
white	IN	O
solids.	JJ	O
Example	.	O
7	RB	O
General	CD	O
Method	NNP	O
(C)	NNP	O
for	)	O
Curtius	IN	O
rearrangement.	NNP	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
6a-c	IN	O
(2.0	NNP	O
mmol)	CD	O
in	)	O
dry	IN	O
t-BuOH	JJ	O
(0.3	NN	O
M)	CD	O
was	)	O
added	VBD	O
diphenyl	VBN	O
phosphorazidate	NN	O
(2.2	NN	O
mmol)	CD	O
and	)	O
TEA	CC	O
(3.0	NNP	O
mmol).	CD	O
The	.	O
reaction	DT	O
solution	NN	O
was	NN	O
heated	VBD	O
at	VBN	O
85°	IN	O
C.	CD	O
for	NNP	O
two	IN	O
days,	CD	O
then	,	O
cooled	RB	O
to	VBD	O
room	TO	O
temperature	NN	O
and	NN	O
concentrated.	CC	O
The	.	O
resulting	DT	O
solution	VBG	O
was	NN	O
partitioned	VBD	O
between	VBN	O
ether	IN	O
(50	NN	O
mL)	CD	O
and	)	O
NaHCO3	CC	O
(50	NNP	O
mL).	CD	O
The	.	O
aqueous	DT	O
layer	JJ	O
was	NN	O
extracted	VBD	O
with	VBN	O
ether	IN	O
(2×50	NN	O
mL).	CD	O
The	.	O
combined	DT	O
organic	JJ	O
layers	JJ	O
were	NNS	O
dried	VBD	O
over	VBN	O
Na2SO4	IN	O
and	NNP	O
concentrated.	CC	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
chromatography	NN	O
to	NN	O
yield	TO	O
7a-c	VB	O
(75-82%)	JJ	O
as	)	O
white	IN	O
solids.	JJ	O
Example	.	O
8	RB	O
General	CD	O
Method	NNP	O
(D)	NNP	O
for	)	O
Boc-deprotection.	IN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
7a-c	IN	O
(1.0	NNP	O
mmol)	CD	O
in	)	O
CH2Cl2	IN	O
(5	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
TFA	VBN	O
(5	NNP	O
mL).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
stirred	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
for	NN	O
30	IN	O
min.	CD	O
The	.	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
yellow	DT	O
oil	JJ	O
was	NN	O
put	VBD	O
under	VBN	O
vacuum	IN	O
for	NN	O
24	IN	O
h	CD	O
to	NN	O
give	TO	O
crude	VB	O
amine	JJ	O
3a-c	JJ	O
as	JJ	O
yellow	IN	O
oils,	JJ	O
which	,	O
was	WDT	O
used	VBD	O
in	VBN	O
the	IN	O
next	DT	O
step	JJ	O
without	NN	O
further	IN	O
purification.	JJ	O
Example	.	O
9	RB	O
General	CD	O
Method	NNP	O
(E)	NNP	O
for	)	O
Reductive	IN	O
amination.	JJ	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
aldehyde	IN	O
(0.1	NN	O
mmol)	CD	O
in	)	O
DCM	IN	O
(3	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
amine	VBN	O
(0.11	NN	O
mmol),	CD	O
followed	,	O
by	VBN	O
TEA	IN	O
(0.2	NNP	O
mmol),	CD	O
and	,	O
NaHB(OAc)3	CC	O
(0.12	CD	O
mmol).	CD	O
The	.	O
mixture	DT	O
was	NN	O
stirred	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
for	NN	O
an	IN	O
additional	DT	O
3	JJ	O
h,	CD	O
and	,	O
then	CC	O
concentrated.	RB	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
2:1-4:1)	,	O
to	)	O
give	TO	O
the	VB	O
product	DT	O
as	NN	O
colorless	IN	O
oil.	JJ	O
Example	.	O
10	RB	O
General	CD	O
Method	NNP	O
(F)	NNP	O
for	)	O
Boc-deprotection	IN	O
of	NNP	O
Inhibitor	IN	O
Compound.	NNP	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
tri-Boc-protected	IN	O
inhibitor	JJ	O
(0.2	NN	O
mmol)	CD	O
in	)	O
MeOH	IN	O
(0.5	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
6	VBN	O
N	CD	O
HCl	NNP	O
(1.0	NNP	O
mL).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
sit	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
for	NN	O
16	IN	O
h,	CD	O
and	,	O
then	CC	O
concentrated.	RB	O
The	.	O
resulting	DT	O
pale	VBG	O
yellow	JJ	O
oil	JJ	O
was	NN	O
put	VBD	O
under	VBN	O
vacuum	IN	O
for	NN	O
30	IN	O
h	CD	O
to	NN	O
give	TO	O
final	VB	O
inhibitors	JJ	O
(95-99%).	NNS	O
Example	.	O
11	JJ	O
2-m-Tolylcyclopropanecarboxylic	CD	O
acid	JJ	O
(6a).	NN	O
Compound	.	O
6a	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
A	NN	O
and	NNP	O
B	CC	O
(77%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.30-1.40	VBZ	O
(ddd,	JJ	O
J=4.5,	,	O
7.0,	,	O
7.5	,	O
Hz,	CD	O
1H),	,	O
1.60-1.65	,	O
(dd,	JJ	O
J=5.0,	,	O
9.0	,	O
Hz,	CD	O
1H),	,	O
1.85-1.90	,	O
(ddd,	JJ	O
J=4.5,	,	O
5.0,	,	O
7.5	,	O
Hz,	CD	O
1H),	,	O
2.50-2.60	,	O
(ddd,	JJ	O
J=4.5,	,	O
7.0,	,	O
9.0	,	O
Hz,	CD	O
1H),	,	O
6.85-6.95	,	O
(m,	JJ	O
1H),	,	O
7.00-7.05	,	O
(m,	JJ	O
1H),	,	O
7.15-7.22	,	O
(m,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
17.5,	VBD	O
21.4,	,	O
24.0,	,	O
27.1,	,	O
123.2,	,	O
127.0,	,	O
127.4,	,	O
128.4,	,	O
138.2,	,	O
139.4,	,	O
180.1;	,	O
LCQ-MS	:	O
(M−H+)	NNP	O
calcd	)	O
for	NN	O
C11H13O2	IN	O
177.	NNP	O
found	CD	O
177.	VBD	O
Example	.	O
12	JJ	O
2-(3-Clorophenyl)cyclopropanecarboxylic	CD	O
acid	JJ	O
(6b).	NN	O
Compound	.	O
6b	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
A	NN	O
and	NNP	O
B	CC	O
(80%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.30-1.40	VBZ	O
(ddd,	JJ	O
J=2.0,	,	O
3.5,	,	O
7.0	,	O
Hz,	CD	O
1H),	,	O
1.60-1.65	,	O
(dd,	JJ	O
J=5.0,	,	O
9.0	,	O
Hz,	CD	O
1H),	,	O
1.85-1.91	,	O
(m,	JJ	O
1H),	,	O
2.50-2.60	,	O
(m,	JJ	O
1H),	,	O
6.85-7.02	,	O
(m,	JJ	O
1H),	,	O
7.05-7.10	,	O
(m,	JJ	O
1H),	,	O
7.15-7.22	,	O
(m,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
17.8,	VBD	O
24.4,	,	O
26.9,	,	O
31.8,	,	O
113.3,	,	O
113.5,	,	O
113.8,	,	O
114.0,	,	O
122.30,	,	O
122.32,	,	O
130.2,	,	O
130.3,	,	O
142.4,	,	O
142.5,	,	O
162.2,	,	O
164.2,	,	O
179.8;	,	O
LC-MS	:	O
(M−H+)	NNP	O
calcd	)	O
for	NN	O
C10H10ClO2	IN	O
197.	NNP	O
found	CD	O
197.	VBD	O
Example	.	O
13	JJ	O
2-(3-Fluorophenyl)cyclopropanecarboxylic	CD	O
acid	JJ	O
(6c).	NN	O
Compound	.	O
6c	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
A	NN	O
and	NNP	O
B	CC	O
(75%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
0.87-0.91	VBZ	O
(dd,	JJ	O
J=6.0,	,	O
13.5	,	O
Hz,	CD	O
1H),	,	O
1.21-1.29	,	O
(m,	JJ	O
1H),	,	O
1.39-1.43	,	O
(ddd,	JJ	O
J=5.0,	,	O
6.5,	,	O
8.0	,	O
Hz,	CD	O
1H),	,	O
1.67-1.72	,	O
(m,	JJ	O
1H),	,	O
1.90-1.94	,	O
(m,	JJ	O
1H),	,	O
2.58-2.63	,	O
(m,	JJ	O
1H),	,	O
6.79-6.82	,	O
(dd,	JJ	O
J=2.0,	,	O
5.5	,	O
Hz,	CD	O
1H),	,	O
6.90-6.95	,	O
(m,	JJ	O
2H),	,	O
7.24-7.28	,	O
(m,	JJ	O
1H),	,	O
8.90-11.00	,	O
(br	JJ	O
s,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
17.8,	VBD	O
24.4,	,	O
26.9,	,	O
31.8,	,	O
113.3,	,	O
113.5,	,	O
113.8,	,	O
114.0,	,	O
122.30,	,	O
122.32,	,	O
130.2,	,	O
130.3,	,	O
142.4,	,	O
142.5,	,	O
162.2,	,	O
164.2,	,	O
179.8;	,	O
LCQ-MS	:	O
(M−H+)	NNP	O
calcd	)	O
for	NN	O
C10H8FO2	IN	O
179.	NNP	O
found	CD	O
179.	VBD	O
Example	.	O
14	JJ	O
tert-Butyl	CD	O
2-m-tolylcyclopropylcarbamate	JJ	O
(7a).	JJ	O
Compound	.	O
7a	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
C	NN	O
(82%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.00-1.20	VBZ	O
(m,	JJ	O
2H),	,	O
1.46	,	O
(s,	CD	O
9H),	,	O
1.95-2.05	,	O
(ddd,	JJ	O
J=3.0,	,	O
6.5,	,	O
9.5	,	O
Hz,	CD	O
1H),	,	O
2.31	,	O
(s,	CD	O
3H),	,	O
2.74	,	O
(br	CD	O
s,	NN	O
1H),	,	O
4.85	,	O
(br	CD	O
s,	NN	O
1H),	,	O
6.91-6.93	,	O
(m,	JJ	O
2H),	,	O
6.97-6.99	,	O
(d,	JJ	O
J=7.5	,	O
Hz,	NNP	O
1H),	,	O
7.13-7.16	,	O
(dd,	JJ	O
J=7.5,	,	O
8.0	,	O
Hz,	CD	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
16.3,	VBD	O
21.4,	,	O
24.5,	,	O
28.4,	,	O
32.6,	,	O
120.2,	,	O
120.3,	,	O
123.4,	,	O
126.1,	,	O
126.8,	,	O
127.2,	,	O
128.2,	,	O
130.1,	,	O
137.9,	,	O
140.6;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C15H21NO2	IN	O
248.	NNP	O
found	CD	O
248.	VBD	O
Example	.	O
15	JJ	O
tert-Butyl	CD	O
2-(3-chloroluorophenyl)cyclopropylcarbamate	JJ	O
(7b).	NN	O
Compound	.	O
7b	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
C	NN	O
(77%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.14-1.17	VBZ	O
(dd,	JJ	O
J=6.5,	,	O
7.0	,	O
Hz,	CD	O
2H),	,	O
1.45	,	O
(s,	CD	O
9H),	,	O
1.99-2.03	,	O
(ddd,	JJ	O
J=2.5,	,	O
7.5,	,	O
10.5	,	O
Hz,	CD	O
1H),	,	O
2.72	,	O
(br	CD	O
s,	NN	O
1H),	,	O
4.88	,	O
(br	CD	O
s,	NN	O
1H),	,	O
6.95-7.02	,	O
(d,	JJ	O
J=7.0	,	O
Hz,	NNP	O
1H),	,	O
7.10-7.25	,	O
(m,	JJ	O
3H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
16.3,	VBD	O
24.5,	,	O
28.4,	,	O
32.6,	,	O
120.1,	,	O
120.3,	,	O
124.8,	,	O
126.2,	,	O
126.6,	,	O
129.5,	,	O
129.9,	,	O
134.1,	,	O
142.9;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C14H19ClNO2	IN	O
268.	NNP	O
found	CD	O
268.	VBD	O
Example	.	O
16	JJ	O
tert-Butyl	CD	O
2-(3-fluorophenyl)cyclopropylcarbamate	JJ	O
(7c).	NN	O
Compound	.	O
7c	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
C	NN	O
(75%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.10-1.25	VBZ	O
(m,	JJ	O
2H),	,	O
1.40-1.55	,	O
(m,	JJ	O
10H),	,	O
2.00-2.10	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.73	,	O
(br	CD	O
s,	NN	O
1H),	,	O
5.04	,	O
(br	CD	O
s,	NN	O
1H),	,	O
6.82-6.88	,	O
(m,	JJ	O
2H),	,	O
6.92-6.94	,	O
(d,	JJ	O
J=7.5	,	O
Hz,	NNP	O
1H),	,	O
7.20-7.25	,	O
(dd,	JJ	O
J=7.5,	,	O
14.0	,	O
Hz,	CD	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
16.6,	VBD	O
25.1,	,	O
28.6,	,	O
32.9,	,	O
113.0,	,	O
113.2,	,	O
113.4,	,	O
113.6,	,	O
122.4,	,	O
129.9,	,	O
130.0,	,	O
130.1,	,	O
143.77,	,	O
143.83,	,	O
162.2,	,	O
164.1;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C14H19FNO2	IN	O
252.	NNP	O
found	CD	O
252.	VBD	O
Example	.	O
17	RB	O
Compounds	CD	O
8a	NNS	O
and	CD	O
8b.	CC	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
amine	IN	O
3c	NN	O
(450	CD	O
mg,	CD	O
3.0	,	O
mmol)	CD	O
in	)	O
DCM	IN	O
was	NNP	O
added	VBD	O
camphanic	VBN	O
chloride	JJ	O
(650	NN	O
mg,	CD	O
3.0	,	O
mmol),	CD	O
followed	,	O
by	VBN	O
TEA	IN	O
(510	NNP	O
μL,	CD	O
3.75	,	O
mmol).	CD	O
The	.	O
reaction	DT	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
30	IN	O
min,	CD	O
and	,	O
then	CC	O
concentrated.	RB	O
The	.	O
resulting	DT	O
oil	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
chromatography	NN	O
(EtOAc/Hexanes,	NN	O
1:4)	,	O
to	)	O
generate	TO	O
8a	VB	O
(445	CD	O
mg,	CD	O
45%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
0.92	VBZ	O
(s,	CD	O
3H),	,	O
1.12	,	O
(s,	CD	O
6H),	,	O
1.19-1.22	,	O
(m,	JJ	O
1H),	,	O
1.28-1.30	,	O
(m,	JJ	O
2H),	,	O
1.65-1.75	,	O
(m,	JJ	O
1H),	,	O
1.85-2.00	,	O
(m,	JJ	O
2H),	,	O
2.05-2.15	,	O
(m,	JJ	O
1H),	,	O
2.50-2.60	,	O
(m,	JJ	O
1H),	,	O
2.90-2.98	,	O
(m,	JJ	O
1H),	,	O
6.68	,	O
(br	CD	O
s,	NN	O
1H),	,	O
6.84-6.90	,	O
(m,	JJ	O
2H),	,	O
6.95-6.97	,	O
(d,	JJ	O
J=7.5	,	O
Hz,	NNP	O
1H),	,	O
7.21-7.25	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
9.7,	VBD	O
15.8,	,	O
16.5,	,	O
16.7,	,	O
24.67,	,	O
24.78,	,	O
29.0,	,	O
30.3,	,	O
31.6,	,	O
54.0,	,	O
55.3,	,	O
92.4,	,	O
113.1,	,	O
113.27,	,	O
113.32,	,	O
113.5,	,	O
122.30,	,	O
122.32,	,	O
129.8,	,	O
129.9,	,	O
142.6,	,	O
142.7,	,	O
162.0,	,	O
163.9,	,	O
168.3,	,	O
178.2;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C19H23FNO3	IN	O
332.1662.	NNP	O
found	CD	O
332.1673;	VBD	O
and	:	O
8b	CC	O
(360	CD	O
mg,	CD	O
36%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
0.91	VBZ	O
(s,	CD	O
3H),	,	O
1.11	,	O
(s,	CD	O
6H),	,	O
1.20-1.35	,	O
(m,	JJ	O
3H),	,	O
1.65-1.75	,	O
(m,	JJ	O
1H),	,	O
1.85-2.00	,	O
(m,	JJ	O
2H),	,	O
2.00-2.10	,	O
(m,	JJ	O
1H),	,	O
2.50-2.58	,	O
(m,	JJ	O
1H),	,	O
2.89-2.95	,	O
(m,	JJ	O
1H),	,	O
6.67	,	O
(br	CD	O
s,	NN	O
1H),	,	O
6.84-6.90	,	O
(m,	JJ	O
2H),	,	O
6.95-6.97	,	O
(d,	JJ	O
J=8.0	,	O
Hz,	NNP	O
1H),	,	O
7.21-7.24	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
9.7,	VBD	O
16.0,	,	O
16.5,	,	O
16.7,	,	O
24.61,	,	O
24.63,	,	O
29.0,	,	O
30.3,	,	O
31.5,	,	O
54.0,	,	O
55.3,	,	O
92.38,	,	O
92.40,	,	O
113.1,	,	O
113.29,	,	O
113.32,	,	O
113.4	,	O
113.5,	CD	O
113.6,	,	O
122.30,	,	O
122.32,	,	O
129.8,	,	O
129.9,	,	O
142.66,	,	O
142.72,	,	O
162.0,	,	O
163.9,	,	O
168.2,	,	O
168.3,	,	O
178.2;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C19H23FNO3	IN	O
332.1662.	NNP	O
found	CD	O
332.1677.	VBD	O
Example	.	O
18	JJ	O
(1S,2R)-2-(3-Fluorophenyl)cyclopropanamine	CD	O
(3d).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
8a	IN	O
(330	CD	O
mg,	CD	O
1.0	,	O
mmol)	CD	O
in	)	O
EtOH	IN	O
(5	NNP	O
mL)	CD	O
was	)	O
slowly	VBD	O
added	RB	O
12	JJ	O
N	CD	O
HCl	NNP	O
(10	NNP	O
mL).	CD	O
The	.	O
resulting	DT	O
mixture	JJ	O
was	NN	O
heated	VBD	O
under	VBN	O
reflux	IN	O
for	NN	O
72	IN	O
h	CD	O
and	NN	O
then	CC	O
cooled	RB	O
to	VBD	O
room	TO	O
temperature.	NN	O
The	.	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation,	JJ	O
and	,	O
the	CC	O
resulting	DT	O
crude	JJ	O
material	JJ	O
was	NN	O
purified	VBD	O
with	VBN	O
flash	IN	O
chromatography	JJ	O
(2-5%	NN	O
MeOH	NN	O
in	NNP	O
DCM)	IN	O
to	)	O
give	TO	O
3d	VB	O
as	CD	O
a	IN	O
yellow	DT	O
oil	JJ	O
(105	NN	O
mg,	CD	O
70%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.10-1.30	VBZ	O
(br	JJ	O
s,	JJ	O
1H),	,	O
1.40-1.60	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.30-2.50	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.70-2.90	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
6.70-6.72	,	O
(m,	JJ	O
1H),	,	O
6.72-6.77	,	O
(m,	JJ	O
1H),	,	O
6.89-7.00	,	O
(m,	JJ	O
1H),	,	O
7.10-7.30	,	O
(m,	JJ	O
1H),	,	O
7.80-8.20	,	O
(br	JJ	O
s,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
13.2,	VBD	O
21.5,	,	O
31.6,	,	O
113.5,	,	O
113.7,	,	O
114.2,	,	O
114.4,	,	O
122.29,	,	O
122.31,	,	O
130.4,	,	O
130.5,	,	O
140.1,	,	O
140.2;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C9H11FN	IN	O
152.0876.	NNP	O
found	CD	O
152.0870.	VBD	O
Example	.	O
19	JJ	O
(1R,2S)-2-(3-Fluorophenyl)cyclopropanamine	CD	O
(3e).	NN	O
3e	.	O
was	CD	O
synthesized	VBD	O
using	VBN	O
a	VBG	O
similar	DT	O
procedure	JJ	O
to	NN	O
that	TO	O
of	DT	O
3d	IN	O
using	CD	O
8b	VBG	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(67%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.10-1.30	VBZ	O
(br	JJ	O
s,	JJ	O
1H),	,	O
1.40-1.60	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.30-2.50	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.70-2.90	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
6.70-6.72	,	O
(m,	JJ	O
1H),	,	O
6.72-6.77	,	O
(m,	JJ	O
1H),	,	O
6.89-7.00	,	O
(m,	JJ	O
1H),	,	O
7.10-7.30	,	O
(m,	JJ	O
1H),	,	O
7.80-8.20	,	O
(br	JJ	O
s,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
13.2,	VBD	O
21.5,	,	O
31.6,	,	O
113.5,	,	O
113.7,	,	O
114.2,	,	O
114.4,	,	O
122.29,	,	O
122.31,	,	O
130.4,	,	O
130.5,	,	O
140.1,	,	O
140.2;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C9H11FN	IN	O
152.0876.	NNP	O
found	CD	O
152.0870.	VBD	O
Example	.	O
20	JJ	O
(3R,4R)-tert-Butyl	CD	O
3-((6-(bis(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-((1S,2R/1R,2S)-2-m-tolylcyclopropylamino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(9a).	NN	O
Compound	.	O
9a	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
D	NN	O
(87%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
0.90-0.97	VBZ	O
(m,	JJ	O
1H),	,	O
1.00-1.05	,	O
(m,	JJ	O
1H),	,	O
1.40-1.45	,	O
(m,	JJ	O
27H),	,	O
1.84-1.91	,	O
(m,	JJ	O
1H),	,	O
2.27-2.32	,	O
(m,	JJ	O
6H),	,	O
2.33-2.40	,	O
(m,	JJ	O
1H),	,	O
2.60-2.75	,	O
(m,	JJ	O
1H),	,	O
2.75-2.83	,	O
(m,	JJ	O
1H),	,	O
2.85-2.93	,	O
(m,	JJ	O
2H),	,	O
2.95-3.00	,	O
(m,	JJ	O
1H),	,	O
3.05-3.15	,	O
(m,	JJ	O
1H),	,	O
3.25-3.30	,	O
(m,	JJ	O
1H),	,	O
3.31-3.34	,	O
(m,	JJ	O
1H),	,	O
3.35-3.55	,	O
(m,	JJ	O
1H),	,	O
3.57-3.74	,	O
(m,	JJ	O
1H),	,	O
3.75-3.85	,	O
(m,	JJ	O
1H),	,	O
6.85-6.95	,	O
(m,	JJ	O
4H),	,	O
6.92-7.01	,	O
(m,	JJ	O
2H),	,	O
7.10-7.20	,	O
(m,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(100	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
13.7,	VBD	O
14.1,	,	O
14.2,	,	O
17.2,	,	O
17.3,	,	O
17.4,	,	O
19.1,	,	O
20.9,	,	O
21.0,	,	O
21.1,	,	O
21.4,	,	O
22.2,	,	O
24.96,	,	O
24.99,	,	O
25.0,	,	O
25.5,	,	O
27.9,	,	O
28.5,	,	O
29.7,	,	O
30.6,	,	O
34.6,	,	O
34.7,	,	O
41.0,	,	O
41.1,	,	O
42.6,	,	O
43.2,	,	O
48.8,	,	O
48.9,	,	O
49.0,	,	O
49.1,	,	O
50.3,	,	O
60.4,	,	O
64.4,	,	O
68.4,	,	O
78.6,	,	O
79.2,	,	O
79.3,	,	O
79.4,	,	O
82.8,	,	O
82.9,	,	O
119.5,	,	O
119.6,	,	O
122.7,	,	O
122.8,	,	O
122.9,	,	O
126.3,	,	O
126.5,	,	O
126.6,	,	O
126.7,	,	O
126.8,	,	O
128.17,	,	O
128.24,	,	O
128.3,	,	O
128.5,	,	O
128.6,	,	O
132.0,	,	O
132.1,	,	O
137.8,	,	O
137.9,	,	O
141.3,	,	O
142.3,	,	O
149.6,	,	O
151.4,	,	O
151.5,	,	O
151.8,	,	O
154.8,	,	O
159.1,	,	O
159.2,	,	O
171.2;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C38H57N4O7	IN	O
681.4227.	NNP	O
found	CD	O
681.4224.	VBD	O
Example	.	O
21	JJ	O
(3R,4R)-tert-Butyl	CD	O
3-((6-(bis(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-((1S,2R/1R,2S)-2-(3-clorophenyl)cyclopropylamino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(9b).	NN	O
Compound	.	O
9b	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
D	NN	O
(87%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
0.92-0.99	VBZ	O
(m,	JJ	O
1H),	,	O
1.07-1.11	,	O
(m,	JJ	O
1H),	,	O
1.40-1.45	,	O
(m,	JJ	O
27H),	,	O
1.85-1.90	,	O
(m,	JJ	O
1H),	,	O
2.29-2.33	,	O
(m,	JJ	O
3H),	,	O
2.34-2.38	,	O
(m,	JJ	O
1H),	,	O
2.60-2.75	,	O
(m,	JJ	O
1H),	,	O
2.76-2.83	,	O
(m,	JJ	O
1H),	,	O
2.85-2.93	,	O
(m,	JJ	O
2H),	,	O
2.95-3.00	,	O
(m,	JJ	O
1H),	,	O
3.05-3.15	,	O
(m,	JJ	O
1H),	,	O
3.25-3.30	,	O
(m,	JJ	O
1H),	,	O
3.31-3.34	,	O
(m,	JJ	O
1H),	,	O
3.35-3.52	,	O
(m,	JJ	O
1H),	,	O
3.57-3.74	,	O
(m,	JJ	O
1H),	,	O
3.75-3.85	,	O
(m,	JJ	O
1H),	,	O
6.85-6.92	,	O
(m,	JJ	O
2H),	,	O
6.93-7.05	,	O
(m,	JJ	O
2H),	,	O
7.08-7.20	,	O
(m,	JJ	O
4H);	,	O
13C	:	O
NMR	CD	O
(100	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
17.4,	VBD	O
17.5,	,	O
17.6,	,	O
18.7,	,	O
20.9,	,	O
21.0,	,	O
22.2,	,	O
24.9,	,	O
25.0,	,	O
25.3,	,	O
26.2,	,	O
27.9,	,	O
28.5,	,	O
34.6,	,	O
34.7,	,	O
35.6,	,	O
41.3,	,	O
41.4,	,	O
41.5,	,	O
41.6,	,	O
42.5,	,	O
43.1,	,	O
48.7,	,	O
48.8,	,	O
49.1,	,	O
50.3,	,	O
52.0,	,	O
68.4,	,	O
68.5,	,	O
76.7,	,	O
78.6,	,	O
79.2,	,	O
79.3,	,	O
79.4,	,	O
82.8,	,	O
82.9,	,	O
119.5,	,	O
119.6,	,	O
122.7,	,	O
124.0,	,	O
124.07,	,	O
124.10,	,	O
124.12,	,	O
124.3,	,	O
125.5,	,	O
125.6,	,	O
125.7,	,	O
125.81,	,	O
125.83,	,	O
125.86,	,	O
125.94,	,	O
128.5,	,	O
128.6,	,	O
129.4,	,	O
129.5,	,	O
129.6,	,	O
132.0,	,	O
132.1,	,	O
134.1,	,	O
134.2,	,	O
143.6,	,	O
144.6,	,	O
144.7,	,	O
149.6,	,	O
151.47,	,	O
151.53,	,	O
151.8,	,	O
154.8,	,	O
159.7;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C37H53ClN4O7	IN	O
701.3681.	NNP	O
found	CD	O
701.3884.	VBD	O
Example	.	O
22	JJ	O
(3R,4R)-tert-Butyl	CD	O
3-((6-(bis(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-((1S,2R/1R,2S)-2-(3-fluorophenyl)cyclopropylamino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(9c).	NN	O
Compound	.	O
9c	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
D	NN	O
(81%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
0.95-1.00	VBZ	O
(m,	JJ	O
1H),	,	O
1.06-1.10	,	O
(m,	JJ	O
1H),	,	O
1.40-1.46	,	O
(m,	JJ	O
27H),	,	O
1.86-1.90	,	O
(m,	JJ	O
1H),	,	O
2.26-2.33	,	O
(m,	JJ	O
3H),	,	O
2.35-2.40	,	O
(m,	JJ	O
1H),	,	O
2.60-2.75	,	O
(m,	JJ	O
1H),	,	O
2.76-2.85	,	O
(m,	JJ	O
1H),	,	O
2.86-2.92	,	O
(m,	JJ	O
2H),	,	O
2.95-2.98	,	O
(m,	JJ	O
1H),	,	O
3.05-3.13	,	O
(m,	JJ	O
1H),	,	O
3.24-3.30	,	O
(m,	JJ	O
1H),	,	O
3.30-3.35	,	O
(m,	JJ	O
1H),	,	O
3.36-3.51	,	O
(m,	JJ	O
1H),	,	O
3.57-3.75	,	O
(m,	JJ	O
1H),	,	O
3.77-3.85	,	O
(m,	JJ	O
1H),	,	O
6.85-6.92	,	O
(m,	JJ	O
2H),	,	O
6.93-7.20	,	O
(m,	JJ	O
4H);	,	O
13C	:	O
NMR	CD	O
(100	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
17.4,	VBD	O
17.5,	,	O
17.6,	,	O
18.7,	,	O
20.9,	,	O
21.0,	,	O
22.2,	,	O
24.9,	,	O
25.0,	,	O
25.3,	,	O
26.2,	,	O
27.9,	,	O
28.5,	,	O
34.6,	,	O
34.7,	,	O
35.6,	,	O
41.3,	,	O
41.4,	,	O
41.5,	,	O
41.6,	,	O
42.5,	,	O
43.1,	,	O
48.7,	,	O
48.8,	,	O
49.1,	,	O
50.3,	,	O
52.0,	,	O
68.4,	,	O
68.5,	,	O
76.7,	,	O
78.6,	,	O
79.2,	,	O
79.3,	,	O
79.4,	,	O
82.8,	,	O
82.9,	,	O
119.5,	,	O
119.6,	,	O
122.7,	,	O
124.0,	,	O
124.07,	,	O
124.10,	,	O
124.12,	,	O
124.3,	,	O
125.5,	,	O
125.6,	,	O
125.7,	,	O
125.81,	,	O
125.83,	,	O
125.86,	,	O
125.94,	,	O
128.5,	,	O
128.6,	,	O
129.4,	,	O
129.5,	,	O
129.6,	,	O
132.0,	,	O
132.1,	,	O
134.1,	,	O
134.2,	,	O
143.6,	,	O
144.6,	,	O
144.7,	,	O
149.6,	,	O
151.47,	,	O
151.53,	,	O
151.8,	,	O
154.8,	,	O
159.7;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H60F3N4O8	IN	O
685.3977.	NNP	O
found	CD	O
685.3991.	VBD	O
Example	.	O
23	JJ	O
(3R,4R)-tert-Butyl	CD	O
3-((6-(bis(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-((1S,2R)-2-(3-fluorophenyl)cyclopropylamino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(9d).	NN	O
Compound	.	O
9d	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
D	NN	O
(82%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
0.95-1.01	VBZ	O
(m,	JJ	O
1H),	,	O
1.10-1.15	,	O
(m,	JJ	O
1H),	,	O
1.40-1.45	,	O
(m,	JJ	O
27H),	,	O
1.89-1.92	,	O
(m,	JJ	O
1H),	,	O
2.28-2.32	,	O
(m,	JJ	O
3H),	,	O
2.33-2.37	,	O
(m,	JJ	O
1H),	,	O
2.60-2.75	,	O
(m,	JJ	O
1H),	,	O
2.76-2.83	,	O
(m,	JJ	O
1H),	,	O
2.85-2.93	,	O
(m,	JJ	O
2H),	,	O
2.95-3.00	,	O
(m,	JJ	O
1H),	,	O
3.05-3.15	,	O
(m,	JJ	O
1H),	,	O
3.27-3.31	,	O
(m,	JJ	O
1H),	,	O
3.32-3.34	,	O
(m,	JJ	O
1H),	,	O
3.35-3.55	,	O
(m,	JJ	O
1H),	,	O
3.57-3.74	,	O
(m,	JJ	O
1H),	,	O
3.75-3.85	,	O
(m,	JJ	O
1H),	,	O
6.65-6.72	,	O
(m,	JJ	O
1H),	,	O
6.80-6.89	,	O
(m,	JJ	O
2H),	,	O
6.90-6.95	,	O
(m,	JJ	O
2H),	,	O
7.15-7.20	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(100	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
14.2,	VBD	O
17.4,	,	O
17.5,	,	O
21.0,	,	O
22.7,	,	O
24.7,	,	O
24.8,	,	O
27.9,	,	O
28.5,	,	O
29.7,	,	O
31.6,	,	O
34.6,	,	O
34.7,	,	O
36.6,	,	O
41.4,	,	O
41.5,	,	O
42.5,	,	O
43.1,	,	O
44.7,	,	O
48.7,	,	O
48.8,	,	O
49.1,	,	O
50.3,	,	O
50.9,	,	O
60.4,	,	O
68.3,	,	O
78.6,	,	O
79.2,	,	O
79.3,	,	O
79.4,	,	O
82.8,	,	O
82.9,	,	O
112.2,	,	O
112.4,	,	O
112.6,	,	O
119.5,	,	O
119.6,	,	O
121.6,	,	O
122.7,	,	O
128.5,	,	O
128.6,	,	O
129.6,	,	O
129.7,	,	O
131.9,	,	O
132.0,	,	O
132.1,	,	O
132.2,	,	O
149.6,	,	O
151.5,	,	O
151.8,	,	O
154.6,	,	O
154.8,	,	O
159.0,	,	O
159.1,	,	O
162.0,	,	O
163.9;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C37H54FN4O7	IN	O
685.3977.	NNP	O
found	CD	O
685.3979.	VBD	O
Example	.	O
24	JJ	O
4-Methyl-6-(((3R,4R)-4-(2-((1S,2R/1R,2S)-2-m-tolylcyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)pyridin-2-amine	CD	O
(2a).	NN	O
Inhibitor	.	O
2a	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
E	NN	O
as	NNP	O
a	IN	O
mixture	DT	O
of	NN	O
two	IN	O
diastereomers	CD	O
(90%):	NNS	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
1.10-1.30	VBZ	O
(m,	JJ	O
1H),	,	O
1.35-1.45	,	O
(m,	JJ	O
1H),	,	O
2.10-2.15	,	O
(m,	JJ	O
3H),	,	O
2.15-2.20	,	O
(m,	JJ	O
3H),	,	O
2.20-2.50	,	O
(m,	JJ	O
1H),	,	O
2.50-2.80	,	O
(m,	JJ	O
2H),	,	O
2.81-3.00	,	O
(m,	JJ	O
2H),	,	O
3.19-3.25	,	O
(m,	JJ	O
1H),	,	O
3.30-3.40	,	O
(m,	JJ	O
2H),	,	O
3.47-3.52	,	O
(m,	JJ	O
1H),	,	O
3.55-3.70	,	O
(m,	JJ	O
1H),	,	O
3.71-3.85	,	O
(m,	JJ	O
1H),	,	O
4.00-4.15	,	O
(m,	JJ	O
1H),	,	O
6.35-6.60	,	O
(m,	JJ	O
2H),	,	O
6.85-6.90	,	O
(m,	JJ	O
2H),	,	O
6.91-7.15	,	O
(m,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
12.2,	VBD	O
12.3,	,	O
15.1,	,	O
20.2,	,	O
20.4,	,	O
20.5,	,	O
20.6,	,	O
20.7,	,	O
21.0,	,	O
21.6,	,	O
23.2,	,	O
28.8,	,	O
28.9,	,	O
30.1,	,	O
30.5,	,	O
31.8,	,	O
37.4,	,	O
38.5,	,	O
41.2,	,	O
41.3,	,	O
47.0,	,	O
47.2,	,	O
47.5,	,	O
49.2,	,	O
49.3,	,	O
63.6,	,	O
64.5,	,	O
78.1,	,	O
78.3,	,	O
110.2,	,	O
110.3,	,	O
113.9,	,	O
114.0,	,	O
122.9,	,	O
123.1,	,	O
123.3,	,	O
126.3,	,	O
126.5,	,	O
126.6,	,	O
126.7,	,	O
126.8,	,	O
127.5,	,	O
127.6,	,	O
127.7,	,	O
128.6,	,	O
128.7,	,	O
128.78,	,	O
128.82,	,	O
128.9,	,	O
129.0,	,	O
131.8,	,	O
131.9,	,	O
137.9,	,	O
138.1,	,	O
138.7,	,	O
138.9,	,	O
139.0,	,	O
145.59,	,	O
145.62,	,	O
153.8,	,	O
158.1;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H30FN4O2	IN	O
381.2654.	NNP	O
found	CD	O
381.2653.	VBD	O
Example	.	O
25	JJ	O
6-(((3R,4R)-4-(2-((1S,2R/1R,2S)-2-(3-Clorophenyl)cyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine	CD	O
(2b).	NN	O
Compound	.	O
2b	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
E	NN	O
as	NNP	O
a	IN	O
mixture	DT	O
of	NN	O
two	IN	O
diastereomers	CD	O
(91%):	NNS	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
1.10-1.30	VBZ	O
(m,	JJ	O
1H),	,	O
1.35-1.50	,	O
(m,	JJ	O
1H),	,	O
2.15-2.20	,	O
(m,	JJ	O
3H),	,	O
2.25-2.30	,	O
(m,	JJ	O
1H),	,	O
2.35-2.50	,	O
(m,	JJ	O
1H),	,	O
2.55-2.70	,	O
(m,	JJ	O
2H),	,	O
2.70-2.77	,	O
(m,	JJ	O
1H),	,	O
2.81-3.00	,	O
(m,	JJ	O
2H),	,	O
3.19-3.25	,	O
(m,	JJ	O
1H),	,	O
3.30-3.40	,	O
(m,	JJ	O
1H),	,	O
3.49-3.52	,	O
(m,	JJ	O
1H),	,	O
3.55-3.70	,	O
(m,	JJ	O
1H),	,	O
3.75-3.85	,	O
(m,	JJ	O
1H),	,	O
4.05	,	O
(br	CD	O
s,	NN	O
0.5H),	,	O
4.12	,	O
(br	CD	O
s,	NN	O
0.5H),	,	O
6.34	,	O
(s,	CD	O
0.5H),	,	O
6.39	,	O
(s,	CD	O
0.5H),	,	O
6.51	,	O
(s,	CD	O
0.5H),	,	O
6.53	,	O
(s,	CD	O
0.5H),	,	O
6.95-7.01	,	O
(m,	JJ	O
1H),	,	O
7.05-7.20	,	O
(m,	JJ	O
3H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
12.3,	VBD	O
12.4,	,	O
12.6,	,	O
20.3,	,	O
20.4,	,	O
20.5,	,	O
21.1,	,	O
28.8,	,	O
28.9,	,	O
30.6,	,	O
37.4,	,	O
38.6,	,	O
41.2,	,	O
41.3,	,	O
47.0,	,	O
47.1,	,	O
47.2,	,	O
47.5,	,	O
49.2,	,	O
49.3,	,	O
63.5,	,	O
64.5,	,	O
78.2,	,	O
78.4,	,	O
110.31,	,	O
110.34,	,	O
113.9,	,	O
114.0,	,	O
124.7,	,	O
124.75,	,	O
124.82,	,	O
126.1,	,	O
126.16,	,	O
126.23,	,	O
126.7,	,	O
126.9,	,	O
127.0,	,	O
130.0,	,	O
130.1,	,	O
130.2,	,	O
133.8,	,	O
133.9,	,	O
134.0,	,	O
140.2,	,	O
140.7,	,	O
145.52,	,	O
145.54,	,	O
153.8,	,	O
158.1;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C22H30ClN4O	IN	O
401.2108.	NNP	O
found	CD	O
401.2093.	VBD	O
Example	.	O
26	JJ	O
6-(((3R,4R)-4-(2-((1S,2R/1R,2S)-2-(3-Fluorophenyl)cyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine	CD	O
(2c).	NN	O
Compound	.	O
2c	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
E	NN	O
as	NNP	O
a	IN	O
mixture	DT	O
of	NN	O
two	IN	O
diastereomers	CD	O
(99%):	NNS	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
1.30-1.40	VBZ	O
(m,	JJ	O
1H),	,	O
1.41-1.48	,	O
(m,	JJ	O
1H),	,	O
2.10-2.20	,	O
(m,	JJ	O
3H),	,	O
2.30-2.50	,	O
(m,	JJ	O
1H),	,	O
2.51-2.77	,	O
(m,	JJ	O
2H),	,	O
2.80-2.90	,	O
(m,	JJ	O
1H),	,	O
2.91-3.03	,	O
(m,	JJ	O
1H),	,	O
3.04-3.40	,	O
(m,	JJ	O
3H),	,	O
3.41-3.72	,	O
(m,	JJ	O
2H),	,	O
3.73-3.88	,	O
(m,	JJ	O
1H),	,	O
3.90-4.11	,	O
(m,	JJ	O
1H),	,	O
4.40-4.50	,	O
(m,	JJ	O
1H),	,	O
6.30-6.60	,	O
(m,	JJ	O
2H),	,	O
6.70-6.90	,	O
(m,	JJ	O
2H),	,	O
7.00-7.20	,	O
(m,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
12.6,	VBD	O
12.9,	,	O
20.7,	,	O
20.9,	,	O
21.2,	,	O
21.4,	,	O
29.1,	,	O
37.7,	,	O
37.8,	,	O
38.6,	,	O
41.5,	,	O
45.3,	,	O
47.3,	,	O
47.6,	,	O
47.7,	,	O
49.6,	,	O
63.8,	,	O
64.5,	,	O
78.3,	,	O
78.5,	,	O
109.0,	,	O
110.5,	,	O
113.2,	,	O
113.4,	,	O
113.8,	,	O
114.0,	,	O
114.3,	,	O
122.4,	,	O
127.2,	,	O
128.1,	,	O
129.2,	,	O
130.1,	,	O
136.4,	,	O
140.7,	,	O
140.9,	,	O
145.9,	,	O
146.6,	,	O
153.0,	,	O
154.0,	,	O
158.3,	,	O
161.8,	,	O
163.8;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H30FN4O2	IN	O
385.2404.	NNP	O
found	CD	O
385.2393.	VBD	O
Example	.	O
27	JJ	O
6-(((3R,4R)-4-(2-((1S,2R)-2-(3-Fluorophenyl)cyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine	CD	O
(2d).	NN	O
Compound	.	O
2d	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
general	VBG	O
method	JJ	O
E	NN	O
(95%):	NNP	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
1.30-1.40	VBZ	O
(m,	JJ	O
1H),	,	O
1.41-1.46	,	O
(m,	JJ	O
1H),	,	O
2.18	,	O
(s,	CD	O
3H),	,	O
2.19-2.20	,	O
(m,	JJ	O
1H),	,	O
2.40-2.50	,	O
(m,	JJ	O
1H),	,	O
2.55-2.70	,	O
(m,	JJ	O
2H),	,	O
2.81-3.00	,	O
(m,	JJ	O
3H),	,	O
3.19-3.23	,	O
(dd,	JJ	O
J=3.5,	,	O
13.5	,	O
Hz,	CD	O
1H),	,	O
3.30-3.40	,	O
(m,	JJ	O
2H),	,	O
3.49-3.52	,	O
(m,	JJ	O
1H),	,	O
3.55-3.61	,	O
(m,	JJ	O
1H),	,	O
3.75-3.85	,	O
(m,	JJ	O
1H),	,	O
4.06	,	O
(br	CD	O
s,	NN	O
1H),	,	O
6.38	,	O
(s,	CD	O
1H),	,	O
6.54	,	O
(s,	CD	O
1H),	,	O
6.80-6.95	,	O
(m,	JJ	O
3H),	,	O
7.15-7.25	,	O
(dd,	JJ	O
J=5.5,	,	O
10.5	,	O
Hz,	CD	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
12.6,	VBD	O
20.4,	,	O
21.0,	,	O
28.8,	,	O
30.1,	,	O
38.4,	,	O
41.3,	,	O
47.1,	,	O
47.5,	,	O
49.3,	,	O
64.3,	,	O
78.3,	,	O
110.3,	,	O
112.9,	,	O
113.1,	,	O
113.6,	,	O
113.8,	,	O
114.0,	,	O
122.1,	,	O
128.9,	,	O
129.0,	,	O
130.4,	,	O
130.5,	,	O
131.8,	,	O
131.9,	,	O
133.1,	,	O
140.6,	,	O
140.7,	,	O
145.6,	,	O
153.9,	,	O
158.1;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H30FN4O2	IN	O
385.2404.	NNP	O
found	CD	O
385.2384.	VBD	O
Example	.	O
28	JJ	O
(3S,4S)/(3R,4R)-tert-Butyl	CD	O
3-((6-(benzyl(tert-butoxycarbonyeamino)-4-methylpyridin-2-yl)methyl)-4-(2-(tert-butoxycarbonyl(2-(3-fluorophenyl)cyclopropyl)amino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(12).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
aldehyde	IN	O
11	JJ	O
(100	CD	O
mg,	CD	O
0.18	,	O
mmol)	CD	O
in	)	O
DCM	IN	O
(2	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
3e	VBN	O
(60	CD	O
mg,	CD	O
0.37	,	O
mmol),	CD	O
followed	,	O
by	VBN	O
TEA	IN	O
(125	NNP	O
μL,	CD	O
0.9	,	O
mmol).	CD	O
The	.	O
mixture	DT	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
5	IN	O
min	CD	O
before	NN	O
NaHB(OAc)3	IN	O
(50	CD	O
mg,	CD	O
0.23	,	O
mmol)	CD	O
was	)	O
added.	VBD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
stirred	VBD	O
for	VBN	O
an	IN	O
additional	DT	O
3	JJ	O
h	CD	O
then	NN	O
partitioned	RB	O
between	VBD	O
EtOAc	IN	O
(50	NNP	O
mL)	CD	O
and	)	O
brine	CC	O
(25	NN	O
mL).	CD	O
The	.	O
organic	DT	O
layer	JJ	O
was	NN	O
dried	VBD	O
over	VBN	O
Na2SO4	IN	O
and	NNP	O
concentrated	CC	O
to	VBN	O
yield	TO	O
crude	VB	O
secondary	JJ	O
amine.	JJ	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
the	IN	O
resulting	DT	O
crude	VBG	O
amine	JJ	O
in	NN	O
MeOH	IN	O
(1.5	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
(Boc)2O	VBN	O
(120	CD	O
mg,	CD	O
0.56	,	O
mmol)	CD	O
and	)	O
Et3N	CC	O
(75	NNP	O
μL,	CD	O
0.56	,	O
mmol).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
stirred	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
for	NN	O
6	IN	O
h	CD	O
and	NN	O
then	CC	O
partitioned	RB	O
between	VBD	O
EtOAc	IN	O
(50	NNP	O
mL)	CD	O
and	)	O
brine	CC	O
(20	NN	O
mL).	CD	O
The	.	O
organic	DT	O
layer	JJ	O
was	NN	O
dried	VBD	O
over	VBN	O
Na2SO4,	IN	O
and	,	O
the	CC	O
solvents	DT	O
were	NNS	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
resulting	DT	O
material	VBG	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:4-1:2)	,	O
to	)	O
yield	TO	O
12	VB	O
(70	CD	O
mg,	CD	O
60%)	,	O
as	)	O
a	IN	O
colorless	DT	O
oil	NN	O
(71%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.10-1.22	VBZ	O
(m,	JJ	O
2H),	,	O
1.35-1.50	,	O
(m,	JJ	O
28H),	,	O
1.65-1.80	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.10-2.20	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.20-2.35	,	O
(m,	JJ	O
3H),	,	O
2.40-2.80	,	O
(m,	JJ	O
3H),	,	O
2.80-2.95	,	O
(m,	JJ	O
1H),	,	O
2.97-3.10	,	O
(m,	JJ	O
1H),	,	O
3.16-3.21	,	O
(m,	JJ	O
1H),	,	O
3.22-3.44	,	O
(m,	JJ	O
3H),	,	O
3.45-3.70	,	O
(m,	JJ	O
3H),	,	O
4.04-4.10	,	O
(m,	JJ	O
1H),	,	O
5.10-5.25	,	O
(br	JJ	O
s,	JJ	O
2H),	,	O
6.55-6.65	,	O
(m,	JJ	O
1H),	,	O
6.65-6.95	,	O
(m,	JJ	O
3H),	,	O
7.10-7.27	,	O
(m,	JJ	O
6H),	,	O
6.31-6.45	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
14.0,	VBD	O
14.4,	,	O
14.5,	,	O
19.4,	,	O
21.3,	,	O
21.4,	,	O
22.9,	,	O
28.4,	,	O
28.7,	,	O
28.8,	,	O
30.0,	,	O
30.9,	,	O
31.8,	,	O
34.8,	,	O
34.9,	,	O
40.0,	,	O
40.1,	,	O
42.9,	,	O
49.1,	,	O
49.5,	,	O
50.2,	,	O
50.5,	,	O
51.1,	,	O
60.7,	,	O
64.6,	,	O
78.2,	,	O
79.4,	,	O
79.7,	,	O
80.2,	,	O
81.4,	,	O
81.5,	,	O
112.9,	,	O
113.0,	,	O
117.2,	,	O
117.3,	,	O
120.2,	,	O
122.1,	,	O
126.8,	,	O
127.1,	,	O
127.2,	,	O
127.3,	,	O
128.3,	,	O
130.0,	,	O
140.1,	,	O
148.7,	,	O
148.8,	,	O
154.1,	,	O
154.6,	,	O
154.7,	,	O
155.0,	,	O
157.9,	,	O
162.2,	,	O
164.1,	,	O
171.4,	,	O
171.5;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C44H60FN4O7	IN	O
775.4441.	NNP	O
found	CD	O
775.4441.	VBD	O
Example	.	O
29	JJ	O
6-(((3S,4S)/(3R,4R)-4-(2-(2-(3-Fluorophenyl)cyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine	CD	O
(10).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
12	IN	O
(0.2	CD	O
mmol)	CD	O
in	)	O
EtOH	IN	O
(20	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
Pd(OH)2/C	VBN	O
(100	CD	O
mg).	CD	O
The	.	O
reaction	DT	O
vessel	NN	O
was	NN	O
charged	VBD	O
with	VBN	O
H2,	IN	O
heated	,	O
at	VBD	O
60°	IN	O
C.	CD	O
for	NNP	O
30	IN	O
h,	CD	O
then	,	O
cooled	RB	O
to	VBD	O
room	TO	O
temperature.	NN	O
The	.	O
catalyst	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
filtration,	IN	O
and	,	O
the	CC	O
resulting	DT	O
solution	JJ	O
was	NN	O
concentrated	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
crude	DT	O
material	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:4-1:2)	,	O
to	)	O
yield	TO	O
13	VB	O
as	CD	O
a	IN	O
white	DT	O
foamy	JJ	O
solid	NN	O
To	NN	O
a	TO	O
solution	DT	O
of	NN	O
the	IN	O
resulting	DT	O
13	VBG	O
in	CD	O
MeOH	IN	O
(0.5	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
6	VBN	O
N	CD	O
HCl	NNP	O
(1.0	NNP	O
mL).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
sit	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
16	IN	O
h.	CD	O
The	PDT	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
recrystallized	VBD	O
using	VBN	O
cold	VBG	O
diethyl	JJ	O
ether	NN	O
to	NN	O
provide	TO	O
10	VB	O
as	CD	O
a	IN	O
pale	DT	O
yellow	JJ	O
solid	JJ	O
(20	NN	O
mg,	CD	O
25%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
1.18-1.20	VBZ	O
(m,	JJ	O
3H),	,	O
2.20	,	O
(s,	CD	O
3H),	,	O
2.60-2.72	,	O
(m,	JJ	O
2H),	,	O
2.75-2.90	,	O
(m,	JJ	O
2H),	,	O
3.00-3.10	,	O
(m,	JJ	O
2H),	,	O
3.15-3.33	,	O
(m,	JJ	O
3H),	,	O
3.34-3.42	,	O
(m,	JJ	O
1H),	,	O
3.44-3.60	,	O
(m,	JJ	O
3H),	,	O
3.70-3.80	,	O
(m,	JJ	O
1H),	,	O
4.09	,	O
(s,	CD	O
1H),	,	O
6.46-4.67	,	O
(m,	JJ	O
1H),	,	O
6.56	,	O
(s,	CD	O
1H),	,	O
6.90-7.10	,	O
(m,	JJ	O
3H),	,	O
7.20-7.25	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
15.2,	VBD	O
15.5,	,	O
21.3,	,	O
29.2,	,	O
38.4,	,	O
38.5,	,	O
41.6,	,	O
41.7,	,	O
44.2,	,	O
44.4,	,	O
47.3,	,	O
49.5,	,	O
55.6,	,	O
64.0,	,	O
64.4,	,	O
78.4,	,	O
110.6,	,	O
114.3,	,	O
114.4,	,	O
114.5,	,	O
116.2,	,	O
116.4,	,	O
125.4,	,	O
125.6,	,	O
130.8,	,	O
130.9,	,	O
138.3,	,	O
145.9,	,	O
146.0,	,	O
154.1,	,	O
158.4,	,	O
161.9,	,	O
163.9;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C22H32FN4O	IN	O
387.2560.	NNP	O
found	CD	O
385.2556.	VBD	O
Example	.	O
30	JJ	O
1-(2-Bromo-1-fluoroethyl)-3-fluorobenzene	CD	O
(11).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
3-fluorostyrene	IN	O
(10,	NNP	O
5.0	,	O
g,	CD	O
41	,	O
mmol)	CD	O
in	)	O
CH2Cl2	IN	O
at	NNP	O
0°	IN	O
C.	CD	O
was	NNP	O
added	VBD	O
NBS	VBN	O
(8.8	NNP	O
g,	CD	O
49.2	,	O
mmol).	CD	O
After	.	O
30	IN	O
min,	CD	O
Et3N.3HF	,	O
(20	NNP	O
mL,	CD	O
123	,	O
mmol)	CD	O
was	)	O
added.	VBD	O
The	.	O
reaction	DT	O
solution	NN	O
was	NN	O
warmed	VBD	O
to	VBN	O
room	TO	O
temperature	NN	O
and	NN	O
stirred	CC	O
for	VBD	O
16	IN	O
h.	CD	O
The	PDT	O
reaction	DT	O
was	NN	O
quenched	VBD	O
with	VBN	O
saturated	IN	O
NaHCO3	JJ	O
then	NNP	O
partitioned	RB	O
between	VBD	O
EtOAc	IN	O
(500	NNP	O
mL)	CD	O
and	)	O
H2O	CC	O
(300	NNP	O
mL).	CD	O
The	.	O
organic	DT	O
layer	JJ	O
was	NN	O
washed	VBD	O
with	VBN	O
brine	IN	O
(300	NN	O
mL),	CD	O
dried	,	O
over	VBN	O
Na2SO4,	IN	O
and	,	O
concentrated.	CC	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:18-1:9)	,	O
to	)	O
yield	TO	O
11	VB	O
as	CD	O
a	IN	O
colorless	DT	O
liquid	NN	O
(5.8	NN	O
g,	CD	O
85%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
3.55-3.80	VBZ	O
(m,	JJ	O
2H),	,	O
5.59-5.61	,	O
(dd,	JJ	O
J=4.0,	,	O
7.0	,	O
Hz,	CD	O
0.5H),	,	O
5.68-5.70	,	O
(dd,	JJ	O
J=4.5,	,	O
7.5	,	O
Hz,	CD	O
0.5H),	,	O
7.00-7.20	,	O
(m,	JJ	O
3H),	,	O
7.30-7.50	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
34.0,	VBD	O
34.3,	,	O
91.4,	,	O
91.4,	,	O
92.8,	,	O
113.0,	,	O
113.2,	,	O
116.3,	,	O
116.4,	,	O
116.5,	,	O
121.6,	,	O
121.7,	,	O
130.6,	,	O
130.7,	,	O
139.7,	,	O
139.8,	,	O
139.9,	,	O
162.1,	,	O
164.1;	,	O
GC-MS	:	O
calcd	NNP	O
for	NN	O
C8H7BrF2	IN	O
220.	NNP	O
found	CD	O
220.	VBD	O
Example	.	O
31	JJ	O
1-(2-Azido-1-fluoroethyl)-3-fluorobenzene	CD	O
(12).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
11	IN	O
(2.3	CD	O
g,	CD	O
10.5	,	O
mmol)	CD	O
in	)	O
dry	IN	O
DMSO	JJ	O
(15	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
NaN3	VBN	O
(1.0	NNP	O
g,	CD	O
15.7	,	O
mmol).	CD	O
The	.	O
reaction	DT	O
solution	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
at	VB	O
65°	IN	O
C.	CD	O
for	NNP	O
4	IN	O
h	CD	O
then	NN	O
cooled	RB	O
to	VBD	O
room	TO	O
temperature.	NN	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
partitioned	VBD	O
between	VBN	O
EtOAc	IN	O
(300	NNP	O
mL)	CD	O
and	)	O
H2O	CC	O
(200	NNP	O
mL).	CD	O
The	.	O
organic	DT	O
layer	JJ	O
was	NN	O
washed	VBD	O
with	VBN	O
H2O	IN	O
(200	NNP	O
mL),	CD	O
brine	,	O
(200	NN	O
mL),	CD	O
and	,	O
dried	CC	O
over	VBD	O
Na2SO4.	IN	O
The	.	O
solvents	DT	O
were	NNS	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation	JJ	O
and	NN	O
the	CC	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:18-1:9)	,	O
to	)	O
yield	TO	O
12	VB	O
(1.6	CD	O
g,	CD	O
85%)	,	O
as	)	O
a	IN	O
yellow	DT	O
oil:	JJ	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
3.40-3.50	VBZ	O
(dd,	JJ	O
J=3.0,	,	O
13.5,	,	O
0.5H),	,	O
3.50-3.60	,	O
(dd,	JJ	O
J=3.0,	,	O
13.5	,	O
Hz,	CD	O
0.5H),	,	O
3.60-3.75	,	O
(m,	JJ	O
1H),	,	O
5.50-5.60	,	O
(dd,	JJ	O
J=3.0,	,	O
8.0	,	O
Hz,	CD	O
0.5H),	,	O
5.65-5.80	,	O
(dd,	JJ	O
J=3.0,	,	O
8.0	,	O
Hz,	CD	O
0.5H),	,	O
7.00-7.20	,	O
(m,	JJ	O
3H),	,	O
7.30-7.50	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
55.9,	VBD	O
56.1,	,	O
91.82,	,	O
91.84,	,	O
93.2,	,	O
93.3,	,	O
112.78,	,	O
112.84,	,	O
112.96,	,	O
113.03,	,	O
116.19,	,	O
116.20,	,	O
116.36,	,	O
116.38,	,	O
121.24,	,	O
121.27,	,	O
121.30,	,	O
121.33,	,	O
130.7,	,	O
130.8,	,	O
139.09,	,	O
139.15,	,	O
139.25,	,	O
139.31,	,	O
162.1,	,	O
164.1;	,	O
GC-MS	:	O
calcd	NNP	O
for	NN	O
C8H7F2N3	IN	O
183.	NNP	O
found	CD	O
183.	VBD	O
2-Fluoro-2-(3-fluorophenyl)ethanamine	.	O
(4c).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
azide	IN	O
12	JJ	O
(1.8	CD	O
g,	CD	O
Example	,	O
32	NNP	O
10.0	CD	O
mmol)	CD	O
in	)	O
EtOH	IN	O
(30	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
1	VBN	O
N	CD	O
HCl	NNP	O
(15	NNP	O
mL)	CD	O
and	)	O
Pd(OH)2/C	CC	O
(20%,	CD	O
200	,	O
mg).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
under	VB	O
one	IN	O
atmosphere	CD	O
of	NN	O
H2	IN	O
for	NNP	O
24	IN	O
h.	CD	O
The	PDT	O
catalyst	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
filtration,	IN	O
and	,	O
the	CC	O
solvent	DT	O
was	NN	O
evaporated.	VBD	O
The	.	O
resulting	DT	O
yellowish	VBG	O
solid	JJ	O
was	NN	O
partitioned	VBD	O
between	VBN	O
diethyl	IN	O
ether	NN	O
(200	NN	O
mL)	CD	O
and	)	O
1	CC	O
N	CD	O
HCl	NNP	O
(200	NNP	O
mL).	CD	O
The	.	O
aqueous	DT	O
layer	JJ	O
was	NN	O
washed	VBD	O
with	VBN	O
diethyl	IN	O
ether	NN	O
(200	NN	O
mL)	CD	O
then	)	O
concentrated	RB	O
to	VBD	O
yield	TO	O
amine	VB	O
4c	JJ	O
as	CD	O
a	IN	O
hydrochloride	DT	O
salt	NN	O
(1.69	NN	O
g,	CD	O
8.8	,	O
mmol,	CD	O
98%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
3.33-3.35	VBZ	O
(dd,	JJ	O
J=3.5,	,	O
4.0	,	O
Hz,	CD	O
1H),	,	O
3.36-3.39	,	O
(dd,	JJ	O
J=3.5,	,	O
4.0	,	O
Hz,	CD	O
1H),	,	O
5.71-5.74	,	O
(dd,	JJ	O
J=5.0,	,	O
6.0	,	O
Hz,	CD	O
0.5H),	,	O
5.81-5.83	,	O
(dd,	JJ	O
J=5.0,	,	O
6.0	,	O
Hz,	CD	O
0.5H),	,	O
7.05-7.13	,	O
(m,	JJ	O
3H),	,	O
7.33-7.48	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
44.0,	VBD	O
44.2,	,	O
89.3,	,	O
90.7,	,	O
112.67,	,	O
112.73,	,	O
112.85,	,	O
112.92,	,	O
116.5,	,	O
116.7,	,	O
121.57,	,	O
121.59,	,	O
121.63,	,	O
131.1,	,	O
131.2,	,	O
137.35,	,	O
137.45,	,	O
137.51,	,	O
161.8,	,	O
163.8;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C8H10F2N	IN	O
158.	NNP	O
found	CD	O
158;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C8H10F2N	IN	O
158.07758.	NNP	O
found	CD	O
158.07738.	VBD	O
Example	.	O
33	JJ	O
1-(2-Bromo-1,1-difluoroethyl)-3-fluorobenzene	CD	O
(14).	NN	O
To	.	O
a	TO	O
flask	DT	O
containing	NN	O
2-bromo-3′-fluoroacetophenone	VBG	O
(13,	CD	O
2.15	,	O
g,	CD	O
10	,	O
mmol)	CD	O
was	)	O
added	VBD	O
DAST	VBN	O
(1.38	NNP	O
mL,	CD	O
10.5	,	O
mmol).	CD	O
The	.	O
flask	DT	O
was	NN	O
sealed	VBD	O
and	VBN	O
the	CC	O
reaction	DT	O
was	NN	O
allowed	VBD	O
to	VBN	O
proceed	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
seven	IN	O
days.	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
partitioned	VBD	O
between	VBN	O
EtOAc	IN	O
(300	NNP	O
mL)	CD	O
and	)	O
saturated	CC	O
NaHCO3	VBN	O
(300	NNP	O
mL).	CD	O
The	.	O
organic	DT	O
layer	JJ	O
was	NN	O
washed	VBD	O
with	VBN	O
brine	IN	O
(300	NN	O
mL)	CD	O
and	)	O
dried	CC	O
over	VBN	O
Na2SO4.	IN	O
The	.	O
solvents	DT	O
were	NNS	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:18-1:9)	,	O
to	)	O
yield	TO	O
14	VB	O
(1.65	CD	O
g,	CD	O
70%)	,	O
as	)	O
a	IN	O
brown	DT	O
liquid:	JJ	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
3.74-3.80	VBZ	O
(t,	JJ	O
J=14.0	,	O
Hz,	NNP	O
2H),	,	O
7.18-7.27	,	O
(m,	JJ	O
2H),	,	O
7.31-7.34	,	O
(m,	JJ	O
1H),	,	O
7.44-7.48	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
33.2,	VBD	O
33.5,	,	O
33.8,	,	O
113.08,	,	O
113.13,	,	O
113.28,	,	O
113.33,	,	O
113.38,	,	O
117.87,	,	O
117.89,	,	O
118.04,	,	O
118.06,	,	O
118.07,	,	O
118.22,	,	O
118.24,	,	O
121.4,	,	O
121.5,	,	O
130.7,	,	O
130.8,	,	O
161.8,	,	O
183.8;	,	O
GC-MS	:	O
calcd	NNP	O
for	NN	O
C8H6BrF3	IN	O
238.	NNP	O
found	CD	O
238.	VBD	O
Example	.	O
34	JJ	O
1-(2-Azido-1,1-difluoroethyl)-3-fluorobenzene	CD	O
(15).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
14	IN	O
(2.4	CD	O
g,	CD	O
10	,	O
mmol)	CD	O
in	)	O
anhydrous	IN	O
DMSO	JJ	O
(15	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
NaN3	VBN	O
(1.0	NNP	O
g,	CD	O
15.7	,	O
mmol).	CD	O
The	.	O
reaction	DT	O
solution	NN	O
turned	NN	O
purple	VBD	O
upon	JJ	O
heating.	IN	O
After	.	O
being	IN	O
stirred	VBG	O
at	VBN	O
110°	IN	O
C.	CD	O
for	NNP	O
8	IN	O
h,	CD	O
the	,	O
reaction	DT	O
mixture	NN	O
was	NN	O
cooled	VBD	O
to	VBN	O
room	TO	O
temperature	NN	O
and	NN	O
partitioned	CC	O
between	VBD	O
EtOAc	IN	O
(300	NNP	O
mL)	CD	O
and	)	O
H2O	CC	O
(200	NNP	O
mL).	CD	O
The	.	O
organic	DT	O
layer	JJ	O
was	NN	O
washed	VBD	O
with	VBN	O
H2O	IN	O
(200	NNP	O
mL),	CD	O
brine	,	O
(200	NN	O
mL),	CD	O
and	,	O
dried	CC	O
over	VBD	O
Na2SO4.	IN	O
The	.	O
solvents	DT	O
were	NNS	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:9)	,	O
to	)	O
yield	TO	O
azide	VB	O
15	RB	O
(1.7	CD	O
g,	CD	O
88%)	,	O
as	)	O
a	IN	O
yellow	DT	O
oil:	JJ	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
3.60-3.75	VBZ	O
(m,	JJ	O
2H),	,	O
7.00-7.15	,	O
(m,	JJ	O
2H),	,	O
7.15-7.35	,	O
(m,	JJ	O
1H),	,	O
7.40-7.60	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
55.8,	VBD	O
56.1,	,	O
56.4,	,	O
112.95,	,	O
113.01,	,	O
113.06,	,	O
113.14,	,	O
113.19,	,	O
113.25,	,	O
117.89,	,	O
117.90,	,	O
118.06,	,	O
118.07,	,	O
118.08,	,	O
119.78,	,	O
119.81,	,	O
121.25,	,	O
121.28,	,	O
121.30,	,	O
121.33,	,	O
121.35,	,	O
121.38,	,	O
130.8,	,	O
130.9,	,	O
136.7,	,	O
161.9,	,	O
163.9;	,	O
GC-MS	:	O
calcd	NNP	O
for	NN	O
C8H6F3N3	IN	O
201.	NNP	O
found	CD	O
201.	VBD	O
2,2-Fifluoro-2-(3-fluorophenyl)ethanamine	.	O
(4d).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
15	IN	O
(2.0	CD	O
g,	CD	O
10.0	,	O
mmol)	CD	O
in	)	O
EtOH	IN	O
(30	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
1	VBN	O
N	CD	O
HCl	NNP	O
(15	NNP	O
mL)	CD	O
and	)	O
Pd(OH)2/C	CC	O
(20%,	CD	O
200	,	O
mg).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
under	VB	O
one	IN	O
atmosphere	CD	O
of	NN	O
H2	IN	O
for	NNP	O
24	IN	O
h.	CD	O
The	PDT	O
catalyst	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
filtration	IN	O
and	NN	O
the	CC	O
solvent	DT	O
was	NN	O
evaporated.	VBD	O
The	.	O
resulting	DT	O
yellowish	VBG	O
solid	JJ	O
was	NN	O
partitioned	VBD	O
between	VBN	O
diethyl	IN	O
ether	NN	O
(200	NN	O
mL)	CD	O
and	)	O
1	CC	O
N	CD	O
HCl	NNP	O
(200	NNP	O
mL).	CD	O
The	.	O
aqueous	DT	O
layer	JJ	O
was	NN	O
washed	VBD	O
with	VBN	O
diethyl	IN	O
ether	NN	O
(200	NN	O
mL)	CD	O
then	)	O
concentrated	RB	O
to	VBD	O
yield	TO	O
amine	VB	O
4d	JJ	O
as	CD	O
a	IN	O
white	DT	O
solid	JJ	O
(1.6	JJ	O
g,	CD	O
91%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
3.60-4.66	VBZ	O
(t,	JJ	O
J=15.0	,	O
Hz,	NNP	O
2H),	,	O
7.17-7.30	,	O
(m,	JJ	O
3H),	,	O
7.40-7.45	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
44.6,	VBD	O
44.8,	,	O
45.0,	,	O
112.6,	,	O
112.8,	,	O
118.5,	,	O
118.7,	,	O
121.3,	,	O
131.4,	,	O
131.5,	,	O
161.6,	,	O
163.6;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C8H9F3N	IN	O
176.	NNP	O
found	CD	O
176;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C8H9F3N	IN	O
176.06816.	NNP	O
found	CD	O
176.06843.	VBD	O
Example	.	O
35	JJ	O
(3S,4S)/(3R,4R)-tert-Butyl-3-((6-(benzyl(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-(tert-butoxycarbonyl(2-(3-fluorophenoxy)ethyl)amino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(17a).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
aldehyde	IN	O
3	JJ	O
(50	CD	O
mg,	CD	O
0.093	,	O
mmol)	CD	O
in	)	O
THF	IN	O
(2	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
4a	VBN	O
(30	CD	O
mg,	CD	O
0.186	,	O
mmol).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
10	IN	O
min	CD	O
before	NN	O
NaHB(OAc)3	IN	O
(25	CD	O
mg,	CD	O
0.116	,	O
mmol)	CD	O
was	)	O
added.	VBD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
stirred	VBD	O
for	VBN	O
an	IN	O
additional	DT	O
3	JJ	O
h	CD	O
then	NN	O
partitioned	RB	O
between	VBD	O
EtOAc	IN	O
(50	NNP	O
mL)	CD	O
and	)	O
brine	CC	O
(25	NN	O
mL).	CD	O
The	.	O
organic	DT	O
layer	JJ	O
was	NN	O
dried	VBD	O
over	VBN	O
Na2SO4	IN	O
and	NNP	O
concentrated	CC	O
to	VBN	O
yield	TO	O
crude	VB	O
16a.	JJ	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
crude	IN	O
16a	NN	O
in	CD	O
MeOH	IN	O
(1.5	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
(Boc)2O	VBN	O
(30	CD	O
mg,	CD	O
0.140	,	O
mmol)	CD	O
and	)	O
Et3N	CC	O
(20	NNP	O
μL,	CD	O
0.140	,	O
mmol).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
stirred	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
for	NN	O
16	IN	O
h	CD	O
and	NN	O
then	CC	O
partitioned	RB	O
between	VBD	O
EtOAc	IN	O
(50	NNP	O
mL)	CD	O
and	)	O
brine	CC	O
(20	NN	O
mL).	CD	O
The	.	O
organic	DT	O
layer	JJ	O
was	NN	O
dried	VBD	O
over	VBN	O
Na2SO4,	IN	O
and	,	O
the	CC	O
solvents	DT	O
were	NNS	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
resulting	DT	O
material	VBG	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:4-1:2)	,	O
to	)	O
yield	TO	O
17a	VB	O
(35	CD	O
mg,	CD	O
60%)	,	O
as	)	O
a	IN	O
colorless	DT	O
oil:	JJ	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.30-1.50	VBZ	O
(m,	JJ	O
27H),	,	O
2.20-2.40	,	O
(m,	JJ	O
3H),	,	O
2.45-2.60	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.60-2.80	,	O
(m,	JJ	O
1H),	,	O
2.80-3.00	,	O
(m,	JJ	O
1H),	,	O
3.00-3.15	,	O
(m,	JJ	O
2H),	,	O
3.16-3.80	,	O
(m,	JJ	O
10H),	,	O
3.90-4.20	,	O
(m,	JJ	O
2H),	,	O
5.10-5.20	,	O
(m,	JJ	O
2H),	,	O
6.50-6.80	,	O
(m,	JJ	O
3H),	,	O
7.10-7.30	,	O
(m,	JJ	O
5H),	,	O
7.35-7.50	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(100	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
21.4,	VBD	O
28.4,	,	O
28.6,	,	O
28.7,	,	O
34.7,	,	O
34.8,	,	O
42.3,	,	O
42.4,	,	O
42.8,	,	O
43.0,	,	O
47.7,	,	O
47.9,	,	O
48.1,	,	O
48.3,	,	O
48.9,	,	O
49.0,	,	O
49.4,	,	O
50.1,	,	O
50.4,	,	O
50.5,	,	O
51.0,	,	O
66.7,	,	O
67.1,	,	O
67.2,	,	O
68.2,	,	O
68.3,	,	O
79.0,	,	O
79.3,	,	O
79.4,	,	O
79.8,	,	O
80.1,	,	O
80.2,	,	O
81.3,	,	O
81.4,	,	O
102.2,	,	O
102.3,	,	O
102.4,	,	O
102.5,	,	O
107.7,	,	O
107.9,	,	O
110.3,	,	O
117.2,	,	O
117.3,	,	O
120.2,	,	O
126.7,	,	O
126.8,	,	O
127.1,	,	O
127.2,	,	O
128.3,	,	O
130.4,	,	O
130.5,	,	O
140.0,	,	O
148.8,	,	O
154.1,	,	O
154.5;	,	O
154.6,	:	O
154.7,	,	O
155.5,	,	O
157.8,	,	O
157.9,	,	O
160.2,	,	O
162.6,	,	O
165.0;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H60F3N4O8	IN	O
779.	NNP	O
found	CD	O
779;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H60F3N4O8	IN	O
779.43897.	NNP	O
found	CD	O
779.43823.	VBD	O
Example	.	O
36	JJ	O
(3S,4S)/(3R,4R)-tert-Butyl	CD	O
3-((6-(benzyl(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-(tert-butoxycarbonyl(2-(3-fluorophenyl)cyclopropyl)amino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(17b).	NN	O
17b	.	O
was	CD	O
synthesized	VBD	O
using	VBN	O
a	VBG	O
procedure	DT	O
analogous	NN	O
to	JJ	O
that	TO	O
for	DT	O
17a	IN	O
(51%):	CD	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.10-1.22	VBZ	O
(m,	JJ	O
2H),	,	O
1.35-1.50	,	O
(m,	JJ	O
28H),	,	O
1.65-1.80	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.10-2.20	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
2.20-2.35	,	O
(m,	JJ	O
3H),	,	O
2.40-2.80	,	O
(m,	JJ	O
3H),	,	O
2.80-2.95	,	O
(m,	JJ	O
1H),	,	O
2.97-3.10	,	O
(m,	JJ	O
1H),	,	O
3.16-3.21	,	O
(m,	JJ	O
1H),	,	O
3.22-3.44	,	O
(m,	JJ	O
3H),	,	O
3.45-3.70	,	O
(m,	JJ	O
3H),	,	O
4.04-4.10	,	O
(m,	JJ	O
1H),	,	O
5.10-5.25	,	O
(br	JJ	O
s,	JJ	O
2H),	,	O
6.55-6.65	,	O
(m,	JJ	O
1H),	,	O
6.65-6.95	,	O
(m,	JJ	O
3H),	,	O
7.10-7.27	,	O
(m,	JJ	O
6H),	,	O
6.31-6.45	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
14.0,	VBD	O
14.4,	,	O
14.5,	,	O
19.4,	,	O
21.3,	,	O
21.4,	,	O
22.9,	,	O
28.4,	,	O
28.7,	,	O
28.8,	,	O
30.0,	,	O
30.9,	,	O
31.8,	,	O
34.8,	,	O
34.9,	,	O
40.0,	,	O
40.1,	,	O
42.9,	,	O
49.1,	,	O
49.5,	,	O
50.2,	,	O
50.5,	,	O
51.1,	,	O
60.7,	,	O
64.6,	,	O
78.2,	,	O
79.4,	,	O
79.7,	,	O
80.2,	,	O
81.4,	,	O
81.5,	,	O
112.9,	,	O
113.0,	,	O
117.2,	,	O
117.3,	,	O
120.2,	,	O
122.1,	,	O
126.8,	,	O
127.1,	,	O
127.2,	,	O
127.3,	,	O
128.3,	,	O
130.0,	,	O
140.1,	,	O
148.7,	,	O
148.8,	,	O
154.1,	,	O
154.6,	,	O
154.7,	,	O
155.0,	,	O
157.9,	,	O
162.2,	,	O
164.1,	,	O
171.4,	,	O
171.5;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C44H60FN4O7	IN	O
775.	NNP	O
found	CD	O
775;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C44H60FN4O7	IN	O
775.44405.	NNP	O
found	CD	O
775.44418.	VBD	O
Example	.	O
37	JJ	O
(3S,4S)/(3R,4R)-tert-Butyl	CD	O
3-((6-(benzyl(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-(tert-butoxycarbonyl(2-fluoro-2-(3-fluorophenypethypamino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(17c).	NN	O
17c	.	O
was	CD	O
synthesized	VBD	O
using	VBN	O
a	VBG	O
procedure	DT	O
analogous	NN	O
to	JJ	O
that	TO	O
for	DT	O
17a	IN	O
(48%):	CD	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.35-1.55	VBZ	O
(m,	JJ	O
27H),	,	O
2.20-2.35	,	O
(m,	JJ	O
3H),	,	O
2.50-2.80	,	O
(m,	JJ	O
2H),	,	O
2.80-2.95	,	O
(m,	JJ	O
1H),	,	O
3.00-3.22	,	O
(m,	JJ	O
2H),	,	O
3.23-3.90	,	O
(m,	JJ	O
9H),	,	O
5.15-5.25	,	O
(m,	JJ	O
2H),	,	O
5.50-5.80	,	O
(m,	JJ	O
1H),	,	O
6.50-6.70	,	O
(m,	JJ	O
1H),	,	O
7.00-7.17	,	O
(m,	JJ	O
3H),	,	O
7.17-7.27	,	O
(m,	JJ	O
6H),	,	O
7.30-7.50	,	O
(m,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
14.4,	VBD	O
19.1,	,	O
21.3,	,	O
21.4,	,	O
28.1,	,	O
28.3,	,	O
28.4,	,	O
28.6,	,	O
28.7,	,	O
28.8,	,	O
29.9,	,	O
34.7,	,	O
42.5,	,	O
42.9,	,	O
49.1,	,	O
49.5,	,	O
50.1,	,	O
51.1,	,	O
54.7,	,	O
54.8,	,	O
60.6,	,	O
68.2,	,	O
78.9,	,	O
79.4,	,	O
79.9,	,	O
80.5,	,	O
81.4,	,	O
81.5,	,	O
92.1,	,	O
94.1,	,	O
112.5,	,	O
112.6,	,	O
112.7,	,	O
112.8,	,	O
115.5,	,	O
115.6,	,	O
115.7,	,	O
117.3,	,	O
120.2,	,	O
121.2,	,	O
126.6,	,	O
126.7,	,	O
126.8,	,	O
127.2,	,	O
127.3,	,	O
127.5,	,	O
128.3,	,	O
128.7,	,	O
130.4,	,	O
130.6,	,	O
132.6,	,	O
140.1,	,	O
140.6,	,	O
148.8,	,	O
154.1,	,	O
154.6,	,	O
154.7,	,	O
155.2,	,	O
155.6,	,	O
157.8,	,	O
162.1,	,	O
164.1,	,	O
171.4;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H59F2N4O7	IN	O
781.	NNP	O
found	CD	O
781;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H59F2N4O7	IN	O
781.43463.	NNP	O
found	CD	O
781.43446.	VBD	O
Example	.	O
38	JJ	O
(3S,4S)/(3R,4R)-tert-Butyl	CD	O
3-((6-(benzyl(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-(tert-butoxycarbonyl(2,2-difluoro-2-(3-fluorophenypethypamino)ethoxy)pyrrolidine-1-carboxylate	CD	O
(17d).	NN	O
17d	.	O
was	CD	O
synthesized	VBD	O
using	VBN	O
a	VBG	O
procedure	DT	O
analogous	NN	O
to	JJ	O
that	TO	O
for	DT	O
17a	IN	O
(55%):	CD	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.35-1.55	VBZ	O
(m,	JJ	O
27H),	,	O
2.20-2.40	,	O
(s,	JJ	O
3H),	,	O
2.50-2.80	,	O
(m,	JJ	O
2H),	,	O
2.80-2.95	,	O
(m,	JJ	O
1H),	,	O
3.00-3.21	,	O
(m,	JJ	O
2H),	,	O
3.30-3.79	,	O
(m,	JJ	O
6H),	,	O
3.80-4.00	,	O
(m,	JJ	O
2H),	,	O
5.10-5.25	,	O
(s,	JJ	O
2H),	,	O
6.60-6.70	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
7.00-7.30	,	O
(m,	JJ	O
8H),	,	O
7.31-7.60	,	O
(m,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
14.4,	VBD	O
21.2,	,	O
21.3,	,	O
27.8,	,	O
28.1,	,	O
28.4,	,	O
28.5,	,	O
28.7,	,	O
29.9,	,	O
34.8,	,	O
42.3,	,	O
42.9,	,	O
47.5,	,	O
47.7,	,	O
49.0,	,	O
49.4,	,	O
50.1,	,	O
50.4,	,	O
50.9,	,	O
60.6,	,	O
67.9,	,	O
76.9,	,	O
78.9,	,	O
79.3,	,	O
79.7,	,	O
79.8,	,	O
80.6,	,	O
81.4,	,	O
113.0,	,	O
113.1,	,	O
117.2,	,	O
117.5,	,	O
120.1,	,	O
121.4,	,	O
126.7,	,	O
126.8,	,	O
126.9,	,	O
127.0,	,	O
127.1,	,	O
127.2,	,	O
127.5,	,	O
127.6,	,	O
128.3,	,	O
128.5,	,	O
128.6,	,	O
130.4,	,	O
140.0	,	O
148.8,	CD	O
154.1,	,	O
154.5,	,	O
154.9,	,	O
157.8,	,	O
161.5,	,	O
163.4;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H58F3N4O7	IN	O
799.	NNP	O
found	CD	O
799;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H58F3N4O7	IN	O
799.42521.	NNP	O
found	CD	O
799.42577.	VBD	O
Example	.	O
39	JJ	O
6-(((3S,4S)/(3R,4R)-4-(2-(2-(3-Fluorophenoxy)ethylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine	CD	O
(2a).	NN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
17a	IN	O
(30	CD	O
mg,	CD	O
39	,	O
μmol)	CD	O
in	)	O
EtOH	IN	O
(5.0	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
a	VBN	O
1:1	DT	O
mixture	CD	O
of	NN	O
EtOH/concentrated	IN	O
HCl	NNP	O
(10	NNP	O
mL)	CD	O
and	)	O
Pd(OH)2/C	CC	O
(20%,	CD	O
30	,	O
mg).	CD	O
The	.	O
mixture	DT	O
was	NN	O
charged	VBD	O
with	VBN	O
H2	IN	O
under	NNP	O
the	IN	O
pressure	DT	O
of	NN	O
500	IN	O
psi.	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
40	IN	O
h.	CD	O
The	PDT	O
catalyst	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
filtration	IN	O
through	NN	O
Celite,	IN	O
and	,	O
the	CC	O
resulting	DT	O
Celite	VBG	O
cake	NNP	O
was	NN	O
washed	VBD	O
with	VBN	O
EtOH	IN	O
(4×3	NNP	O
mL)	CD	O
and	)	O
2	CC	O
N	CD	O
HCl	NNP	O
(3	NNP	O
mL).	CD	O
The	.	O
combined	DT	O
filtrates	JJ	O
were	NNS	O
concentrated	VBD	O
to	VBN	O
yield	TO	O
inhibitor	VB	O
2a,	NN	O
a	,	O
yellow	DT	O
solid,	JJ	O
as	,	O
a	IN	O
hydrochloride	DT	O
salt	NN	O
(15	NN	O
mg,	CD	O
85%):	,	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
2.08	VBZ	O
(s,	CD	O
3H),	,	O
2.60-2.63	,	O
(m,	JJ	O
2H),	,	O
2.70-2.80	,	O
(m,	JJ	O
1H),	,	O
2.97-3.03	,	O
(m,	JJ	O
1H),	,	O
3.13-3.16	,	O
(m,	JJ	O
1H),	,	O
3.17-3.37	,	O
(m,	JJ	O
3H),	,	O
3.38-3.50	,	O
(m,	JJ	O
3H),	,	O
3.54	,	O
(br	CD	O
s,	NN	O
1H),	,	O
3.73	,	O
(br	CD	O
s,	NN	O
1H),	,	O
4.05	,	O
(br	CD	O
s,	NN	O
1H),	,	O
4.17	,	O
(br	CD	O
s,	NN	O
2H),	,	O
6.33	,	O
(s,	CD	O
1H),	,	O
6.44	,	O
(s,	CD	O
1H),	,	O
6.50-6.55	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
6.58-6.70	,	O
(m,	JJ	O
3H),	,	O
7.06-7.08	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
21.3,	VBD	O
29.4,	,	O
41.7,	,	O
46.6,	,	O
47.0,	,	O
47.3,	,	O
49.5,	,	O
63.0,	,	O
64.0,	,	O
78.6,	,	O
108.4,	,	O
108.6,	,	O
108.7,	,	O
110.4,	,	O
110.5,	,	O
114.3,	,	O
130.9,	,	O
131.0,	,	O
145.8,	,	O
154.0,	,	O
158.3,	,	O
158.7,	,	O
158.8,	,	O
162.4,	,	O
164.4;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H30FN4O2	IN	O
389.	NNP	O
found	CD	O
389;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H30FN4O2	IN	O
389.23473.	NNP	O
found	CD	O
389.23444.	VBD	O
Example	.	O
40	JJ	O
6-(((3S,4S)/(3R,4R)-4-(2-(2-(3-Fluorophenyl)cyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine	CD	O
(2b).	NN	O
Inhibitor	.	O
2b	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
a	VBG	O
procedure	DT	O
analogous	NN	O
to	JJ	O
that	TO	O
for	DT	O
2a	IN	O
(91%):	CD	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
1.18-1.20	VBZ	O
(m,	JJ	O
3H),	,	O
2.20	,	O
(s,	CD	O
3H),	,	O
2.60-2.72	,	O
(m,	JJ	O
2H),	,	O
2.75-2.90	,	O
(m,	JJ	O
2H),	,	O
3.00-3.10	,	O
(m,	JJ	O
2H),	,	O
3.15-3.33	,	O
(m,	JJ	O
3H),	,	O
3.34-3.42	,	O
(m,	JJ	O
1H),	,	O
3.44-3.60	,	O
(m,	JJ	O
3H),	,	O
3.70-3.80	,	O
(m,	JJ	O
1H),	,	O
4.09	,	O
(s,	CD	O
1H),	,	O
6.46-4.67	,	O
(m,	JJ	O
1H),	,	O
6.56	,	O
(s,	CD	O
1H),	,	O
6.90-7.10	,	O
(m,	JJ	O
3H),	,	O
7.20-7.25	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
15.2,	VBD	O
15.5,	,	O
21.3,	,	O
29.2,	,	O
38.4,	,	O
38.5,	,	O
41.6,	,	O
41.7,	,	O
44.2,	,	O
44.4,	,	O
47.3,	,	O
49.5,	,	O
55.6,	,	O
64.0,	,	O
64.4,	,	O
78.4,	,	O
110.6,	,	O
114.3,	,	O
114.4,	,	O
114.5,	,	O
116.2,	,	O
116.4,	,	O
125.4,	,	O
125.6,	,	O
130.8,	,	O
130.9,	,	O
138.3,	,	O
145.9,	,	O
146.0,	,	O
154.1,	,	O
158.4,	,	O
161.9,	,	O
163.9;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C22H30FN4O	IN	O
385.	NNP	O
found	CD	O
385;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C22H30FN4O	IN	O
385.24036.	NNP	O
found	CD	O
385.23933.	VBD	O
Example	.	O
41	JJ	O
6-(((3S,4S)/(3R,4R)-4-(2-(2-Fluoro-2-(3-fluorophenyl)propylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine	CD	O
(2c).	NN	O
Inhibitor	.	O
2c	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
a	VBG	O
procedure	DT	O
analogous	NN	O
to	JJ	O
that	TO	O
for	DT	O
2a	IN	O
(90%):	CD	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
2.14	VBZ	O
(s,	CD	O
3H),	,	O
2.61-2.77	,	O
(m,	JJ	O
2H),	,	O
2.78-2.95	,	O
(m,	JJ	O
2H),	,	O
2.96-3.10	,	O
(m,	JJ	O
1H),	,	O
3.11-3.25	,	O
(m,	JJ	O
2H),	,	O
3.26-3.40	,	O
(m,	JJ	O
2H),	,	O
3.41-4.60	,	O
(m,	JJ	O
3H),	,	O
3.63-3.80	,	O
(m,	JJ	O
1H),	,	O
4.00-4.15	,	O
(m,	JJ	O
1H),	,	O
5.78-5.80	,	O
(d,	JJ	O
J=9.0	,	O
Hz,	NNP	O
0.5H),	,	O
5.81-5.90	,	O
(d,	JJ	O
J=9.0	,	O
Hz,	NNP	O
0.5H),	,	O
6.41-6.43	,	O
(d,	JJ	O
J=7.5	,	O
Hz,	NNP	O
1H),	,	O
6.50-6.55	,	O
(d,	JJ	O
J=8.0	,	O
Hz,	NNP	O
1H),	,	O
6.80-6.95	,	O
(m,	JJ	O
1H),	,	O
6.96-7.15	,	O
(m,	JJ	O
2H),	,	O
7.16-7.40	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
21.29,	VBD	O
21.34,	,	O
29.23,	,	O
29.28,	,	O
29.32,	,	O
29.8,	,	O
31.4,	,	O
41.6,	,	O
41.7,	,	O
47.1,	,	O
47.3,	,	O
47.6,	,	O
48.4,	,	O
49.5,	,	O
51.6,	,	O
52.1,	,	O
63.9,	,	O
64.0,	,	O
64.2,	,	O
78.4,	,	O
88.6,	,	O
89.9,	,	O
110.6,	,	O
112.8,	,	O
113.0,	,	O
114.2,	,	O
114.3,	,	O
114.4,	,	O
114.8,	,	O
115.6,	,	O
115.8,	,	O
116.7,	,	O
116.8,	,	O
121.8,	,	O
124.9,	,	O
126.9,	,	O
127.4,	,	O
128.9,	,	O
129.1,	,	O
130.8,	,	O
130.9,	,	O
131.1,	,	O
131.2,	,	O
137.1,	,	O
138.9,	,	O
139.0,	,	O
145.8,	,	O
145.9,	,	O
154.0,	,	O
158.4,	,	O
161.8,	,	O
161.9,	,	O
163.7,	,	O
163.8;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H29F2N4O	IN	O
391.	NNP	O
found	CD	O
391;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H29F2N4O	IN	O
391.23094.	NNP	O
found	CD	O
391.23012.	VBD	O
Example	.	O
42	JJ	O
6-(((3S,4S)/(3R,4R)-4-(2-(2,2-Difluoro-2-(3-fluorophenypethylamino)ethoxy)pyrrolidin-3-yemethyl)-4-methylpyridin-2-amine	CD	O
(2d).	NN	O
Inhibitor	.	O
2d	NN	O
was	CD	O
synthesized	VBD	O
using	VBN	O
a	VBG	O
procedure	DT	O
analogous	NN	O
to	JJ	O
that	TO	O
for	DT	O
2a	IN	O
(91%):	CD	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
2.19	VBZ	O
(s,	CD	O
3H),	,	O
2.68-2.70	,	O
(m,	JJ	O
2H),	,	O
2.80-2.92	,	O
(m,	JJ	O
1H),	,	O
2.93-3.10	,	O
(m,	JJ	O
1H),	,	O
3.20-3.30	,	O
(d,	JJ	O
J=13.0	,	O
Hz,	NNP	O
1H),	,	O
3.38	,	O
(s,	CD	O
3H),	,	O
3.50-3.60	,	O
(d,	JJ	O
J=14.0	,	O
Hz,	NNP	O
1H),	,	O
3.65	,	O
(br	CD	O
s,	NN	O
1H),	,	O
3.70-3.90	,	O
(m,	JJ	O
3H),	,	O
4.15	,	O
(s,	CD	O
1H),	,	O
6.45	,	O
(s,	CD	O
1H),	,	O
6.55	,	O
(s,	CD	O
1H),	,	O
7.10-7.35	,	O
(m,	JJ	O
3H),	,	O
7.42	,	O
(br	CD	O
s,	NN	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
21.3,	VBD	O
29.3,	,	O
41.5,	,	O
47.3,	,	O
47.7,	,	O
47.8,	,	O
49.4,	,	O
51.9,	,	O
63.8,	,	O
78.5,	,	O
110.6,	,	O
112.5,	,	O
114.2,	,	O
118.6,	,	O
118.8,	,	O
121.2,	,	O
131.5,	,	O
145.8,	,	O
154.1,	,	O
158.4,	,	O
161.6;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H28F3N4O	IN	O
409.	NNP	O
found	CD	O
409;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H28F3N4O	IN	O
409.22152.	NNP	O
found	CD	O
409.22076.	VBD	O
Examples	.	O
43-57	NNS	O
can	CD	O
be	MD	O
considered	VB	O
in	VBN	O
the	IN	O
context	DT	O
of	NN	O
Schemes	IN	O
5-8,	NNP	O
above.	,	O
Example	.	O
43	RB	O
General	CD	O
Method	NNP	O
(A)	NNP	O
for	)	O
Reductive	IN	O
Amination.	JJ	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
aldehyde	IN	O
8a	JJ	O
or	CD	O
8b	CC	O
(0.1	CD	O
mmol)	CD	O
in	)	O
THF	IN	O
(3	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
ethanamine	VBN	O
(0.2	NN	O
mmol),	CD	O
followed	,	O
by	VBN	O
NaHB(OAc)3	IN	O
(0.12	CD	O
mmol).	CD	O
The	.	O
mixture	DT	O
was	NN	O
stirred	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
for	NN	O
an	IN	O
additional	DT	O
3	JJ	O
h,	CD	O
and	,	O
then	CC	O
concentrated.	RB	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
2:1-4:1)	,	O
to	)	O
yield	TO	O
the	VB	O
corresponding	DT	O
secondary	JJ	O
amines	JJ	O
as	NNS	O
colorless	IN	O
oils	NN	O
which	NNS	O
were	WDT	O
used	VBD	O
without	VBN	O
further	IN	O
purification.	JJ	O
Example	.	O
44	RB	O
General	CD	O
Method	NNP	O
(B)	NNP	O
for	)	O
Boc-protection.	IN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
secondary	IN	O
amine	JJ	O
(0.5	NN	O
mmol)	CD	O
in	)	O
MeOH	IN	O
(10	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
(Boc)2O	VBN	O
(164	CD	O
mg,	CD	O
0.75	,	O
mmol)	CD	O
and	)	O
TEA	CC	O
(140	NNP	O
μL,	CD	O
1.0	,	O
mmol).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
stir	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
30	IN	O
min.	CD	O
The	.	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation,	JJ	O
and	,	O
the	CC	O
resulting	DT	O
material	VBG	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:4-1:2)	,	O
to	)	O
yield	TO	O
9a-f	VB	O
as	JJ	O
a	IN	O
colorless	DT	O
oil.	NN	O
Example	.	O
45	RB	O
General	CD	O
Method	NNP	O
(C)	NNP	O
for	)	O
Catalytic	IN	O
hydrogenation.	JJ	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
9a-f	IN	O
(0.2	NNP	O
mmol)	CD	O
in	)	O
EtOH	IN	O
(20	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
Pd(OH)2/C	VBN	O
(100	CD	O
mg).	CD	O
The	.	O
reaction	DT	O
vessel	NN	O
was	NN	O
charged	VBD	O
with	VBN	O
H2,	IN	O
heated	,	O
at	VBD	O
60°	IN	O
C.	CD	O
for	NNP	O
24-48	IN	O
h,	JJ	O
then	,	O
cooled	RB	O
to	VBD	O
room	TO	O
temperature.	NN	O
The	.	O
catalyst	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
filtration,	IN	O
and	,	O
the	CC	O
resulting	DT	O
solution	JJ	O
was	NN	O
concentrated	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
crude	DT	O
material	JJ	O
was	NN	O
purified	VBD	O
by	VBN	O
flash	IN	O
column	JJ	O
chromatography	NN	O
(EtOAc/hexanes,	NN	O
1:4	,	O
1:2)	CD	O
to	)	O
yield	TO	O
10a-f	VB	O
as	JJ	O
a	IN	O
white	DT	O
foamy	JJ	O
solid.	NN	O
Example	.	O
46	RB	O
General	CD	O
Method	NNP	O
(D)	NNP	O
for	)	O
Boc-deprotection.	IN	O
To	.	O
a	TO	O
solution	DT	O
of	NN	O
10a-f	IN	O
(50	JJ	O
μmol)	CD	O
in	)	O
MeOH	IN	O
(0.5	NNP	O
mL)	CD	O
was	)	O
added	VBD	O
6	VBN	O
N	CD	O
HCl	NNP	O
(1.0	NNP	O
mL).	CD	O
The	.	O
reaction	DT	O
mixture	NN	O
was	NN	O
allowed	VBD	O
to	VBN	O
sit	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
12	IN	O
h.	CD	O
The	PDT	O
solvent	DT	O
was	NN	O
removed	VBD	O
by	VBN	O
rotary	IN	O
evaporation.	JJ	O
The	.	O
crude	DT	O
product	JJ	O
was	NN	O
recrystallized	VBD	O
using	VBN	O
cold	VBG	O
diethyl	JJ	O
ether	NN	O
to	NN	O
provide	TO	O
2da-2dd	VB	O
and	JJ	O
2e-2f	CC	O
as	JJ	O
pale	IN	O
yellow	JJ	O
solids.	JJ	O
Example	.	O
47	RB	O
9a	CD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
A	NNS	O
and	DT	O
B	CC	O
using	NNP	O
aldehyde	VBG	O
8b	RB	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.35-1.55	VBZ	O
(m,	JJ	O
27H),	,	O
2.20-2.40	,	O
(s,	JJ	O
3H),	,	O
2.50-2.80	,	O
(m,	JJ	O
2H),	,	O
2.80-2.95	,	O
(m,	JJ	O
1H),	,	O
3.00-3.21	,	O
(m,	JJ	O
2H),	,	O
3.30-3.79	,	O
(m,	JJ	O
6H),	,	O
3.80	,	O
4.00	CD	O
(m,	CD	O
2H),	,	O
5.10-5.25	,	O
(s,	JJ	O
2H),	,	O
6.60-6.70	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
7.00-7.30	,	O
(m,	JJ	O
8H),	,	O
7.31	,	O
7.60	CD	O
(m,	CD	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
14.4,	VBD	O
21.2,	,	O
21.3,	,	O
27.8,	,	O
28.1,	,	O
28.4,	,	O
28.5,	,	O
28.7,	,	O
29.9,	,	O
34.8,	,	O
42.3,	,	O
42.9,	,	O
47.5,	,	O
47.7,	,	O
49.0,	,	O
49.4,	,	O
50.1,	,	O
50.4,	,	O
50.9,	,	O
60.6,	,	O
67.9,	,	O
76.9,	,	O
78.9,	,	O
79.3,	,	O
79.7,	,	O
79.8,	,	O
80.6,	,	O
81.4,	,	O
113.0,	,	O
113.1,	,	O
117.2,	,	O
117.5,	,	O
120.1,	,	O
121.4,	,	O
126.7,	,	O
126.8,	,	O
126.9,	,	O
127.0,	,	O
127.1,	,	O
127.2,	,	O
127.5,	,	O
127.6,	,	O
128.3,	,	O
128.5,	,	O
128.6,	,	O
130.4,	,	O
140.0	,	O
148.8,	CD	O
154.1,	,	O
154.5,	,	O
154.9,	,	O
157.8,	,	O
161.5,	,	O
163.4;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H58F3N4O7	IN	O
799.	NNP	O
found	CD	O
799;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H58F3N4O7	IN	O
799.4252.	NNP	O
found	CD	O
799.4258.	VBD	O
Example	.	O
48	RB	O
9b	CD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
A	NNS	O
and	DT	O
B	CC	O
using	NNP	O
aldehyde	VBG	O
8a	RB	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.35-1.55	VBZ	O
(m,	JJ	O
27H),	,	O
2.20-2.40	,	O
(s,	JJ	O
3H),	,	O
2.50-2.80	,	O
(m,	JJ	O
2H),	,	O
2.80-2.95	,	O
(m,	JJ	O
1H),	,	O
3.00-3.21	,	O
(m,	JJ	O
2H),	,	O
3.30-3.79	,	O
(m,	JJ	O
6H),	,	O
3.80	,	O
4.00	CD	O
(m,	CD	O
2H),	,	O
5.10-5.25	,	O
(s,	JJ	O
2H),	,	O
6.60-6.70	,	O
(br	JJ	O
s,	JJ	O
1H),	,	O
7.00-7.30	,	O
(m,	JJ	O
8H),	,	O
7.31-7.60	,	O
(m,	JJ	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
14.4,	VBD	O
21.2,	,	O
21.3,	,	O
27.8,	,	O
28.1,	,	O
28.4,	,	O
28.5,	,	O
28.7,	,	O
29.9,	,	O
34.8,	,	O
42.3,	,	O
42.9,	,	O
47.5,	,	O
47.7,	,	O
49.0,	,	O
49.4,	,	O
50.1,	,	O
50.4,	,	O
50.9,	,	O
60.6,	,	O
67.9,	,	O
76.9,	,	O
78.9,	,	O
79.3,	,	O
79.7,	,	O
79.8,	,	O
80.6,	,	O
81.4,	,	O
113.0,	,	O
113.1,	,	O
117.2,	,	O
117.5,	,	O
120.1,	,	O
121.4,	,	O
126.7,	,	O
126.8,	,	O
126.9,	,	O
127.0,	,	O
127.1,	,	O
127.2,	,	O
127.5,	,	O
127.6,	,	O
128.3,	,	O
128.5,	,	O
128.6,	,	O
130.4,	,	O
140.0	,	O
148.8,	CD	O
154.1,	,	O
154.5,	,	O
154.9,	,	O
157.8,	,	O
161.5,	,	O
163.4;	,	O
LCQ-MS	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H58F3N4O7	IN	O
799.	NNP	O
found	CD	O
799;	VBD	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H58F3N4O7	IN	O
799.4252.	NNP	O
found	CD	O
799.4248	VBD	O
Example	CD	O
49	NNP	O
9c	CD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
A	NNS	O
and	DT	O
B	CC	O
using	NNP	O
aldehyde	VBG	O
8a	RB	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.20-1.50	VBZ	O
(m,	JJ	O
27H),	,	O
2.25	,	O
2.35	CD	O
(m,	CD	O
3H),	,	O
2.45-2.65	,	O
(m,	JJ	O
1H),	,	O
2.66-2.70	,	O
(m,	JJ	O
1H),	,	O
2.80-2.95	,	O
(m,	JJ	O
1H),	,	O
3.00-3.10	,	O
(m,	JJ	O
1H),	,	O
3.10-3.20	,	O
(m,	JJ	O
1H),	,	O
3.25-3.70	,	O
(m,	JJ	O
7H),	,	O
3.80-4.00	,	O
(m,	JJ	O
2H),	,	O
5.10-5.20	,	O
(m,	JJ	O
2H),	,	O
6.60	,	O
6.70	CD	O
(m,	CD	O
1H),	,	O
7.00-7.15	,	O
(m,	JJ	O
2H),	,	O
7.16-7.20	,	O
(m,	JJ	O
1H),	,	O
7.21-7.27	,	O
(m,	JJ	O
4H),	,	O
7.35-7.60	,	O
(m,	JJ	O
3H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
13.7,	VBD	O
14.2,	,	O
19.1,	,	O
21.0,	,	O
21.1,	,	O
24.7,	,	O
27.91,	,	O
27.96,	,	O
28.01,	,	O
28.2,	,	O
28.3,	,	O
28.5,	,	O
30.6,	,	O
34.4,	,	O
34.5,	,	O
34.6,	,	O
42.0,	,	O
42.1,	,	O
42.6,	,	O
42.7,	,	O
47.4,	,	O
47.5,	,	O
47.6,	,	O
47.8,	,	O
48.8,	,	O
49.3,	,	O
49.9,	,	O
50.1,	,	O
50.3,	,	O
50.8,	,	O
53.4,	,	O
53.8,	,	O
54.0,	,	O
60.4,	,	O
64.4,	,	O
67.7,	,	O
67.8,	,	O
68.0,	,	O
78.7,	,	O
78.8,	,	O
79.1,	,	O
79.2,	,	O
79.3,	,	O
79.6,	,	O
80.3,	,	O
81.17,	,	O
81.22,	,	O
115.2,	,	O
115.4,	,	O
115.6,	,	O
115.7,	,	O
117.0,	,	O
117.1,	,	O
119.9,	,	O
126.5,	,	O
126.6,	,	O
126.9,	,	O
127.0,	,	O
127.5,	,	O
128.1,	,	O
131.5,	,	O
139.7,	,	O
139.8,	,	O
148.6,	,	O
153.9,	,	O
154.3,	,	O
154.4,	,	O
154.5,	,	O
154.6,	,	O
154.7,	,	O
154.8,	,	O
155.1,	,	O
157.4,	,	O
157.5,	,	O
157.6,	,	O
162.7,	,	O
164.6,	,	O
171.2;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H58F3N4O7	IN	O
799.4258.	NNP	O
found	CD	O
799.4237.	VBD	O
Example	.	O
50	RB	O
9d	CD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
A	NNS	O
and	DT	O
B	CC	O
using	NNP	O
aldehyde	VBG	O
8a	RB	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.20-1.50	VBZ	O
(m,	JJ	O
27H),	,	O
2.25	,	O
2.35	CD	O
(m,	CD	O
3H),	,	O
2.45-2.65	,	O
(m,	JJ	O
1H),	,	O
2.66-2.71	,	O
(m,	JJ	O
1H),	,	O
2.80-2.95	,	O
(m,	JJ	O
1H),	,	O
3.00-3.10	,	O
(m,	JJ	O
1H),	,	O
3.10-3.20	,	O
(m,	JJ	O
1H),	,	O
3.25-3.70	,	O
(m,	JJ	O
7H),	,	O
3.80-4.00	,	O
(m,	JJ	O
2H),	,	O
5.10-5.20	,	O
(m,	JJ	O
2H),	,	O
6.60	,	O
6.70	CD	O
(m,	CD	O
1H),	,	O
7.00-7.60	,	O
(m,	JJ	O
12H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
13.7,	VBD	O
14.2,	,	O
19.1,	,	O
21.0,	,	O
21.1,	,	O
24.7,	,	O
27.91,	,	O
27.96,	,	O
28.01,	,	O
28.2,	,	O
28.3,	,	O
28.5,	,	O
30.6,	,	O
34.4,	,	O
34.5,	,	O
34.6,	,	O
42.0,	,	O
42.1,	,	O
42.6,	,	O
42.7,	,	O
47.4,	,	O
47.5,	,	O
47.6,	,	O
47.8,	,	O
48.8,	,	O
49.3,	,	O
49.9,	,	O
50.1,	,	O
50.3,	,	O
50.8,	,	O
53.4,	,	O
53.8,	,	O
54.0,	,	O
60.4,	,	O
64.4,	,	O
67.7,	,	O
67.8,	,	O
68.0,	,	O
78.7,	,	O
78.8,	,	O
79.1,	,	O
79.2,	,	O
79.3,	,	O
79.6,	,	O
80.3,	,	O
81.17,	,	O
81.22,	,	O
115.2,	,	O
115.4,	,	O
115.6,	,	O
115.7,	,	O
117.0,	,	O
117.1,	,	O
119.9,	,	O
126.5,	,	O
126.6,	,	O
126.9,	,	O
127.0,	,	O
127.5,	,	O
128.1,	,	O
131.5,	,	O
139.7,	,	O
139.8,	,	O
148.6,	,	O
153.9,	,	O
154.3,	,	O
154.4,	,	O
154.5,	,	O
154.6,	,	O
154.7,	,	O
154.8,	,	O
155.1,	,	O
157.4,	,	O
157.5,	,	O
157.6,	,	O
162.7,	,	O
164.6,	,	O
171.2;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C43H59F2N4O7	IN	O
781.4352.	NNP	O
found	CD	O
781.4366.	VBD	O
Example	.	O
51	RB	O
9f	CD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
A	NNS	O
and	DT	O
B	CC	O
using	NNP	O
aldehyde	VBG	O
8b	RB	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
1.40-1.55	VBZ	O
(m,	JJ	O
27H),	,	O
2.27	,	O
2.29	CD	O
(m,	CD	O
3H),	,	O
2.45-2.67	,	O
(m,	JJ	O
1H),	,	O
2.68-2.75	,	O
(m,	JJ	O
1H),	,	O
2.85-2.95	,	O
(m,	JJ	O
1H),	,	O
3.00-3.11	,	O
(m,	JJ	O
1H),	,	O
3.12-3.20	,	O
(m,	JJ	O
1H),	,	O
3.30-3.45	,	O
(m,	JJ	O
3H),	,	O
3.46-3.65	,	O
(m,	JJ	O
3H),	,	O
4.05-4.20	,	O
(m,	JJ	O
2H),	,	O
5.16	,	O
(s,	CD	O
2H),	,	O
6.67	,	O
(s,	CD	O
1H),	,	O
7.17-7.20	,	O
(m,	JJ	O
1H),	,	O
7.21-7.26	,	O
(m,	JJ	O
4H),	,	O
7.30-7.45	,	O
(m,	JJ	O
2H),	,	O
7.50	,	O
7.70	CD	O
(m,	CD	O
1H),	,	O
7.75-7.85	,	O
(m,	JJ	O
1H),	,	O
8.60-8.71	,	O
(m,	JJ	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
CDCl3)	,	O
δ	)	O
14.2,	VBD	O
21.11,	,	O
21.13,	,	O
24.7,	,	O
28.0,	,	O
28.1,	,	O
28.2,	,	O
28.3,	,	O
28.5,	,	O
29.7,	,	O
34.4,	,	O
34.5,	,	O
36.6,	,	O
42.2,	,	O
42.6,	,	O
42.7,	,	O
47.6,	,	O
47.7,	,	O
48.0,	,	O
48.8,	,	O
49.2,	,	O
49.89,	,	O
49.92,	,	O
50.1,	,	O
50.2,	,	O
50.8,	,	O
60.4,	,	O
67.5,	,	O
67.6,	,	O
67.7,	,	O
78.7,	,	O
79.1,	,	O
79.6,	,	O
80.2,	,	O
81.1,	,	O
81.2,	,	O
117.0,	,	O
117.1,	,	O
120.0,	,	O
120.4,	,	O
120.5,	,	O
124.76,	,	O
124.84,	,	O
126.4,	,	O
126.5,	,	O
126.6,	,	O
126.9,	,	O
127.0,	,	O
128.06,	,	O
128.11,	,	O
136.9,	,	O
137.0,	,	O
139.8,	,	O
139.9,	,	O
148.5,	,	O
149.3,	,	O
149.5,	,	O
153.8,	,	O
154.3,	,	O
154.4,	,	O
154.5,	,	O
154.7,	,	O
155.0,	,	O
155.4,	,	O
157.7;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C42H58F2N5O7	IN	O
782.4304.	NNP	O
found	CD	O
782.4299.	VBD	O
Example	.	O
52	RB	O
Inhibitor	CD	O
compound	NNP	O
2da	VBD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
C	NNS	O
and	NNP	O
D	CC	O
using	NNP	O
9a	VBG	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
2.29	VBZ	O
(s,	CD	O
3H),	,	O
2.78-2.81	,	O
(m,	JJ	O
2H),	,	O
2.95	,	O
3.05	CD	O
(dd,	CD	O
J=8.0,	,	O
15.0	,	O
Hz,	CD	O
1H),	,	O
3.15-3.20	,	O
(t,	JJ	O
J=6.0,	,	O
1H),	,	O
3.31-3.35	,	O
(dd,	JJ	O
J=3.0,	,	O
13.0	,	O
Hz,	CD	O
1H),	,	O
3.40-3.55	,	O
(m,	JJ	O
3H),	,	O
3.63-3.66	,	O
(d,	JJ	O
J=13.0	,	O
Hz,	NNP	O
1H),	,	O
3.71-3.79	,	O
(m,	JJ	O
1H),	,	O
3.87-3.95	,	O
(m,	JJ	O
3H),	,	O
4.24-4.26	,	O
(t,	JJ	O
J=3.0	,	O
Hz,	NNP	O
1H),	,	O
6.55	,	O
(s,	CD	O
1H),	,	O
6.64	,	O
(s,	CD	O
1H),	,	O
7.25-7.29	,	O
(dt,	JJ	O
J=2.5,	,	O
8.5	,	O
Hz,	CD	O
1H),	,	O
7.34-7.36	,	O
(dd,	JJ	O
J=2.5,	,	O
14.0	,	O
Hz,	CD	O
1H),	,	O
7.38-7.40	,	O
(dd,	JJ	O
J=2.5,	,	O
8.0	,	O
Hz,	CD	O
1H),	,	O
7.49	,	O
7.52	CD	O
(dd,	CD	O
J=6.0,	,	O
8.0	,	O
Hz,	CD	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
21.0,	VBD	O
29.1,	,	O
41.3,	,	O
47.0,	,	O
47.5,	,	O
49.2,	,	O
51.5,	,	O
51.7,	,	O
51.9,	,	O
63.6,	,	O
78.3,	,	O
110.4,	,	O
112.3,	,	O
112.5,	,	O
114.0,	,	O
118.2,	,	O
118.4,	,	O
118.6,	,	O
121.0,	,	O
131.2,	,	O
131.3,	,	O
134.2,	,	O
145.5,	,	O
153.9,	,	O
158.1,	,	O
161.4,	,	O
163.3;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H28F3N4O	IN	O
409.2215.	NNP	O
found	CD	O
409.2226.	VBD	O
Example	.	O
53	RB	O
Inhibitor	CD	O
compound	NNP	O
2db	VBD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
C	NNS	O
and	NNP	O
D	CC	O
using	NNP	O
9b	VBG	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
2.29	VBZ	O
(s,	CD	O
3H),	,	O
2.78-2.81	,	O
(m,	JJ	O
2H),	,	O
2.95	,	O
3.05	CD	O
(dd,	CD	O
J=8.0,	,	O
15.0	,	O
Hz,	CD	O
1H),	,	O
3.15-3.20	,	O
(t,	JJ	O
J=6.0,	,	O
1H),	,	O
3.31-3.35	,	O
(dd,	JJ	O
J=3.0,	,	O
13.0	,	O
Hz,	CD	O
1H),	,	O
3.40-3.55	,	O
(m,	JJ	O
3H),	,	O
3.63-3.66	,	O
(d,	JJ	O
J=13.0	,	O
Hz,	NNP	O
1H),	,	O
3.71-3.79	,	O
(m,	JJ	O
1H),	,	O
3.87-3.95	,	O
(m,	JJ	O
3H),	,	O
4.24-4.26	,	O
(t,	JJ	O
J=3.0	,	O
Hz,	NNP	O
1H),	,	O
6.55	,	O
(s,	CD	O
1H),	,	O
6.64	,	O
(s,	CD	O
1H),	,	O
7.25-7.29	,	O
(dt,	JJ	O
J=2.5,	,	O
8.5	,	O
Hz,	CD	O
1H),	,	O
7.34-7.36	,	O
(dd,	JJ	O
J=2.5,	,	O
14.0	,	O
Hz,	CD	O
1H),	,	O
7.38-7.40	,	O
(dd,	JJ	O
J=2.5,	,	O
8.0	,	O
Hz,	CD	O
1H),	,	O
7.49	,	O
7.52	CD	O
(dd,	CD	O
J=6.0,	,	O
8.0	,	O
Hz,	CD	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
21.0,	VBD	O
29.1,	,	O
41.3,	,	O
47.0,	,	O
47.5,	,	O
49.2,	,	O
51.5,	,	O
51.7,	,	O
51.9,	,	O
63.6,	,	O
78.3,	,	O
110.4,	,	O
112.3,	,	O
112.5,	,	O
114.0,	,	O
118.2,	,	O
118.4,	,	O
118.6,	,	O
121.0,	,	O
131.2,	,	O
131.3,	,	O
134.2,	,	O
145.5,	,	O
153.9,	,	O
158.1,	,	O
161.4,	,	O
163.3;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H28F3N4O	IN	O
409.2215.	NNP	O
found	CD	O
409.2223.	VBD	O
Example	.	O
54	RB	O
Inhibitor	CD	O
compound	NNP	O
2dc	VBD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
C	NNS	O
and	NNP	O
D	CC	O
using	NNP	O
9c	VBG	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
2.30	VBZ	O
(s,	CD	O
3H),	,	O
2.78-2.81	,	O
(m,	JJ	O
2H),	,	O
2.95	,	O
3.05	CD	O
(dd,	CD	O
J=8.0,	,	O
15.0	,	O
Hz,	CD	O
1H),	,	O
3.15-3.20	,	O
(t,	JJ	O
J=6.0,	,	O
1H),	,	O
3.31-3.35	,	O
(dd,	JJ	O
J=3.0,	,	O
13.0	,	O
Hz,	CD	O
1H),	,	O
3.40-3.55	,	O
(m,	JJ	O
3H),	,	O
3.63-3.66	,	O
(d,	JJ	O
J=13.0	,	O
Hz,	NNP	O
1H),	,	O
3.71-3.79	,	O
(m,	JJ	O
1H),	,	O
3.87-3.95	,	O
(m,	JJ	O
3H),	,	O
4.24-4.26	,	O
(t,	JJ	O
J=3.0	,	O
Hz,	NNP	O
1H),	,	O
6.55	,	O
(s,	CD	O
1H),	,	O
6.64	,	O
(s,	CD	O
1H),	,	O
7.21-7.25	,	O
(dd,	JJ	O
J=8.5,	,	O
8.5	,	O
Hz,	CD	O
2H),	,	O
7.59-7.62	,	O
(dd,	JJ	O
J=5.0,	,	O
8.5	,	O
Hz,	CD	O
2H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
21.0,	VBD	O
29.0,	,	O
41.3,	,	O
47.0,	,	O
47.4,	,	O
49.2,	,	O
51.7,	,	O
51.9,	,	O
51.9,	,	O
63.6,	,	O
78.3,	,	O
110.4,	,	O
113.9,	,	O
116.0,	,	O
116.1,	,	O
118.7,	,	O
127.42,	,	O
127.47,	,	O
127.55,	,	O
127.59,	,	O
145.5,	,	O
153.9,	,	O
158.1;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H28F3N4O	IN	O
409.2215.	NNP	O
found	CD	O
409.2230.	VBD	O
Example	.	O
55	RB	O
Inhibitor	CD	O
compound	NNP	O
2dd	VBD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
C	NNS	O
and	NNP	O
D	CC	O
using	NNP	O
9d	VBG	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
2.30	VBZ	O
(s,	CD	O
3H),	,	O
2.73-2.84	,	O
(m,	JJ	O
2H),	,	O
2.95	,	O
3.05	CD	O
(dd,	CD	O
J=8.5,	,	O
15.0	,	O
Hz,	CD	O
1H),	,	O
3.10-3.20	,	O
(t,	JJ	O
J=6.0,	,	O
1H),	,	O
3.31-3.35	,	O
(dd,	JJ	O
J=3.0,	,	O
13.5	,	O
Hz,	CD	O
1H),	,	O
3.40-3.55	,	O
(m,	JJ	O
3H),	,	O
3.63-3.66	,	O
(d,	JJ	O
J=13.5	,	O
Hz,	NNP	O
1H),	,	O
3.71-3.79	,	O
(m,	JJ	O
1H),	,	O
3.87-3.95	,	O
(m,	JJ	O
3H),	,	O
4.24-4.26	,	O
(t,	JJ	O
J=3.0	,	O
Hz,	NNP	O
1H),	,	O
6.55	,	O
(s,	CD	O
1H),	,	O
6.64	,	O
(s,	CD	O
1H),	,	O
7.45-7.65	,	O
(m,	JJ	O
5H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
21.0,	VBD	O
29.0,	,	O
41.3,	,	O
47.0,	,	O
47.4,	,	O
49.2,	,	O
51.6,	,	O
51.8,	,	O
52.0,	,	O
63.6,	,	O
78.2,	,	O
110.4,	,	O
113.9,	,	O
119.0,	,	O
120.9,	,	O
124.81,	,	O
124.86,	,	O
124.91,	,	O
129.1,	,	O
131.6,	,	O
131.9,	,	O
132.1,	,	O
145.5,	,	O
153.9,	,	O
158.1;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H29F2N4O	IN	O
391.2309.	NNP	O
found	CD	O
391.2337.	VBD	O
Example	.	O
56	RB	O
Inhibitor	CD	O
compound	NNP	O
2e	VBD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
C	NNS	O
and	NNP	O
D	CC	O
using	NNP	O
9e	VBG	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
0.85-0.95	VBZ	O
(d,	JJ	O
J=2.5,	,	O
3H),	,	O
1.45	,	O
1.55	CD	O
(m,	CD	O
1H),	,	O
1.61-1.70	,	O
(m,	JJ	O
1H),	,	O
1.71-1.97	,	O
(m,	JJ	O
3H),	,	O
2.00-2.10	,	O
(m,	JJ	O
1H),	,	O
2.35-2.45	,	O
(m,	JJ	O
1H),	,	O
2.46	,	O
2.57	CD	O
(m,	CD	O
1H),	,	O
2.90-3.00	,	O
(t,	JJ	O
J=6.0,	,	O
1H),	,	O
3.16-3.21	,	O
(m,	JJ	O
1H),	,	O
3.30-3.50	,	O
(m,	JJ	O
4H),	,	O
3.51	,	O
3.60	CD	O
(d,	CD	O
J=13.5	,	O
Hz,	NNP	O
1H),	,	O
3.61-3.70	,	O
(m,	JJ	O
1H),	,	O
3.75-3.90	,	O
(m,	JJ	O
3H),	,	O
4.14s-4.16	,	O
(t,	JJ	O
J=3.0	,	O
Hz,	NNP	O
1H),	,	O
7.45-7.65	,	O
(m,	JJ	O
5H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
17.5,	VBD	O
17.6,	,	O
18.2,	,	O
26.8,	,	O
27.2,	,	O
27.3,	,	O
32.6,	,	O
32.9,	,	O
40.0,	,	O
40.2,	,	O
48.3,	,	O
48.9,	,	O
49.1,	,	O
49.6,	,	O
50.6,	,	O
52.2,	,	O
58.8,	,	O
65.2,	,	O
79.9,	,	O
80.0,	,	O
115.4,	,	O
115.6,	,	O
116.8,	,	O
117.0,	,	O
126.0,	,	O
132.1,	,	O
132.2,	,	O
140.2,	,	O
163.1,	,	O
165.0,	,	O
168.4;	,	O
LC	:	O
TOF	NNP	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C21H33F2N4O	IN	O
395.2622.	NNP	O
found	CD	O
395.2633.	VBD	O
Example	.	O
57	RB	O
Inhibitor	CD	O
compound	NNP	O
2f	VBD	O
was	CD	O
synthesized	VBD	O
by	VBN	O
general	IN	O
methods	JJ	O
C	NNS	O
and	NNP	O
D	CC	O
using	NNP	O
9f	VBG	O
as	CD	O
a	IN	O
starting	DT	O
material	VBG	O
(55%):	NN	O
1H	:	O
NMR	CD	O
(500	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
1.40-1.50	VBZ	O
(m,	JJ	O
1H),	,	O
1.51-1.60	,	O
(m,	JJ	O
2H),	,	O
1.79	,	O
1.90	CD	O
(m,	CD	O
2H),	,	O
1.91-1.98	,	O
(d,	JJ	O
J=13.5	,	O
Hz,	NNP	O
1H),	,	O
2.20	,	O
(s,	CD	O
3H),	,	O
2.65-2.75	,	O
(m,	JJ	O
1H),	,	O
2.79	,	O
2.85	CD	O
(m,	CD	O
1H),	,	O
2.94-2.96	,	O
(d,	JJ	O
J=7.5	,	O
Hz,	NNP	O
1H),	,	O
2.97-3.00	,	O
(m,	JJ	O
1H),	,	O
3.07-3.12	,	O
(dd,	JJ	O
J=11.5,	,	O
11.5	,	O
Hz,	CD	O
1H),	,	O
3.20-3.26	,	O
(dd,	JJ	O
J=0.5,	,	O
13.0	,	O
Hz,	CD	O
1H),	,	O
3.31-3.47	,	O
(m,	JJ	O
4H),	,	O
3.52-3.55	,	O
(d,	JJ	O
J=13.5	,	O
Hz,	NNP	O
1H),	,	O
3.61-3.64	,	O
(m,	JJ	O
1H),	,	O
3.74-3.82	,	O
(m,	JJ	O
5H),	,	O
4.11	,	O
(s,	CD	O
1H),	,	O
6.52	,	O
(s,	CD	O
1H),	,	O
6.57	,	O
(s,	CD	O
1H);	,	O
13C	:	O
NMR	CD	O
(125	NNP	O
MHz,	CD	O
D2O)	,	O
δ	)	O
20.4,	VBD	O
21.05,	,	O
21.06,	,	O
22.4,	,	O
28.95,	,	O
29.01,	,	O
41.48,	,	O
41.51,	,	O
45.1,	,	O
47.0,	,	O
48.08,	,	O
48.14,	,	O
49.4,	,	O
57.7,	,	O
63.7,	,	O
63.9,	,	O
78.3,	,	O
78.4,	,	O
110.4,	,	O
114.09,	,	O
114.12,	,	O
145.7,	,	O
153.9,	,	O
158.1;	,	O
LC-TOF	:	O
(M+H+)	NNP	O
calcd	)	O
for	NN	O
C20H34F2N5O	IN	O
398.2742.	NNP	O
found	CD	O
398.2726.	VBD	O
Enzyme	.	O
Assays	NNP	O
Example	NNP	O
58	NNP	O
IC50	CD	O
values	NNP	O
for	NNS	O
inhibitors	IN	O
2a-d	NNS	O
were	CD	O
measured	VBD	O
for	VBN	O
the	IN	O
three	DT	O
different	CD	O
isoforms	JJ	O
of	NNS	O
NOS	IN	O
including	NNP	O
rat	VBG	O
nNOS,	NN	O
bovine	,	O
eNOS,	NN	O
and	,	O
murine	CC	O
macrophage	JJ	O
iNOS	NN	O
using	NN	O
L-arginine	VBG	O
as	NNP	O
a	IN	O
substrate.	DT	O
The	.	O
three	DT	O
isozymes	CD	O
were	NNS	O
recombinant	VBD	O
enzymes,	JJ	O
which	,	O
were	WDT	O
overexpressed	VBD	O
(in	VBN	O
E.	IN	O
coli)	NNP	O
and	)	O
isolated	CC	O
as	VBN	O
reported.	IN	O
The	.	O
formation	DT	O
of	NN	O
nitric	IN	O
oxide	JJ	O
was	NN	O
measured	VBD	O
using	VBN	O
a	VBG	O
hemoglobin	DT	O
capture	JJ	O
assay	NN	O
described	VBP	O
previously.	VBN	O
(Hevel,	.	O
supra.)	,	O
All	)	O
NOS	DT	O
isozymes	NNP	O
were	NNS	O
assayed	VBD	O
at	VBN	O
room	IN	O
temperature	NN	O
in	NN	O
a	IN	O
100	DT	O
mM	CD	O
Hepes	NN	O
buffer	NNP	O
(pH	NN	O
7.4)	JJ	O
containing	)	O
10	VBG	O
μM	CD	O
L-arginine,	JJ	O
1.6	,	O
mM	CD	O
CaCl2,	NN	O
11.6	,	O
μg/mL	CD	O
calmodulin,	NNP	O
100	,	O
μM	CD	O
DTT,	NN	O
100	,	O
μM	CD	O
NADPH,	NN	O
6.5	,	O
μM	CD	O
H4B,	NN	O
3.0	,	O
mM	CD	O
oxyhemoglobin	NN	O
(for	NN	O
iNOS	IN	O
assays,	NN	O
no	,	O
Ca2+	DT	O
and	NNP	O
calmodulin	CC	O
was	NN	O
added).	VBD	O
The	.	O
assay	DT	O
was	NN	O
initiated	VBD	O
by	VBN	O
the	IN	O
addition	DT	O
of	NN	O
enzyme,	IN	O
and	,	O
the	CC	O
initial	DT	O
rates	JJ	O
of	NNS	O
the	IN	O
enzymatic	DT	O
reactions	JJ	O
were	NNS	O
determined	VBD	O
by	VBN	O
monitoring	IN	O
the	VBG	O
formation	DT	O
of	NN	O
NO-hemoglobin	IN	O
complex	NNP	O
at	NN	O
401	IN	O
nm	CD	O
from	NN	O
0	IN	O
to	CD	O
60	TO	O
s	CD	O
after.	NN	O
The	.	O
corresponding	DT	O
Ki	JJ	O
values	NNP	O
of	NNS	O
inhibitors	IN	O
were	NNS	O
calculated	VBD	O
from	VBN	O
the	IN	O
IC50	DT	O
values	NNP	O
using	NNS	O
equation	VBG	O
1	NN	O
with	CD	O
known	IN	O
Km	VBN	O
values	NNP	O
(rat	NNS	O
nNOS,	NN	O
1.3	,	O
μM;	CD	O
iNOS,	:	O
8.3	,	O
μM;	CD	O
eNOS,	:	O
1.7	,	O
μM).Ki=IC50/(1+[S]/Km)  (1)	CD	O
Example	)	O
59	)	O
IC50	NN	O
values	CD	O
for	NNP	O
inhibitors	NNS	O
2da-2dd	IN	O
and	NNS	O
2e-f	JJ	O
were	CC	O
measured	JJ	O
for	VBD	O
the	VBN	O
three	IN	O
different	DT	O
isoforms	CD	O
of	JJ	O
NOS	NNS	O
including	IN	O
rat	NNP	O
nNOS,	VBG	O
bovine	NN	O
eNOS,	,	O
and	NN	O
murine	,	O
macrophage	CC	O
iNOS	JJ	O
using	NN	O
L-arginine	NN	O
as	VBG	O
a	NNP	O
substrate.	IN	O
The	DT	O
three	.	O
isozymes	DT	O
were	CD	O
recombinant	NNS	O
enzymes,	VBD	O
which	JJ	O
were	,	O
overexpressed	WDT	O
(in	VBD	O
E.	VBN	O
coli)	IN	O
and	NNP	O
isolated	)	O
as	CC	O
reported.	VBN	O
The	IN	O
formation	.	O
of	DT	O
nitric	NN	O
oxide	IN	O
was	JJ	O
measured	NN	O
using	VBD	O
a	VBN	O
hemoglobin	VBG	O
capture	DT	O
assay	JJ	O
described	NN	O
previously.	VBP	O
All	VBN	O
NOS	.	O
isozymes	DT	O
were	NNP	O
assayed	NNS	O
at	VBD	O
room	VBN	O
temperature	IN	O
in	NN	O
a	NN	O
100	IN	O
mM	DT	O
Hepes	CD	O
buffer	NN	O
(pH	NNP	O
7.4)	NN	O
containing	JJ	O
10	)	O
μM	VBG	O
L-arginine,	CD	O
1.6	JJ	O
mM	,	O
CaCl2,	CD	O
11.6	NN	O
μg/mL	,	O
calmodulin,	CD	O
100	NNP	O
μM	,	O
DTT,	CD	O
100	NN	O
μM	,	O
NADPH,	CD	O
6.5	NN	O
μM	,	O
H4B,	CD	O
3.0	NN	O
μM	,	O
oxyhemoglobin	CD	O
(for	NN	O
iNOS	NN	O
assays,	IN	O
no	NN	O
Ca2+	,	O
and	DT	O
calmodulin	NNP	O
was	CC	O
added).	NN	O
The	VBD	O
assay	.	O
was	DT	O
initiated	NN	O
by	VBD	O
the	VBN	O
addition	IN	O
of	DT	O
enzyme,	NN	O
and	IN	O
the	,	O
initial	CC	O
rates	DT	O
of	JJ	O
the	NNS	O
enzymatic	IN	O
reactions	DT	O
were	JJ	O
determined	NNS	O
by	VBD	O
monitoring	VBN	O
the	IN	O
formation	VBG	O
of	DT	O
NO-hemoglobin	NN	O
complex	IN	O
at	NNP	O
401	NN	O
nm	IN	O
for	CD	O
60	NN	O
s.	IN	O
The	CD	O
corresponding	PDT	O
Ki	DT	O
values	JJ	O
of	NNP	O
inhibitors	NNS	O
were	IN	O
calculated	NNS	O
from	VBD	O
the	VBN	O
IC50	IN	O
values	DT	O
using	NNP	O
equation	NNS	O
1	VBG	O
with	NN	O
known	CD	O
Km	IN	O
values,	VBN	O
as	NNP	O
above.	,	O
Inhibitor	IN	O
Complex	.	O
Crystal	NNP	O
Preparation	NNP	O
Example	NNP	O
60	NNP	O
The	NNP	O
nNOS	CD	O
or	DT	O
eNOS	NN	O
heme	CC	O
domain	JJ	O
protein	NN	O
used	NN	O
for	NN	O
crystallographic	VBN	O
studies	IN	O
were	JJ	O
produced	NNS	O
by	VBD	O
limited	VBN	O
trypsin	IN	O
digest	JJ	O
from	NN	O
the	NN	O
corresponding	IN	O
full	DT	O
length	JJ	O
enzymes	JJ	O
and	NN	O
further	NNS	O
purified	CC	O
through	JJ	O
a	VBN	O
Superdex	IN	O
200	DT	O
gel	NNP	O
filtration	CD	O
column	NN	O
(GE	NN	O
Healthcare)	NN	O
as	NNP	O
described	)	O
previously.	IN	O
(See,	VBN	O
Li,	.	B
H.;	,	I
Shimizu,	,	I
H.;	:	I
Flinspach,	,	I
M.;	:	I
Jamal,	,	I
J.;	:	I
Yang,	,	I
W.;	:	I
Xian,	,	I
M.;	:	I
Cai,	,	I
T.;	:	I
Wen,	,	I
E.	:	I
Z.;	,	I
Jia,	NNP	I
Q.;	:	I
Wang,	,	I
P.	:	I
G.;	,	I
Poulos,	NNP	I
T.	:	I
L.,	,	I
The	NNP	I
novel	,	I
binding	DT	I
mode	NN	I
of	VBG	I
N-alkyl-N′-hydroxyguanidine	NN	I
to	IN	I
neuronal	NNP	I
nitric	TO	I
oxide	JJ	I
synthase	JJ	I
provides	JJ	I
mechanistic	NN	I
insights	VBZ	I
into	JJ	I
NO	NNS	I
biosynthesis.	IN	I
Biochemistry	DT	I
2002,	.	I
41,	NN	I
13868-13875;	,	I
and	,	O
Flinspach,	:	B
M.	CC	I
L.;	,	I
Li,	NNP	I
H.;	:	I
Jamal,	,	I
J.;	:	I
Yang,	,	I
W.;	:	I
Huang,	,	I
H.;	:	I
Hah,	,	I
J.	:	I
M.;	,	I
Gomez	NNP	I
Vidal,	:	I
J.	NNP	I
A.;	,	I
Litzinger,	.	I
E.	:	I
A.;	,	I
Silverman,	NNP	I
R.	:	I
B.;	,	I
Poulos,	NNP	I
T.	:	I
L.,	,	I
Structural	NNP	I
basis	,	I
for	NNP	I
dipeptide	NN	I
amide	IN	I
isoform-selective	JJ	I
inhibition	IN	I
of	JJ	I
neuronal	NN	I
nitric	IN	I
oxide	JJ	I
synthase.	JJ	I
Nat	NN	I
Struct	.	I
Mol	NNP	I
Biol	NNP	I
2004,	NNP	I
11,	NNP	I
54-59.)The	,	O
enzyme-inhibitor	,	O
complex	)	O
crystals	DT	O
were	NN	O
obtained	JJ	O
by	NNS	O
soaking	VBD	O
rather	VBN	O
than	IN	O
co-crystallization,	VBG	O
as	RB	O
reported.	IN	O
The	,	O
nNOS	IN	O
heme	.	O
domain	DT	O
at	JJ	O
7-9	NN	O
mg/mL	NN	O
containing	IN	O
20	JJ	O
mM	NN	O
histidine	VBG	O
or	CD	O
the	JJ	O
eNOS	NN	O
heme	CC	O
domain	DT	O
at	JJ	O
20	NN	O
mg/mL	NN	O
with	IN	O
2	CD	O
mM	NN	O
imidazole	IN	O
were	CD	O
used	NNS	O
for	JJ	O
the	VBD	O
sitting	VBN	O
drop	IN	O
vapor	DT	O
diffusion	VBG	O
crystallization	NN	O
setup	NN	O
under	NN	O
the	NN	O
conditions	NN	O
previously	IN	O
reported.	DT	O
Fresh	NNS	O
crystals	RB	O
(1-2	.	O
day	JJ	O
old)	NNS	O
were	JJ	O
first	NN	O
passed	)	O
stepwise	VBD	O
through	RB	O
cryo-protectant	VBN	O
solutions	NN	O
described	IN	O
and	JJ	O
then	NNS	O
soaked	VBN	O
with	CC	O
10	RB	O
mM	VBD	O
inhibitor	IN	O
for	CD	O
4-6	NNS	O
h	NN	O
at	IN	O
4°	JJ	O
C.	NN	O
before	IN	O
being	CD	O
mount	NNP	O
on	IN	O
nylon	VBG	O
loops	NN	O
and	IN	O
flash	JJ	O
cooled	NNS	O
by	CC	O
plunging	NN	O
into	VBN	O
liquid	IN	O
nitrogen.	VBG	O
(See,	IN	O
Li,	JJ	B
H.;	.	I
Shimizu,	,	I
H.;	,	I
Flinspach,	:	I
M.;	,	I
Jamal,	:	I
J.;	,	I
Yang,	:	I
W.;	,	I
Xian,	:	I
M.;	,	I
Cai,	:	I
T.;	,	I
Wen,	:	I
E.	,	I
Z.;	:	I
Jia,	,	I
Q.;	NNP	I
Wang,	:	I
P.	,	I
G.;	:	I
Poulos,	,	I
T.	NNP	I
L.,	:	I
The	,	I
novel	NNP	I
binding	,	I
mode	DT	I
of	NN	I
N-alkyl-N′-hydroxyguanidine	VBG	I
to	NN	I
neuronal	IN	I
nitric	NNP	I
oxide	TO	I
synthase	JJ	I
provides	JJ	I
mechanistic	JJ	I
insights	NN	I
into	VBZ	I
NO	JJ	I
biosynthesis.	NNS	I
Biochemistry	IN	I
2002,	DT	I
41,	.	I
13868-13875;	NN	I
Flinspach,	,	B
M.	,	I
L.;	:	I
Li,	,	I
H.;	NNP	I
Jamal,	:	I
J.;	,	I
Yang,	:	I
W.;	,	I
Huang,	:	I
H.;	,	I
Hah,	:	I
J.	,	I
M.;	:	I
Gomez-Vidal,	,	I
J.	NNP	I
A.;	:	I
Litzinger,	,	I
E.	.	I
A.;	:	I
Silverman,	,	I
R.	NNP	I
B.;	:	I
Poulos,	,	I
T.	NNP	I
L.,	:	I
Structural	,	I
basis	NNP	I
for	,	I
dipeptide	NNP	I
amide	NN	I
isoform-selective	IN	I
inhibition	JJ	I
of	IN	I
neuronal	JJ	I
nitric	NN	I
oxide	IN	I
synthase.	JJ	I
Nat	JJ	I
Struct	NN	I
Mol	.	I
Biol	NNP	I
2004,	NNP	I
11,	NNP	I
54-59.)Crystals	NNP	O
were	,	O
stored	,	O
in	)	O
liquid	NNS	O
nitrogen	VBD	O
until	VBN	O
data	IN	O
collection.	JJ	O
X-ray	NN	O
Diffraction	IN	O
Data	NNS	O
Collection,	.	O
Processing,	JJ	O
and	NNP	O
Structure	NNP	O
Refinement	,	O
Example	,	O
61	CC	O
The	NNP	O
cryogenic	NNP	O
(100K)	NNP	O
x-ray	CD	O
diffraction	DT	O
data	NN	O
were	)	O
collected	JJ	O
remotely	NN	O
at	NNS	O
various	VBD	O
beamlines	VBN	O
at	RB	O
Stanford	IN	O
Synchrotron	JJ	O
Radiation	NNS	O
Lightsource	IN	O
through	NNP	O
the	NNP	O
data	NNP	O
collection	NNP	O
control	IN	O
software	DT	O
Blu-Ice	NNS	O
and	NN	O
the	NN	O
crystal	NN	O
mounting	NNP	O
robot.	CC	O
McPhillips,	DT	B
T.	NN	I
M.;	VBG	I
McPhillips,	.	I
S.	,	I
E.;	NNP	I
Chiu,	:	I
H.	,	I
J.;	NNP	I
Cohen,	:	I
A.	,	I
E.;	NNP	I
Deacon,	:	I
A.	,	I
M.;	NNP	I
Ellis,	:	I
P.	,	I
J.;	NNP	I
Garman,	:	I
E.;	,	I
Gonzalez,	NNP	I
A.;	:	I
Sauter,	,	I
N.	:	I
K.;	,	I
Phizackerley,	:	I
R.	,	I
P.;	NNP	I
Soltis,	:	I
S.	,	I
M.;	NNP	I
Kuhn,	:	I
P.,	,	I
Blu-Ice	NNP	I
and	:	I
the	,	I
Distributed	,	I
Control	NNP	I
System:	CC	I
software	DT	I
for	NNP	I
data	NNP	I
acquisition	:	I
and	NN	I
instrument	IN	I
control	NNS	I
at	NN	I
macromolecular	CC	I
crystallography	NN	I
beamlines.	NN	I
J	IN	I
Synchrotron	JJ	I
Radiat	NN	I
2002,	.	I
9,	NNP	I
401-406.)(	NNP	O
Raw	NNP	O
data	,	O
frames	,	O
were	)	O
indexed,	NNP	O
integrated,	NNS	O
and	NNS	O
scaled	VBD	O
using	,	O
HKL2000.	,	O
(6)	CC	O
Typically,	VBD	O
each	VBG	O
data	.	O
set	)	O
consisted	,	O
of	DT	O
90	NN	O
to	NN	O
100	VBD	O
degree	IN	O
of	CD	O
data	TO	O
with	CD	O
0.5	NN	O
degree	IN	O
frame	NNS	O
width	IN	O
for	CD	O
both	NN	O
nNOS	NN	O
and	NN	O
eNOS	IN	O
crystals	DT	O
because	JJ	O
of	CC	O
their	JJ	O
identical	NNS	O
orthorhombic	IN	O
P212121	IN	O
space	PRP$	O
group	JJ	O
symmetry.	NN	O
The	NNP	O
binding	NN	O
of	NN	O
inhibitors	.	O
was	DT	O
detected	NN	O
by	IN	O
the	NNS	O
initial	VBD	O
difference	VBN	O
Fourier	IN	O
maps	DT	O
calculated	JJ	O
with	NN	O
REFMAC.	NNP	O
Murshudov,	NNS	B
G.	VBD	I
N.;	IN	I
Vagin,	.	I
A.	,	I
A.;	NNP	I
Dodson,	:	I
E.	,	I
J.,	.	I
Refinement	:	I
of	,	I
Macromolecular	NNP	I
Structures	,	I
by	NNP	I
the	IN	I
Maximum-Likelihood	NNP	I
Method.	NNP	I
Acta	IN	I
Cryst.	DT	I
1997,	NNP	I
D53,	.	I
240	NNP	I
255.)(	.	O
The	,	O
inhibitor	,	O
molecules	CD	O
were	)	O
then	DT	O
modeled	NN	O
in	NNS	O
O	VBD	O
Jones,	RB	B
T.	VBN	I
A.;	IN	I
Zou,	NNP	I
J.-Y.;	,	I
Cowan,	NNP	I
S.	:	I
W.;	,	I
Kjeldgaarrd,	:	I
M.,	,	I
Improved	NNP	I
methods	:	I
for	,	I
building	,	I
models	NNP	I
in	NNS	I
electron	IN	I
density	NN	I
and	NNS	I
the	IN	I
location	JJ	I
of	NN	I
errors	CC	I
in	DT	I
these	NN	I
models.	IN	I
Acta	NNS	I
Cryst.	IN	I
1991,	DT	I
A47,	.	I
110-119)	NNP	I
(or	.	O
COOT	,	O
Emsley,	,	B
P.;	)	I
Cowtan,	CC	I
K.,	NNP	I
Coot:	,	I
model-building	:	I
tools	,	I
for	,	I
molecular	:	I
graphics.	JJ	I
Acta	NNS	I
Cryst.	IN	I
2004,	JJ	I
D60,	.	I
2126-2132)	NNP	I
(and	.	O
refined	,	O
using	,	O
REFMAC.	)	O
Water	CC	O
molecules	VBN	O
were	VBG	O
added	.	O
in	NNP	O
REFMAC	NNS	O
and	VBD	O
checked	VBN	O
by	IN	O
COOT.	NNP	O
The	CC	O
TLS	VBN	O
protocol	IN	O
was	.	O
implemented	DT	O
in	NNP	O
the	NN	O
final	VBD	O
stage	VBN	O
of	IN	O
refinements	DT	O
with	JJ	O
each	NN	O
subunit	IN	O
as	NNS	O
one	IN	O
TLS	DT	O
group.	NN	O
Winn,	IN	B
M.	CD	I
D.;	NNP	I
Isupov,	.	I
M.	,	I
N.;	NNP	I
Murshudov,	:	I
G.	,	I
N.,	NNP	I
Use	:	I
of	,	I
TLS	NNP	I
parameters	,	I
to	NNP	I
model	IN	I
anisotropic	NNP	I
displacements	NNS	I
in	TO	I
macromolecular	VB	I
refinement.	JJ	I
Acta	NNS	I
Cryst.	IN	I
2001,	JJ	I
D57,	.	I
122-133.)